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Abstract 
Spinal cord injury can cause detrimental damage or complete loss in sensory and motor function. 
Current treatments, such as pharmaceutical interventions and physical therapy, provide limited 
improvements to restoring sensorimotor function following spinal cord injury. A non-
conventional treatment using light irradiation in the red to near infrared range has been shown to 
promote recovery in a variety of injuries and conditions including spinal cord injury. This thesis 
examines the effects of red (670 nm) light irradiation on sensorimotor recovery following a mild 
T10 hemicontusion spinal cord injury in rats. To demonstrate that this treatment could potentially 
access the human cord, the penetration of 670 nm irradiation in different human tissues in both 
human participants and cadavers were examined. 670 nm irradiation with a light emitting diode 
(LED) at an intensity of 100 mW/cm2 was shown to penetrate 50 mm of human tissue, 
independent of skin tone, indicating that red light treatment could reach the spinal cord of humans 
with intensities ≥ 100 mW/cm2. Following spinal cord injury in rats, the development of 
mechanical hypersensitivity, the functional integrity of dorsal column pathways (measured from 
surface field potential electrophysiology recording) and locomotor function (evaluated from the 
Basso, Beattie and Bresnahan locomotor test), together with cellular changes in the spinal cord 
(evaluated from immunohistochemistry) were investigated. Animals with spinal cord injury were 
separated into hypersensitive and normosensitive subpopulations based on their mechanical 
sensitivity. Daily 30 min 670 nm irradiation (35 mW/cm2) is effective at reducing the chance of 
developing mechanical hypersensitivity following spinal cord injury, as well as reducing the 
mechanical sensitivity in the normosensitive subpopulation from 1-day, and the hypersensitive 
subpopulation from 7-days post-injury. The treatment also improves sensory conduction along 
the dorsal column pathway and accelerates locomotor recovery. These functional improvements 
are accompanied with: an overall reduction of microglial/macrophage activation, but a specific 
increase in the proportion of the anti-inflammatory subtype; reduced astrocyte reactivity; reduced 
iNOS expressing microglia/macrophages; and reduced density of cells undergoing 
apoptosis/necrosis. Together, the findings in this thesis highlight the potential for the use of red 
light as a non-invasive and inexpensive treatment/adjunct therapy for spinal cord injured patients.   
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Spinal cord injury is a devastating condition of the spinal cord resulting from traumatic or 
non-traumatic causes. Traumatic causes include spinal injury from motor accidents, falls, violence 
and sports, while non-traumatic causes include spinal injury from vascular disorders, spinal canal 
stenosis, cancer and infectious conditions. By the end of last decade, there were more than 10,000 
people living with this disease in Australia, with approximately 1 new case every day (Cripps, 
2009; Norton, 2010). These patients, more than 80% being males, suffer from temporary and/or 
permanent loss of sensory, motor, and/or autonomic function. Having the highest incidence in the 
15-24 age group, most patients require lifetime care and support leading to a nation-wide ongoing 
cost of A$500 million per year (Norton, 2010).  
The severity of the symptoms largely depends on the extent of the injury as well as the spinal 
level involved. The extent of injury determines how much function remains. Patients with 
complete spinal cord injury lose all function below the level of the injury while patients with 
incomplete spinal cord injury still have some function remaining below the level of the injury. 
The spinal, or neurological level of the injury, determines the sections of the body that are affected. 
With the highest incidence of cervical spinal cord injury, almost 60% of the patients suffer from 
quadriplegia, either incomplete or complete (Norton, 2010). Quadriplegia is characterised by loss 
of sensorimotor function in all four limbs. Patients with lower level injuries, such as thoracic, 
lumbar or sacral regions, suffer from complete or incomplete paraplegia which is identified as 
loss of sensorimotor function in lower limbs which may include the trunk. The loss of autonomic 
control to the viscera also result in potentially life-threatening complications, such as autonomic 
dysreflexia.  
Unfortunately, recovery in spinal cord injured patients is limited due to the complexity of the 
disease, poor spontaneous recovery, and lack of effective treatments. Patients are usually managed 
with pharmaceuticals to reduce inflammation and muscle spasticity. Medicinal intervention is 
commonly combined with physical therapy to help regain muscle strength. Functional electrical 
stimulation is also used to orchestrate muscle contractions during rehabilitation (Ho et al., 2014). 
New therapies such as stem cell (Doulames and Plant, 2016), injectable hydrogels (Tukmachev 
et al., 2016), and photobiomodulation (Hu et al., 2016) for example, are also under investigation 
and development.  
The current chapter will provide a general review of the literature on spinal cord injury resulting 
from trauma (Section 1.1) and a potential treatment, referred to as photobiomodulation 
(Section 1.2). Lastly, the aim of the project and the structure of this thesis are summarised 
(Section 1.3). 
1.1 Spinal cord injury 
The current section will provide a basic understanding of spinal cord injury including its 
pathophysiology (Section 1.1.1) and common treatment approaches (Section 1.1.2). 
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1.1.1 Pathophysiology of spinal cord injury 
Spinal cord injury is a complex disease. It is commonly characterised into three phases, and these 
phases overlap temporally. The acute phase results from the primary damage of the insult while 
both subacute and chronic phases are due to the secondary damage in the spinal cord. The acute 
phase starts from the time of the injury and usually lasts for seconds to minutes, which is 
immediately followed by the onset of the subacute phase. The subacute phase usually lasts for 
weeks and is followed by the chronic phase which lasts for years (Oyinbo, 2011; Silva et al., 
2014). While the primary injury determines the severity of the symptoms, it is the magnitude of 
the secondary damage that shapes the long-term recovery of the patients. For this reason, 
understanding of the different phases, especially the subacute and chronic phases, are essential 
for the development of effective treatment strategies.  
The primary insult causes mechanical damage to the cells in the spinal cord and the blood-spinal 
cord barrier. Seconds later, the acute phase is underway as the primary event leads to immediate 
ischemia, oedema, and cell death (neural and glial). Loss of ionic homoeostasis and excitotoxicity 
are observed, and a loss of both sensory and motor function, at and below the level of the injury, 
usually ensues. Depending on the level of the injury, autonomic dysfunction is sometimes 
apparent. In response to the injury, resident glial cells are activated to release cytokines into the 
environment, which leads to the subacute phase. The subacute phase is a more complex period. 
Apart from events mentioned above, oxidative stress and pro-inflammatory cytokines result in 
more cell death. Peripheral immune cells are recruited due to the damage of blood-spinal cord 
barrier and signals from resident microglia. This process amplifies inflammation, leading to cavity 
formation and glial scar formation. These two events, together with ongoing neural death, carry 
on into the chronic phase. Limited regeneration is seen as a result of these events; however, 
spontaneous recovery, characterised by remyelination, axonal sprouting, and rewiring due to 
neuroplasticity is also evident. Some sensorimotor function is regained, but this could also result 
in inappropriate connections that may contribute to neuropathic pain. 
It is important to note that the three aforementioned phases overlap with each other. This feature 
makes the pathophysiology of spinal cord injury difficult to understand and challenging to study. 
Therefore, the current section only aims to provide an overview of the current understanding of 
the physiological processes following spinal cord injury. The pathophysiology will be discussed 
in two broad aspects that are relevant to the current thesis: cellular changes in the injured spinal 
cord (Section 1.1.1.1) and systemic functional changes (Section 1.1.1.2). 
1.1.1.1 Cellular changes 
Immediate changes in the cellular environment are observed following spinal cord injury. The 
cellular changes start with vascular changes and disruption of ionic balance and then continue 
with free radical formation and lipid peroxidation. These initial events then lead to prolonged 
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inflammation, cavity formation, Wallerian degeneration and cell death. Although regeneration is 
underway, inhibitors of this process in the spinal cord limit recovery. The current section will 
provide a brief overview of the events following spinal cord injury, which ultimately lead to 
functional deficits.  
Vascular changes 
Spinal cord injury causes immediate and long-term vascular dysfunction both locally and 
systemically. The mechanical insult directly causes damage to the blood-spinal cord barrier, 
leading to haemorrhage. The aggregation of red blood cells and platelets eventually causes local 
thrombosis formation and ischemia (Tator, 1992) while the breakdown of blood-spinal cord 
barrier continues, leading to infiltration of inflammatory cells and oedema (Bareyre and Schwab, 
2003). Systemically, the trauma causes hypotension and bradycardia (Popa et al., 2010). 
Oxidative stress and lipid peroxidation 
Hypoxia and the degradation of haemoglobins can both lead to the production of free radicals 
(Hausmann, 2003; Mautes et al., 2000). These free radicals, namely reactive oxygen and nitrogen 
species (ROS and RNS respectively), such as O2-, OH, and nitric oxide (NO), inhibit or inactivate 
several key metabolic enzymes within the cells that would ultimately exaggerate secondary 
damage (Dumont et al., 2001). They can also react with lipids, nucleic acids, and extracellular 
matrices to cause further damage in the spinal cord (Xu et al., 2005). Lipids, as the main 
constituent of the cell membrane, undergo oxidative degradation (lipid peroxidation), which 
causes membrane lysis and eventually necrotic death (Xiong et al., 2007). The degradation of 
lipids produces reactive aldehyde species such as malondialdehyde and 4-hydroxynonenal, which 
can act as signalling molecules (reviewed in Ayala et al., 2014). Malondialdehyde has also been 
shown to inhibit Na+-K+-ATPase and thus exacerbates ionic imbalance (Arkhipenko Yu et al., 
1985; Ilhan et al., 2001). Free radical formation is a, if not the most, widespread event that leads 
to and carries out secondary damage (Hall and Braughler, 1993). 
Disruption of ionic balance and excitotoxicity 
The mechanical damage disrupts membranes of neurons, which leads to unregulated ionic flux 
(Simon et al., 2009). Following ischemia, Na+-K+-ATPase dysfunction leads to accumulation of 
extracellular K+ and intracellular Na+. This increase in intracellular Na+ stimulates the reverse 
Na+-Ca2+ exchanger, resulting in intracellular accumulation of Ca2+, and thus, activating 
Ca2+-dependent enzymes (Stys, 1998). Excessive Ca2+ causes damage to a variety of cellular 
processes including metabolism and gene expression (Simon et al., 2009). This disruption 
eventually causes cell death. At the same time, high intracellular Na+ induces the Na+-glutamate 
transporters, leading to excessive accumulation of extracellular glutamate. Extracellular 
glutamate not only acts on glutamate receptors on neurons and glial cells, but it also exaggerates 
production of free radicals (Dumont et al., 2001). Glutamate excitotoxicity ultimately causes loss 
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of myelin and loss of neurons (Oyinbo, 2011). Demyelination and neuronal cell death are central 
to the disconnection of the injured spinal cord and consequently functional impairment. 
Inflammatory response 
Upon the initial breakage of blood-spinal cord barrier, neutrophils from the circulatory system 
enter the injured spinal cord immediately (Beck et al., 2010). They are recruited by adhering to 
endothelial cells (Taoka et al., 1997). They remove tissue debris while secreting cytokines and 
free radicals (reviewed in Neirinckx et al., 2014). This change in the microenvironment will then 
activate resident microglia and also recruit monocyte-derived macrophages (Carlson et al., 1998; 
Donnelly and Popovich, 2008). Once activated, these microglia and macrophages secrete 
cytokines, chemokines and ROS into the environment, which magnify inflammatory responses. 
Although inflammation was originally thought to be harmful and cause more damage, recent 
studies have shown that it could help regeneration following spinal cord injury through the 
complex secretory profiles of microglia and macrophages (Allison and Ditor, 2015; David et al., 
2012). These immune cells change their secretory profiles depending on the cellular environment 
and can adopt any phenotype from an extremely pro-inflammatory phenotype to an extremely 
anti-inflammatory phenotype (reviewed in David and Kroner, 2011). Macrophages and microglia 
can be activated by either T helper cell 1 or T helper cell 2. The former is therefore named M1, 
which is the pro-inflammatory phenotype, and the latter is named M2, which is the anti-
inflammatory phenotype (Gordon and Taylor, 2005; Martinez et al., 2009). The M1 phenotype is 
characterised by the secretion of pro-inflammatory cytokines and free radicals such as interferon 
gamma, tumour necrosis factor alpha (TNFα), interleukin-1 beta (IL1β) and NO, while the M2 
phenotype secrets anti-inflammatory cytokines including interleukin-10, transforming growth 
factor beta and interleukin-4. Through their complex secretory profiles, M1 clears up debris by 
phagocytosis but may cause axon die-back while M2 stimulates growth and heals tissue (Kong 
and Gao, 2017). In real-time spinal cord injury, M1 is predominant in the early phase while M2 
is upregulated later (Kigerl et al., 2009). The sequence timing of this M1 and M2 is essential to 
the recovery as the debris needs to be removed first before axonal regeneration. Any manipulation 
that disrupts this order may worsen the injury (Klusman and Schwab, 1997). A balanced and 
controlled inflammation might be the key to successful functional recovery. 
Cavity and scar formation 
Activated microglia/macrophages clear debris in the injury epicentre and therefore form a cavity. 
Astrocytes are activated in response to microglia/macrophage activation (Popovich et al., 1997). 
Similar to microglia/macrophage, astrocytes secrete several cytokines including IL1β, which has 
an important role in pain (reviewed in Ji et al., 2013). Once activated, astrocytes undergo 
hypertrophy and proliferation, a process named gliosis (reviewed in Silver and Miller, 2004). 
Sequel to this, astrocytes produce more intermediate filaments (Fitch and Silver, 2008). Together 
with activated microglia/macrophages and extracellular matrices, they form glial scars around the 
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cavity acting as a physical barrier for the regenerating axons. Chondroitin sulphate proteoglycan, 
heavily involved in glial scar formation (Fawcett and Asher, 1999), is believed to inhibit axonal 
sprouting (Zuo et al., 1998); therefore, providing a chemical barrier for regeneration. However, 
not all parts of gliosis and scar formation are detrimental. Depletion of astrocytes leads to 
increased inflammation, failure of vasculature repair, worsened functional recovery (Faulkner et 
al., 2004; Okada et al., 2006). These studies suggest an essential role of astrocytes and gliosis in 
the pathophysiology of spinal cord injury. A controlled gliosis and cavity formation would be 
beneficial to the recovery.  
Cell death 
Cell death following spinal cord injury occurs through various processes. The first cause is the 
disruption of the cell membrane, either through direct mechanical insult or lipid peroxidation. 
Cells, especially neurons and neuroglia, also die from excitotoxicity due to the excessive Ca2+ 
influx (Simon et al., 2009; Xiong et al., 2007). Excessive Ca2+ triggers a cascade of events, 
including the activation of calpain and caspase. These two enzymes then degrade membranes, 
cytoskeletons and nuclear substrates (Ray et al., 2003). Energy depletion due to hypoxia and 
mitochondrial dysfunction from ROS and RNS also cause cell death. Decreased production of 
ATP leads to the dysfunction of ion channels and therefore exaggerates Ca2+-triggered cell death 
(Boutilier, 2001). In addition, inflammatory cells also contribute to cell death through their 
secretions, and therefore, inducing apoptosis (Shuman et al., 1997). Apart from local cell death, 
neurons and oligodendrocytes distal to the injury epicentre are also subjected to death due to 
severing of axons and/or degeneration of myelin (Casha et al., 2001). 
Wallerian degeneration and demyelination 
Primary damage to the spinal cord results in the severing of axons, loss of myelination, loss of 
neurons and loss of oligodendrocytes at the injury epicentre. Loss of oligodendrocytes at the 
injury epicentre leads to further demyelination. Demyelination poses two main detrimental effects 
depending on the time frame. Acutely, it slows down conduction along the nerve fibres leading 
to delays or conduction block (Hall and Traystman, 2009; McTigue, 2008). In the long term, 
axons, without the protection of myelin, are more susceptible to degeneration, which ultimately 
leads to more neuronal loss (Oyinbo, 2011). In vivo imaging showed both proximal and distal 
axonal degeneration (hundreds of µm) 30 min following spinal cord injury, and this degeneration 
is similar to the delayed Wallerian degeneration in distal disconnected axons (Kerschensteiner et 
al., 2005). This ongoing degeneration and demyelination might be due to apoptosis (Crowe et al., 
1997). Therefore, therapies that target cell death may weaken or even stall degeneration and 
demyelination. 
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Regeneration 
Limited regeneration is observed following spinal cord injury due to two main reasons: the limited 
endogenous regenerative ability of central nervous system (CNS) neurons and the presence of 
various inhibitors in the cellular microenvironment (Lee and Zheng, 2008). Up-regulation of 
intrinsic growth factors is limited in CNS neurons (Huebner and Strittmatter, 2009). In fact, axons 
can start to regenerate 6 hours after injury (Kerschensteiner et al., 2005). Some of them may form 
correct connections due to neural plasticity through collateral sprouting (Onifer et al., 2011). The 
rest will fail due to the lack of navigation and the presence of inhibitors. Endogenous 
oligodendrocyte progenitor cells are also attracted to the injured site for remyelination, but most 
fail to do so, also due to the presence of inhibitors (Levine et al., 2001). These inhibitors are 
mainly present in the myelin or the glial scar. Chondroitin sulphate proteoglycan, secreted by 
reactive astrocytes, is the main inhibitor (reviewed in Morgenstern et al., 2002; Siebert et al., 
2014). It has been shown to inhibit both neurite growth and oligodendrocyte progenitor cells 
(Fawcett and Asher, 1999; Siebert and Osterhout, 2011). Another important inhibitor is Nogo-A, 
which is present in the myelin. Together with other myelin-associated inhibitors, Nogo-A inhibits 
axonal growth (Huebner and Strittmatter, 2009). An increase of the regenerative ability of neurons 
and oligodendrocytes and removal of inhibitors would be largely beneficial to the long-term 
regeneration following spinal cord injury. 
These above-mentioned events cause immediate and prolonged changes in the cellular 
environment which lead to functional deficits.  
1.1.1.2 Functional deficits 
Sensory and motor function of the periphery is maintained and controlled by the spinal cord. Upon 
spinal cord injury, functional deficits may occur in motor control and/or sensory feedback. Pain 
(Page 11) is also present and can persist following spinal cord injury (in > 50% of patients). Spinal 
cord injured patients may also suffer from autonomic dysfunction and paralysis/paresis at, and 
below, the neurological level of injury. Some cardiovascular and respiratory dysfunction can be 
life-threatening in the acute phase, and some of these symptoms may continue into the chronic 
phase (reviewed in Karlsson, 2006). The current section will only focus on the somatic system by 
providing an overview of the arrangement of the motor and sensory pathways, and changes to 
these pathways following spinal cord injury. 
Motor pathways and functional deficits 
The motor pathways (Figure 1.1) are responsible for both voluntary (corticospinal and 
corticobulbar tracts) and involuntary (extrapyramidal tracts) movement of all skeletal muscles in 
the body. All motor tracts consist of upper motor neurons which communicate indirectly, via 
interneurons or rarely via direct contacts with lower motor neurons that reside in the brainstem or 
spinal cord. 
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The corticospinal tract originates from the primary motor cortex, the premotor cortex, the 
supplementary motor area, and other regions including the somatosensory cortex (Bear et al., 
2001). The upper motor neurons of this tract converge and travel through the internal capsule and 
into the medulla where they divide into lateral (~90%) and anterior (~10%) tracts (Purves, 2012). 
Upper motor neuron in the lateral tract decussates in the pyramids of the caudal medulla and 
terminates in the spinal cord, where it synapses via interneurons or directly with lower motor 
neurons in the ventral horn. The lower motor neuron then synapses onto muscles to deliver fine-
motor control of the limb muscles (Mendoza and Foundas, 2007). The anterior tract travels 
straight into the spinal cord and arrives at the medial region of the ventral spinal level. The upper 
motor neuron then decussates and synapses via interneurons or directly with lower motor neurons 
in the contralateral ventral horn. The lower motor neurons then synapses onto muscles to control 
movement of the trunk and proximal musculature (Mendoza and Foundas, 2007). The 
corticobulbar tract originates from similar regions as the corticospinal tract and travels to the 
brainstem, where it generally synapses bilaterally (with the exception of the lower face which 
have no ipsilateral projections) with brainstem lower motor neuron at various levels to control 
muscles of the face and the neck (Young et al., 2008). The corticobulbar tracts are not involved 
in spinal cord injury. 
Upper motor neurons of the extrapyramidal tracts originate in the brainstem and mainly include 
the vestibulospinal, reticulospinal, rubrospinal, and tectospinal tracts (Costanzo, 2014). They are 
responsible for reflex/involuntary activity in skeletal muscles and subsequent movement. Most 
upper motor neurons of the vestibulospinal and reticulospinal tracts terminate in the ipsilateral 
spinal cord, where they synapse via interneurons or directly with lower motor neurons to control 
the posture of (mainly) the ipsilateral muscles (Fitzgerald et al., 2012). The rubrospinal tract 
originates in the red nucleus of the midbrain and decussates. These upper motor neurons travel 
into the spinal cord contralaterally where they synapse with lower motor neurons in the ventral 
horn. The function of rubrospinal tract remains controversial in humans (Cramer and Darby, 
2014). The tectospinal tract originates from the superior colliculus of the midbrain and decussates 
before the upper motor neuron synapses with the lower motor neurons in the ventral horn of upper 
cervical spinal cord. The tectospinal tract controls the movement of the head in relation to visual 
stimuli (Rea, 2015). 
There are a number of differences in motor pathways between human and rodents. The most 
obvious differences are the composition and the location of corticospinal tracts. In rodents, 
corticospinal tracts consist of the dorsal tract, the anterior tract and the dorsolateral tract. The 
dorsal corticospinal tract in rodents, equivalent to the lateral corticospinal tract in human, is the 
main component and is situated in the ventral aspect of the dorsal column. The anterior 
corticospinal tract in rodents is similar to the anterior corticospinal tract in human, situated in the 
ventral part of the spinal cord. The dorsolateral corticospinal tract is a unique feature in rodents 
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(Steward et al., 2004). Its axons diverge from the dorsal corticospinal tract at the pyramidal 
decussation and essentially travel along the dorsolateral column. Its function remains unclear 
(Steward et al., 2004). The other distinct features of motor pathways in rodents are the location 
and the significance of rubrospinal tract. The rubrospinal tract travels laterally and dorsally to the 
dorsolateral corticospinal tract in the spinal cord in rodents (Morris et al., 2011) whereas it travels 
ventrally to the lateral corticospinal tract in humans. In addition, function of the rubrospinal tract 
in rodents is suggested to be homologous to the corticospinal tract in humans (Küchler et al., 
2002). There is evidence showing that the size of rubrospinal tract regress from quadruped (e.g. 
some rodents) to biped (e.g. human), which is related to improved corticospinal tract for fine 
motor control of the forelimbs (ten Donkelaar, 1988). 
After spinal cord injury, neuronal death, axonal degeneration, and demyelination in the spinal 
cord can affect signal transduction along all of these pathways and therefore causing motor 
deficits. Neuronal death in the motor cortex has also been associated with impaired motor function 
(Lee et al., 2004). Around 70% of  patients with injured spinal cords suffer from spasticity, which 
is defined as an increase in muscle tone (reviewed in Adams and Hicks, 2005). As motor function 
relies on sensory feedback, motor deficits are compounded by sensory deficits. 
 
 
Figure 1.1 Organisation of the main motor pathways. 
Schematic of motor pathways showing key components and locations of synapses. Motor neuron 
synapses (mono- or poly-synaptic) are located at the arrowheads. 
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Sensory pathways and functional deficits 
There are three main spinal pathways that receive sensory information from the periphery and 
send it to the brain; the dorsal (posterior) column pathway, anterolateral system and the 
spinocerebellar pathways (Figure 1.2).  
Conscious somatosensory information is transmitted either through the dorsal columns or the 
anterolateral system. Posterior columns are responsible for the perception of fine touch, pressure, 
vibration and proprioception. First order neurons arise from the periphery, enter from the dorsal 
roots and ascend via the dorsal columns. Sensory information from the upper limbs travels in the 
cuneate fasciculus, while that from the lower limbs travels in the gracile fasciculus (Johns, 2014). 
These neurons terminate in the medulla oblongata in the dorsal column nuclei, where they synapse 
onto second order neurons in the cuneate and gracile nuclei respectively. The second order 
neurons cross the midline, then synapse contralaterally with third order neuron in the thalamus, 
after which signals are sent to the primary somatosensory cortex (Goetz, 2007).  
The anterolateral system can be simplified into three main pathways: spinothalamic, 
spinoreticular, and spinomesencephalic tracts (Yaksh and Luo, 2007). Spinothalamic tract carries 
pain/temperature and crude touch/pressure sensations (Rea, 2015). First order neurons enter the 
dorsal horn and immediately synapse with second order neurons. The second order neurons in the 
dorsal horn send their axons to the contralateral side of the spinal cord, then ascend along the 
anterolateral tract to synapse with the third order neuron in the thalamus. These third order neuron 
share some of the same thalamic region as the dorsal column pathway, and also send information 
to the cortex. The first order neurons in the spinoreticular tract and the spinomesencephalic tract 
share the same trajectory as those of the spinothalamic tract (Mai and Paxinos, 2011). The second 
order neurons then decussate and terminate in either the reticular formation of the medulla and 
pons (spinoreticular tract), or the periaqueductal grey in the midbrain (spinomesencephalic tract). 
The spinoreticular tract carries nociceptive signals from tissue injury and is likely to be involved 
in overall arousal (Darby and Frysztak, 2014; Sengul and Watson, 2012). The 
spinomesencephalic tract is involved in descending pain modulation and may be involved in the 
emotional component of pain (Patestas and Gartner, 2016). 
Unconscious proprioceptive information from muscle spindles and Golgi tendons is transmitted 
to the ipsilateral cerebellum via the spinocerebellar tracts (Rea, 2015). It is organised into a 
two-neuron system; the first order neuron receives peripheral input and enters the spinal cord 
through dorsal roots to synapse with the second order neuron in the dorsal horn. The second order 
neuron either sends axons to the ipsilateral, or contralateral spinocerebellar tracts (dorsal and 
ventral spinocerebellar tracts respectively). The second order neuron of the ventral 
spinocerebellar tract decussates twice; at the spinal cord level, then again above the cerebellum, 
thus both of the dorsal and ventral spinocerebellar tracts eventually terminate in the ipsilateral 
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cerebellum. While these two tracts serve the lower limbs, the cuneocerebellar tract receives inputs 
from the upper limbs (Rea, 2015).  
Following spinal cord injury, axonal demyelination largely affects sensory transduction along 
these sensory tracts (Hu et al., 2011). Spinal cord injured patients may suffer disturbance of senses 
at and below the level of injury (Lenggenhager et al., 2012) while many may also develop 
devastating pain conditions (reviewed in Finnerup, 2017). Spontaneous recovery in sensations 
has been demonstrated (reviewed in Dietz and Fouad, 2014), which is likely to be due to plasticity 
at both the spinal and the supraspinal levels (Reed et al., 2016). 
 
 
Figure 1.2 Organisation of the main sensory pathways.  
Schematic of sensory tracts showing key components and locations of synapses. Sensory neuron 
synapses are located at the arrowheads. 
 
Pain 
Pain following spinal cord injury can be broadly classified into two main categories: nociceptive 
and neuropathic. Nociceptive pain occurs when there is tissue damage or inflammation. In the 
case of spinal cord injury, it is due to damage to the spinal cord, the vertebral column and overuse 
of certain muscles during rehabilitation. This type of pain normally disappears after the tissue is 
healed and responds well to physical therapy, non-steroidal anti-inflammatory drugs (NSAIDS), 
and exercise (Costigan et al., 2009; Masri and Keller, 2012). Neuropathic pain, on the other hand, 
is more complicated and is resistant to conventional treatment (Baastrup and Finnerup, 2008). 
This pain is usually long lasting, and its clinical manifestation can be either increased pain 
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response to noxious stimuli (hyperalgesia) or pain response to innocuous mechanical or thermal 
stimuli (allodynia) (Finnerup et al., 2009). Both allodynia and hyperalgesia exist above the level 
of the injury, at the level of the injury (2-4 segments surrounding the level of the injury), and 
below the level of the injury (Masri and Keller, 2012). Many studies have endeavoured to 
understand the mechanism behind chronic pain conditions following spinal cord injury (reviewed 
in Finnerup et al., 2009; reviewed in Masri and Keller, 2012). Changes in the spinal cord, and at 
the supraspinal level, have been associated with the development and the maintenance of 
neuropathic pain. Some of the mechanisms will be explored below. 
Changes at the spinal cord level are mostly due to central sensitization and spinal cord plasticity 
(Zhuo et al., 2011). Hyperexcitable neurons arise from both increased excitability and decreased 
inhibition. Increased excitability may result from ionic imbalance which leads to depolarization 
(Gwak et al., 2012). Extracellular glutamate accumulation (McAdoo et al., 1999) and reduced 
GABA inhibition (Drew et al., 2004; Drew et al., 2001) may also contribute to increased neural 
activity. Apart from neuronal changes, both microglia and astrocytes have been suggested to play 
essential roles in this process, as they are responsible for recycling neurotransmitters and 
monitoring cellular environments in the spinal cord (Gwak et al., 2012). Some cytokines and 
molecules secreted by microglia and astrocytes, e.g. IL1β, TNFα, and NO have been suggested 
to modulate both presynaptic and postsynaptic terminals to enhance synaptic communication 
between neurons (Hulsebosch et al., 2009). Abnormal connections resulting from intraspinal 
sprouting during regeneration has been demonstrated. Primary tactile afferents form connections 
with demyelinated spinothalamic tract, thus leading to the generation of pain sensation from 
normally innocuous stimuli (Christensen and Hulsebosch, 1997). Maladaptive forms of activity-
dependent plasticity, through alterations of NMDA and AMPA receptors, are also a major player 
in neuropathic pain (Zhuo et al., 2011). In fact, a contusion injury induces more pain than a hemi-
section injury (Christensen and Hulsebosch, 1997). This again suggests that intraspinal sprouting 
in tracts that remained in a contusion injury, maybe largely responsible for the development of 
pain. 
Changes at the supraspinal level, that include anatomical and physiological alterations, have also 
been observed in the thalamus and the cortex (Gustin et al., 2010; Wrigley et al., 2009). The 
degrees of the changes in these regions are correlated with the intensity of ongoing pain. Using 
magnetic resonance imaging, Pattany and colleagues (2002) found that decreased N-acetyl and 
increased myo-inositol in the thalamic region were correlated with pain in patients following 
spinal cord injury. N-acetyl is a marker reflecting dysfunction of inhibitory neurons, while myo-
inositol is a marker for glial activation (Finnerup et al., 2009). Disinhibition in the thalamus is 
also thought to alter the firing properties of the neurons, leading to spontaneous firing and evoked 
bursts (Weng et al., 2000). Thalamic microglial activation through cysteine-cysteine chemokine 
ligand 21 has been associated with neuropathic pain following spinal cord injury (Zhao et al., 
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2007). Apart from the thalamus, changes in the cortex have also been associated with pain. 
Cortical expression of endogenous opioid precursors, such as preproenkephalin and 
preprodynophin, was found to be increased in animals with pain behaviour following spinal cord 
injury (Abraham et al., 2001). The increase in endogenous opioid precursors is most obvious in 
the anterior cingulate cortex and the parietal cortex. Together, spinal and supraspinal changes lead 
to neuropathic pain following the injury, which is mainly due to increased activity and reduced 
inhibition. 
1.1.2 Current treatment for spinal cord injury 
Spinal cord patients are often admitted to hospitals as soon as possible to receive surgery (Section 
1.1.2.1). They are usually prescribed medications to address the various complications following 
spinal cord injury (Section 1.1.2.2). A combination of different activities is performed as part of 
the rehabilitation process to help regain sensorimotor function (Section 1.1.2.3). However, most 
of the current therapies are not very effective, and patients suffer from long-term sensory and 
motor deficits. To date, there is no ‘cure’ for spinal cord injury, however, new therapies are 
constantly under development, some of which will be briefly addressed below (Section 1.1.2.4). 
Most of these new therapies target the secondary damage (subacute and chronic phases) which 
shapes the long-term functional recovery. Some of them are quite versatile and therefore can be 
used in combination with other therapies. 
1.1.2.1 Surgical intervention 
Spinal cord injury patients receive surgical intervention to stabilise and decompress the damaged 
spinal cord. By doing this, clinicians hope to minimize secondary damage to the spinal cord and 
improve functional recovery. This practice aims to mitigate ischemia and pressure-related cell 
death, and is based on various studies using animal models (Delamarter et al., 1995; Dimar et al., 
1999). However, some studies have criticised the validity and benefit of this widely practiced 
procedure in clinical settings. The main area of debate relates to the timing of surgical procedures 
(reviewed in Raslan and Nemecek, 2012). 
To date, there is no consensus on the timing of surgical intervention following spinal cord injury. 
Some patients received surgeries within the first 24 hours while others received surgeries later, at 
2, 3, or more than 5 days post-injury (Furlan et al., 2011). Due to a better understanding of the 
injury mechanism and the idea of secondary damage (Section 1.1.1.1), some have suggested a 
‘time window’ for surgical intervention to prevent further secondary injury. However, secondary 
damage overlaps with primary damage temporarily; making it difficult to study the onset and 
determine the ‘time window’. Some studies, both pre-clinical and clinical, have suggested that 
early surgical intervention, between 8 to 24 hours, is beneficial for functional recovery (Furlan et 
al., 2011). However, other studies have concluded that there is no significant benefit of receiving 
early surgical interventions, as compared to late ones (Carlson et al., 1997; Fehlings and Wilson, 
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2010). This inconsistency is likely due to an incomplete understanding of the cellular mechanism 
and variability in injured individuals in terms of injury severity and complications. 
1.1.2.2 Pharmaceutical interventions 
A cocktail of different pharmaceutics is typically prescribed due to the complexity of spinal cord 
injury. These drugs address autonomic dysfunction, spasticity, pain, and depression. In patients 
with cervical or higher thoracic injuries, drugs controlling the heart rate and blood pressure are 
often used to treat any dysfunction in the autonomic nervous system. Muscle relaxant and 
anti-spastic drugs might be given to patients suffering from muscle spasms. Patients who 
experience pain are often given NSAIDS, narcotics, anti-depressants, and gabapentin. While 
medications for autonomic dysreflexia, spasticity, and depression are rather effective, pain-related 
drugs lack efficacy, especially in the case of neuropathic pain.  
To date, there is only one drug being prescribed in clinical practice to provide neuroprotection 
and improve functional recovery (Ahuja and Fehlings, 2016); this synthetic glucocorticoid, called 
methylprednisolone (MP), was first used in the 1970s but still attracts controversy. MP was found 
to reduce lipid peroxidation and enhance neuronal survival (Fehlings et al., 2014). The first 
multicentre, double-blind, randomised clinical trial, carried out almost four decades ago, showed 
no significance difference between MP and control groups in motor and sensory function at 6 
weeks and 6 months post-injury (Bracken et al., 1984). It was later suggested that the dose of MP 
administered in the study was not high enough, which led to a second clinical trial. The same 
group then reported, 6 years after the first trial, that patients who had received MP within 8 hours 
had significantly better motor function than the control group (Bracken et al., 1990). This trial, 
together with the third trial, made MP to be the most commonly prescribed medicine despite its 
consistent adverse effects, such as increased wound infection and gastrointestinal bleeding 
(Chappell, 2002). However, in 2013, the use of MP began to be discouraged as new investigations 
began into its therapeutic and adverse effects (Hurlbert et al., 2013). Currently, other drugs that 
act on some of the cellular changes are in preclinical and clinical trials, which will be addressed 
under ‘Molecular therapy’ in Section 1.1.2.4. 
1.1.2.3 Rehabilitation 
Since there is no ‘cure’ for spinal cord injury, the main purpose of rehabilitation is to regain 
muscle strength and promote neuromuscular plasticity. Physical therapy includes a variety of 
activities which commences days or weeks following the injury (reviewed in Harvey, 2016). The 
main purpose of physical therapy is to strengthen muscles that are still innervated and maximise 
independence with tasks such as bed mobility, wheelchair, and transfers (Taylor-Schroeder et al., 
2011). Locomotor training, mainly on a treadmill, could be assisted with braces, robotics, and 
functional electrical stimulations of certain muscles (Mehrholz et al., 2012). Both physical 
training and functional electrical stimulation have been shown to partially restore motor function 
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due to neural plasticity (Onifer et al., 2011). However, these training strategies have not been 
shown to help the loss of sensation (Larson and Dension, 2013). Apart from these, electrical or 
magnetic brain stimulations, transcutaneous electrical nerve simulations, acupuncture and self-
hypnosis have been investigated for alleviating pain associated with spinal cord injury (reviewed 
in Boldt et al., 2014). However, none has proven to be significantly beneficial in terms of pain 
relief.  
1.1.2.4 Novel therapies 
Since current treatment strategies cannot provide long-term functional benefits following spinal 
cord injury, a variety of novel strategies have been investigated with the aim to repair the injured 
spinal cord. The two main areas of research are cellular therapy and molecular therapy. Most of 
these cells target the secondary damage following the injury to improve regeneration. 
Cellular therapy 
Cellular therapy involves the transplantation of different cells into the injured spinal cord. These 
cells mainly fall into two categories: stem cells and glial cells (reviewed in Tetzlaff et al., 2011). 
These cells are either directly injected into the injured spinal cord or with some aid such as 
hydrogels (Assuncao-Silva et al., 2015). Stem cells, including neural, mesenchymal, embryonic 
and induced pluripotent types, may be injected into the spinal cord directly or after in vitro 
pre-differentiation. These cells are capable of differentiating into neurons and glial cells. They 
are applied so that the damaged/lost cells in the spinal cord can be replaced. However, unclear 
cellular mechanisms, safety issues, and ethical concerns have halted the progress of stem cell 
therapy in clinical trials (Silva et al., 2014). The other cells used in cell transplantation are glial 
cells, which include olfactory ensheathing cells and Schwann cells. These cells are injected into 
the spinal cord to provide a better cellular environment for regeneration. Olfactory ensheathing 
cells and Schwann cells are known to assist axonal regeneration through removal of axonal debris, 
secretion of neurotrophic factors, and production of extracellular matrix (Oudega and Xu, 2006). 
More preclinical studies are required due to limited efficacy and evidence in clinical trials.  
Molecular therapy 
Molecular therapy involves the administration of compounds that could potentially improve 
recovery by altering the inflammatory response, blocking inhibitors, and promoting generation. 
Unfortunately, many of these therapies exhibit inconsistent efficacy and contradictory results.  
Molecules such as interleukin-10, minocycline, and riluzole have been demonstrated to alter 
inflammation; they have thus been used to treat spinal cord injury. Interleukin-10 has been tested 
in animal models due to its ability to inhibit the production of TNFα (Bethea et al., 1999). 
Minocycline, currently in phase III trial, is believed to inhibit microglial activation and prevent 
apoptosis (Heo et al., 2006; Stirling et al., 2005). Riluzole, also in phase III trial, is a sodium 
channel blocker, which indirectly stimulates glutamate uptake and reduces neurotoxicity (Azbill 
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et al., 2000). To overcome inhibition in the cellular environment, drugs that target the myelin and 
the extracellular matrix have been studied. Nogo-A, a protein in the myelin that inhibits axonal 
growth (Caroni and Schwab, 1988), can be targeted using an anti-Nogo antibody or antagonist 
NEP 1-40. Both have been shown to promote axonal growth or even functional recovery 
(Bregman et al., 1995; GrandPre et al., 2000). The molecule that is present in the extracellular 
matrix, chondroitin sulphate proteoglycan, is believed to inhibit axonal regeneration (Zuo et al., 
1998). Degradation of the molecule by chondroitinase ABC has been shown to improve motor 
function following spinal cord injury in an animal model (Tester and Howland, 2008). Apart from 
these, neurotrophic factors are also under investigation for potential regeneration benefits. Nerve 
growth factor, brain-derived neurotrophic factor, neurotrophin-3, glial cell-derived neurotrophic 
factor all have been demonstrated to promote axonal sprouting but they seem to have a differential 
selectivity in different axons (Grill et al., 1997; Kwon et al., 2002; Ramer et al., 2000; Tuszynski 
et al., 2003). This differential selectivity may be due to the differences in high-affinity tyrosine 
kinase receptors in different neurons (Miller and Kaplan, 2001). Therefore, it is difficult to decide 
on the proportion of each neurotrophin in the cocktail to reach the desired outcome.  
1.1.3 Remarks 
Spinal cord injury is a complex disease that requires a better understanding of the injury 
mechanisms. This situation limits the development of efficient treatment strategies for patients. 
As a result, patients suffer from life-long sensorimotor deficits, which cause not only tremendous 
mental stress on the patients and their families/carers, but moreover, represents a massive 
economic cost to their families and society. While primary damage is unlikely to be altered, 
secondary damage needs to be targeted for developing effective treatments. The next section (1.2) 
will focus on a potential treatment that has been shown to alter the immune response and improve 
recovery in several other injury models. 
1.2 Photobiomodulation 
Photobiomodulation (PBM) is defined as the modulation of cellular functions to provide clinical 
benefits by light irradiation using laser or light emitting diodes (LED). Since its first discovery 
by Professor Endre Mester in 1968 (Mester et al., 1968), and subsequently its popularisation by 
NASA in the 1970s, PBM using red (620-700 nm) to near infrared (NIR; 700-1400 nm) light has 
been extensively studied across a variety injury domains including wound healing, tissue repair, 
inflammation, and, more recently, in neuronal injuries and disease. Despite a large volume of 
studies over the past 40 years, PBM still has not become part of the mainstream treatment. This 
is probably due to inconsistent results from animal experiments and clinical trials which have led 
to a general suspicion of its beneficial effects.  
Variability of treatment strategies is a likely contributor to inconsistent findings from PMB 
investigations. A review by AlGhamdi et al. (2012) suggested that the energy density needs to be 
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in the range of 0.5-4 J/cm2 at the cellular level in order to provide clinical benefits. This energy 
density (in ‘J/cm2’ or equivalent) is determined by the irradiance at the cellular site (in ‘W/m2’ or 
equivalent) and the duration of irradiation (in ‘s’ or equivalent). While the time of irradiation can 
be easily managed, the irradiance can be quite variable. The irradiance at the cellular site depends 
not only on the radiosity of the treatment unit (in ‘W/m2’ or equivalent) but also the degree to 
which light can penetrate thorough obscuring layers to the underlying tissues of interest 
undergoing treatment. In fact, the amount of penetration is the key challenge in optimising 
treatment strategies. 
Another contributing factor to the poor acceptance of PBM as a treatment is the poor 
understanding of its mechanism(s) of action. Despite many investigations since the 1980s, the 
cellular pathways leading to purported benefits remain to be fully elucidated. While some 
suggestions about the mechanism were made in the 1990s (Friedmann et al., 1991), it was not 
until more recently that studies have explained possible mechanisms in more detail (reviewed in 
de Freitas and Hamblin, 2016).   
The current section will first discuss the factors affecting light penetration (Section 1.2.1), 
focusing mainly on the photobiological properties of human tissues. A review of PBM 
mechanisms (Section 1.2.2), including both well-evidenced conclusions and other hypotheses will 
follow, and finally, the effects of PBM in different injuries/diseases will be discussed (Section 
1.2.3). This section includes both clinical and preclinical studies.  
1.2.1 Factors affecting penetration 
The amount of energy or the number of photons delivered to the targeted cellular level is 
dependent on many factors. When light hits any biological tissue, it can be either scattered or 
absorbed. The amount scattered will eventually be either absorbed or escape. The quantity of 
‘escaped’ photons is commonly referred to as penetration. Penetration, therefore, reflects the 
amount of attenuation by both absorption and scattering, given the energy input.  
This section will discuss the optical properties of common human tissues, in terms of both 
scattering (Section 1.2.1.1) and absorption (Section 1.2.1.2). A clear understanding of the fate of 
photons that are delivered to tissues is essential to facilitate decisions on light treatment 
parameters necessary to estimate the amount of light reaching the targeted cellular site.  
1.2.1.1 Scattering 
Scattering is a physical process where any form of radiation deviates from the original trajectory 
when passing through a medium. The scattering coefficient (µs), expressed as cm-1, is often used 
to describe the attenuation caused by scattering in a particular medium. The attenuation is 
dependent on a number of factors such as the wavelength of incident light and the medium 
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microstructure. A large scattering coefficient indicates a medium that is ‘prone’ to scattering, and 
therefore more attenuation.  
With PBM, the light must pass through different tissue layers before reaching the target site. These 
layers may include the skin, adipose tissue, muscle, bone, connective tissue, and blood/lymphatic 
tissue. While the scattering coefficient of connective and blood/lymphatic tissue is intricate to 
estimate, that of skin, adipose tissue, muscle, and bone have been well studied. By integrating 
decades of research, Jacques (2013) modelled the scattering coefficient for the major tissues in 
the human body ranging from UV to NIR light (roughly 250-2000 nm). A decreased scattering 
coefficient is observed with a longer wavelength, regardless of tissue type. All scattering 
coefficients are between 1 and 200 cm-1. Skin generally has the largest scattering coefficient 
(4-200 cm-1); that of muscle (1-60 cm-1), bone (4-50 cm-1), and adipose tissue (4-30 cm-1) are very 
similar across the spectrum. Since scattering coefficients of the above-mentioned tissue types are 
within the same order of magnitude, these tissues could therefore be considered as a homogenous 
medium in terms of scattering. 
1.2.1.2 Absorption 
When irradiation enters a medium, chromophores present in the medium absorb photons of 
specific wavelengths, and thereby attenuate the incident light. The absorption coefficient (µa) is, 
therefore, derived to describe the extent of attenuation in cm-1. The absorption coefficient is 
dependent on a number of factors such as the presence of chromophore, the 
wavelength-selectivity of chromophore and the abundance of chromophore. The larger the 
absorption coefficient, the more light is attenuated.  
There are a variety of endogenous chromophores in the human tissue, and the major ones are 
melanin, water, oxygenated and deoxygenated haemoglobins (HbO2 and HbR respectively), 
oxygenated and deoxygenated myoglobins (MbO2 and MbR respectively), and lipids. Each of 
these chromophores has distinctive patterns of absorption across the range of visible to NIR light 
(400-1800 nm; Figure 1.3). Melanin generally has the highest absorption coefficient across the 
range, starting from 103 cm-1 and gradually decreasing to the 101 cm-1 range around 1800 nm. 
Water, on the other hand, starts in the 10-4 cm-1 range and gradually converges with melanin from 
around 1400 nm. Lipids, displaying a pattern similar to water, start from around 10-2 cm-1 and 
gradually increase to 10-1 cm-1 with two local peaks at around 900 nm and 1200 nm. Both HbO2 
and HbR start with a high absorption coefficient in the 103 cm-1 range at 400 nm and dramatically 
decrease to the 100 cm-1 range at 1000 nm. The two chromophores have almost identical 
absorption coefficients from 400 nm to almost 600 nm, with a global peak around 440 nm, a local 
valley at 480 nm, and a local peak around 550 nm. HbO2 has a distinctive drop in its absorption 
coefficient just before 700 nm and then plateaus from around 800 nm. The two myoglobins, on 
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the other hand, have much smaller absorption coefficients compared to the haemoglobins. Their 
coefficients fluctuated within the 10-1 cm-1 range, and the two were almost inseparable.  
 
 
Figure 1.3 Absorption coefficient of major chromophores in the human body.  
Absorption coefficient in cm-1 of water, melanin, lipid, oxygenated haemoglobins (HbO2), 
deoxygenated haemoglobins (HbR), oxygenated myoglobins (MbO2), and deoxygenated 
myoglobins (MbR). Shaded area indicates the proposed optical window for photobiomodulation. 
Figure adapted from Beard (2011), Yao and Wang (2014), and Dean-Ben et al. (2017). 
 
By studying the pattern in the absorption coefficient of these chromophores, an ‘optical window’ 
has been proposed, within which the ‘maximum’ light penetration can be achieved. It starts 
around 650 nm when the absorption coefficient of HbO2 and HbR starts to drop below the 101 cm-1, 
and ends around 1200 nm, when the absorption coefficient of water starts to rise to 100 cm-1 in 
magnitude. Within this range, melanin still has the highest absorption coefficient amongst all the 
major chromophores. This phenomenon has led to various studies investigating the absorption 
coefficient and light penetration in different skin-toned participants. By combining absorption 
coefficient studies on melanin-free epidermis (Saidi, 1992), and melanosomes (Jacques and 
McAuliffe, 1991), Jacques (1998) proposed a function to calculate the absorption coefficient of 
different skin-toned people across a range of wavelengths. Using the average volume fraction of 
the epidermis occupied by melanosomes (fmel), one can construct an absorption coefficient graph 
in light (fmel = 3.5%), medium (fmel = 13.5%), and dark (fmel = 16%) skin-toned individuals (Figure 
1.4). Over the range of the optical window, the absorption coefficient of different skin tones 
ranged between 102 cm-1 and 100 cm-1. The absorption coefficient of dark skin was ten times 
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greater than that of the light skin, while that of the medium skin is somewhere in between. A more 
recent study (Saager et al., 2015) used spatial frequency domain spectroscopy to study the 
absorption coefficient of different skin-toned individuals in vivo. They recruited participants that 
fell into all six categories of Fitzpatrick skin types, which is a numerical scale used to classify 
skin colours (Fitzpatrick, 1988). They found that the volume fraction of the epidermis occupied 
by melanosomes (fmel) ranged from 5% to 20%, which was similar to Jacques’ study. However, 
they found a much smaller difference between the different Fitzpatrick skin types, suggesting that 
the effect of melanin concentration could almost be ignored in the red to NIR range. 
 
 
Figure 1.4 Absorption coefficient of human skin.  
Absorption coefficient (cm-1) of different skin tones showing both theoretical values and 
measured values. Dashed lines are theoretical values calculated using the equation suggested by 
Jacques (1998), assuming 3.5%, 13.5%, and 16% of epidermidis volume occupied by 
melanosomes in light, medium, and dark skins respectively. Solid lines are measured absorption 
coefficient in vivo in Fitzpatrick skin types II, IV, and VI participants (Saager et al., 2015). The 
reported volume fraction of melanosomes in these participants were around 6%, 11%, and 16% 
in Fitzpatrick skin types II, IV, and VI respectively. Shaded area indicates the optical window. 
 
1.2.2 Molecular mechanisms of PBM 
Photobiomodulation is essentially delivering photons of a particular wavelength, or 
electromagnetic energy, to tissues. The absorbed photons interact with the tissues in different 
ways to conserve the total energy of the tissue. They can excite some electrons to a higher energy 
state which later return to equilibrium by giving off the extra energy as vibrations or heat. In 
addition to this process, electrons that are excited to a higher energy state can give out photon 
emissions leading to fluorescence. A third possible fate for the absorbed energy is to react with 
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tissue photoacceptors, which can trigger energy transfer, electron transfer, and/or ligand 
dissociation, broadly known as photochemistry (reviewed in de Freitas and Hamblin, 2016).  
Through 50 years of research, numerous studies have measured the heat change following light 
treatment to better understand its mechanisms. Due to mixed reports on temperature changes 
caused by irradiation (Gomes et al., 2017; Joensen et al., 2011), studies on the PBM mechanism 
mainly focus on the photochemistry aspect. This pathway is rather complicated, and a large 
number of molecules are involved; however, a simplified pathway is illustrated in Figure 1.5. The 
photons are first absorbed by photoacceptors, which undergo a series of energy/electron transfer 
changes (de Freitas and Hamblin, 2016; Karu, 1999). This leads to: 1) the production and/or 
upregulation of signalling molecules such as adenosine triphosphate [ATP] (Parkhomenko et al., 
1993), cyclic adenosine monophosphate [cAMP] (Parkhomenko et al., 1993), ROS (Agostinis et 
al., 2011), NO (Karu et al., 2005), and Ca2+ (Santulli and Marks, 2015); and 2) activation of 
transcription factors such as nuclear factor kappa B [NK-κB] (Chen et al., 2011), receptor 
activator of nuclear factor kappa B ligand [RANKL] (Incerti Parenti et al., 2014), hypoxia 
inducible factor 1 α [HIF-1α] (Cury et al., 2013). Different effector molecules are then transcribed 
and translated for cell migration/proliferation, anti-inflammation, anti-apoptosis. 
While the downstream signalling cascade has been studied extensively, the first step in the 
proposed mechanistic pathway outlined in Figure 1.5 remains to be elucidated. Currently, there 
are two main hypotheses for the initiation of the signalling pathway, one is mitochondria focused 
(Section 1.2.2.1), while the other is not (Section 1.2.2.2). The current section will discuss each of 
these aforementioned hypotheses. 
 
 
Figure 1.5 Signalling pathway of photobiomodulation.  
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Generalised signalling pathway of photobiomodulation using red to NIR light. The light is 
absorbed by photoacceptors, and ultimately leads to cell proliferation/migration, 
anti-inflammation, and cytoprotection. 
 
1.2.2.1 Mitochondria based hypotheses 
The involvement of ATP and cAMP in the signalling pathways has drawn huge attention to the 
mitochondria, especially the electron transport chain on the mitochondrial membrane. Three 
decades ago, a study of the action spectra of the rate of DNA synthesis and the absorption spectra 
of photoacceptors in the respiratory chain, suggested that cytochrome c oxidase (CCO) of the 
electron transport chain acts as the main photoacceptor in PBM using red to NIR light (Karu, 
1989; Karu, 2008; Karu, 2010; Karu and Kolyakov, 2005). Within the ‘optical window’ (Section 
1.2.1), there are two regions where the peak rate of DNA synthesis coincides with the peak CCO 
absorption; one around 670 nm, the other one around 820 nm. By absorbing light energy, CCO 
activity is increased due to increased availability of electrons (Wu et al., 2014). The extra light 
energy increases the mitochondrial membrane potential. This causes changes in ATP synthesis, 
pH and redox potentials which ultimately lead to changes in transcription factors (Karu, 2010). 
Apart from direct light stimulation of CCO, it is also proposed that light energy can accelerate the 
dissociation of NO from CCO to increase its activity (Karu et al., 2005). In a normal cell, NO 
competes with O2 to bind with CCO, therefore inhibiting water and ATP production to regulate 
energy consumption (Antunes et al., 2004). Following PBM, this NO-dependent inhibition is 
reversed leading to increased O2 consumption and ATP production.  
1.2.2.2 Non-mitochondria based hypotheses 
Studies in Drosophila vision led to the discovery of a group of photosensitive ion channels called 
transient receptor potential (TRP) channels (Hardie, 2014). They are mostly located on the plasma 
membrane, allowing cation influx upon various stimuli such as heat, cold, chemical, hormone, 
pressure, and light. Of the different families within this TRP group, TRPV (“Vanilloid”) channels 
have attracted the most attention in the area of PBM. A few studies have tried to investigate the 
role of TRPV channels during PBM, however, some of the studies used blue (405 nm) to green 
(532 nm) light  (Gu et al., 2012; Yang et al., 2007), which has limited penetration through tissue 
layers. Other studies used longer wavelengths (1800-2800 nm) in the infrared range (Albert et al., 
2012; Ryu et al., 2010), however, infrared is mostly absorbed by water in the tissue to produce 
heat. While TRPV channels have been shown to be sensitive to temperature and are upregulated 
by heat (Benham et al., 2003; Hu et al., 2015), there remains a lack of evidence supporting the 
notion that PBM directly activates TRPV channels which provides other biological effects. 
However, it has been shown that internal alkalization following photobiomodulation (which 
occurs in the mitochondria-based hypothesis) could activate TRPV channels (Dhaka et al., 2009)
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TRPV channels may therefore be involved in the mechanism but downstream of those 
mitochondria-based events. 
There are also reports suggesting that light directly interacts with molecules such as transforming 
growth factor beta (Arany et al., 2014), Copper/Zinc Superoxide dismutase (Vladimirov et al., 
1988), or even ATP (Amat et al., 2005). However, there is limited support from subsequent 
research, and it is very likely that they accompany, or are even downstream of, the mitochondrial 
pathway.   
1.2.3 Therapeutic effects of PBM 
Studies of tissue optics (Section 1.2.1) and PBM mechanisms (Section 1.2.2) support the notion 
that wavelengths within optical window are optimal for potential treatment effects. Since its first 
discovery, PBM has been applied in a wide range of conditions to help reduce inflammation, 
reduce pain, and accelerate recovery. The current section will review the benefits of PBM using 
red to NIR light on cell proliferation (Section 1.2.3.1), apoptosis (Section 1.2.3.2), inflammation 
(Section 1.2.3.3), and pain (Section 1.2.3.4). The importance of these benefits in different neural 
and non-neural injuries will also be discussed.  
1.2.3.1 Cell proliferation 
PBM has been shown to enhance cell proliferation in a number of cell types that are associated 
with the macroscopic effects of PBM. Two cell types that have been studied extensively are 
keratinocytes and fibroblasts, both of which are essential for epithelial healing (Werner et al., 
2007). Irradiation with red light has shown to accelerate wound healing by stimulating the 
proliferation in both keratinocytes (Sperandio et al., 2015) and fibroblasts (Esmaeelinejad et al., 
2014; Hawkins and Abrahamse, 2005). This wound healing effect of PBM is largely beneficial in 
oral mucositis (Cauwels and Martens, 2011; Lima et al., 2010) and skin ulcers (Kaviani et al., 
2011). Apart from epithelial cells, vascular endothelial cells have also been shown to proliferate 
faster (Szymanska et al., 2013) to induce angiogenesis (Dungel et al., 2014; Tuby et al., 2006), 
and reduce tissue loss in myocardial infarction (Ad and Oron, 2001) following PBM. PBM has 
also shown beneficial effects in both oral and dental disorders (Amid et al., 2014; Carroll et al., 
2014), partially by promoting osteoblast proliferation (Huertas et al., 2014; Stein et al., 2005). 
1.2.3.2 Anti-apoptosis 
In many diseases and conditions, a variety of cells die from stress and/or toxic compounds, which 
can lead to irreversible negative outcomes. PBM has been shown to be cytoprotective under some 
toxic conditions (Eells et al., 2003; Liang et al., 2006), most likely through up-regulation of CCO 
and therefore metabolic processes in cells (Wong-Riley et al., 2005). Its cytoprotection effect is 
highly valued in the nervous system where there is limited regeneration. Photoreceptor cell death 
is prevalent in age-related macular degeneration (Curcio et al., 1996). Treatment with light has 
been shown to inhibit photoreceptor death (Chu-Tan et al., 2016) and improve visual acuity in 
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patients (Ivandic and Ivandic, 2008). Another serious eye disease is glaucoma, which is associated 
with retinal ganglion cell death (Nickells, 2012). PBM has been shown to inhibit retinal ganglion 
cell death in situ (Del Olmo-Aguado et al., 2016). In Alzheimer’s disease, deposition of Aβ has 
been linked to cell apoptosis (Calissano et al., 2009), which is inhibited by red light therapy 
(Zhang et al., 2012). PBM has also been shown to prevent dopaminergic cell loss in rodent model 
of Parkinson’s disease (Moro et al., 2014). Reduction in non-specific cell death has also been 
observed in other diseases/conditions of the nervous system, including traumatic brain injury 
(Moreira et al., 2009) and spinal cord injury (Hu et al., 2016; Sotoudeh et al., 2015). However, 
future research is needed to investigate these effects in clinical settings and determine whether it 
leads to functional improvements.  
1.2.3.3 Anti-inflammatory effects 
Inflammation is a complex process where the immune system comes into play as a result of injury, 
infection, or autoimmunity. Cells that are responsible for inflammation, mainly macrophages, 
have been studied extensively following light irradiations in different diseases/conditions. Several 
reports have shown decreased numbers of activated macrophages following red light therapy in 
retinal damage (Albarracin et al., 2011; Kokkinopoulos et al., 2013), spinal cord injury (Byrnes 
et al., 2005; Hu et al., 2016; Song et al., 2017), and arthritis (Alves et al., 2013). In addition to 
the reduction in macrophage numbers, light therapy has also been shown to alter macrophage 
polarization, a process that allows macrophages to adopt different phenotypes (see Inflammatory 
response section for macrophage polarization following spinal cord injury). While an in vitro 
study by Chen et al. (2014) reported that human monocytes polarized towards the 
pro-inflammatory population, in vivo studies demonstrated polarization towards the 
anti-inflammatory population (Hu et al., 2016; Song et al., 2017). It is however important to keep 
in mind that microglia/macrophages are very sensitive to changes in the cellular environment and 
may behave differently when activated as compared to the resting state. 
1.2.3.4 Pain inhibition 
Inflammation often results in pain. This has led to investigations of the light effect on pain 
following various injuries. The pain relieving effect of red light treatment has been observed in 
oral mucositis (Cauwels and Martens, 2011), carpel tunnel syndrome (Chang et al., 2008), lateral 
epicondylitis (Lam and Cheing, 2007), arthritis (Hegedus et al., 2009), neck pain (Chow et al., 
2009), and even spinal cord injury (Hu et al., 2016). It is suggested that the analgesic effect is not 
simply the result of reduced inflammation, but that red to NIR light can directly act on peripheral 
opioid receptors (Peres e Serra and Ashmawi, 2010) and afferent fibres (Carroll et al., 2014; Yan 
et al., 2011). 
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1.2.4 Remarks 
While light treatment has been around for decades, there has been minimal uptake into 
mainstream clinical settings. Further studies on the photobiological properties of human tissues 
will allow us to make better decisions on the wavelength and the radiosity of the treatment device 
to reach optimal irradiance at the targeted sites. The other choice of treatment strategy, involving 
the time of treatment, duration of treatment, and interval of treatment, will largely depend on more 
thorough investigations of the PBM mechanism(s) and its effect in different injury models. 
1.3 Summary and aims 
Spinal cord injury is a devastating condition. It is estimated that patients have to deal with lifetime 
costs in the million-dollar range. Although there are therapies that are currently under 
development, combination therapies would be more beneficial due to the complexity of the 
disease. This thesis examines PBM to improve recovery following spinal cord injury. Based on 
the study of light penetration (Section 1.2.1) and PBM mechanism (Section 1.2.2.1), LED 
irradiation with 670 nm is chosen in the current study. Firstly, the penetration of 670 nm in human 
tissues will be studied to investigate factors that affect penetration, and the expected depth of 
penetration over a range of irradiance. This section will provide new knowledge on what can be 
treated with 670 nm. The second part will apply 670 nm in rats with hemi-contused spinal cords 
and observe their functional recovery. Furthermore, changes in the cellular milieu following 
spinal cord injury and 670 nm treatment will be explored, with a particular focus on 
microglia/macrophage activation and polarisation, cytokine production, and apoptosis/necrosis. 
The association of these cellular changes with sensorimotor functional changes will be established. 
The experimental chapters proceed as follows:  
Chapter 2 compares the penetration of 670 nm between human subjects and cadavers across a 
range of light intensities. In addition, the effects of skin tone, tissue thickness, and nature of tissue 
on penetration are also described. 
Chapter 3 examines the effects of 670 nm on sensorimotor function in a mild-moderate contusion 
model, with focus on microglia/macrophage activation/polarisation, apoptosis/necrosis from 1 to 
7 days post-injury, and functional changes at 7 days post-injury.  
Chapter 4 will study the development of hypersensitivity following a mild hemicontusion injury 
and the effects of 670 nm treatment over a seven-day recovery period. The effects of red light 
treatment on astrocyte activation and cytokine production in microglia/macrophages in the injured 
spinal cord are explored. 
Chapter 5 provides overall conclusions drawn from the experimental chapters 2-4.  
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2.1 Abstract 
Red light treatment is emerging as a novel therapy for tissue recovery but data on red light 
penetration through human body tissues are lacking. The aims were to: i) determine the effects of 
light intensity, tissue thickness, skin tone and bone/muscle content on 670 nm light penetration 
through common sites of sports injury and; ii) establish if cadaveric tissues are good models for 
the study of red light penetration. Live and cadaver human subjects were exposed to various 
intensities of 670 nm light at locations across the skull and upper and lower limbs. Red light 
penetration measurements were acquired by a light probe through body site surfaces opposing an 
active light emitting diode (LED) array (intensity range: 15-500 mW/cm2). Penetration was 
examined at different sites with respect to skin tone, tissue thickness and light intensity. At an 
intensity of 100 mW/cm2, 670 nm light can successfully penetrate sites of the upper and lower 
limbs in live tissues of up to 50 mm below the skin surface. Red light penetration is unaffected 
by skin tone, improved with increased light intensity and increased relative bone to muscle 
composition, but decreased with overall tissue thickness. The relationship between tissue 
thickness and red light penetration in live subjects was described mathematically. Penetration 
through live and cadaveric tissue did not differ statistically. Red light can readily penetrate parts 
of the upper limbs, distal lower limbs and the skull at clinically relevant intensities. Cadaveric 
tissues can serve as a good reference for penetration in live participants under certain conditions, 
and may aid future studies examining penetration in regions otherwise inaccessible in live subjects. 
The results from this study will assist clinicians and researchers decide on appropriate red light 
treatment intensities for sports injuries. 
2.2 Introduction 
While important for overall wellbeing, sport often results in injuries that contribute to an increased 
burden on the health care system. In the United States almost half a million young school-aged 
athletes suffered severe injuries during sport, with approximately two-thirds suffering fractures 
and/or ligament sprains (Darrow et al., 2009). The most common sites of injury are the knee/lower 
limb and the upper limb (Baquie and Brukner, 1997; Darrow et al., 2009; Westermann et al., 
2016). Therapies that can effectively treat muscle, bone, tendon, ligament and/or nervous system 
injuries, including managing inflammation and pain, would be beneficial to athletes at all levels 
of competition.  
The biological effects of low power laser was first reported in 1968 (Mester et al., 1968) and the 
use of Light Emitting Diodes (LEDs) for therapeutic applications of photobiomodulation (PBM) 
subsequently popularised following the serendipitous finding of improved wound healing by 
astronauts using LEDs for plant growth experiments in space (Eells et al., 2004; Whelan et al., 
2003; Whelan et al., 2001). Since these initial observations, various studies have emerged 
investigating the effect of PBM on injury, including pain modulation and wound healing in a vast 
variety of in vitro and in vivo experiments. Of interest to sports medicine are observations of 
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improved collagen deposition in skeletal muscle (de Melo et al., 2016), reduced oedema 
(Stergioulas, 2004) and inflammatory infiltrates into tissues (de Melo et al., 2016; Hu et al., 2016), 
the reduction of pain (Bertolini et al., 2011; Hu et al., 2016), improved bone density (Deniz et al., 
2015; Ekizer et al., 2013), and the acceleration of recovery from tendinopathy (Stergioulas et al., 
2008), sprains (Stergioulas, 2004), and peripheral nerve damage (Ishiguro et al., 2010; Rochkind 
et al., 2009).  
Many studies have investigated wavelengths near the 670 nm or 830 nm range, which fall within 
the 650-1200 nm “optical window” for penetrating the skin and underlying tissues (Chung et al., 
2012; Hamblin et al., 2006; Huang et al., 2009) and which are also centred around the putative 
range that promotes biological effects (Whelan et al., 2008). One study that compared a variety 
of in vivo nervous tissue injuries found 670 nm to be overall more effective compared to 830 nm 
(Giacci et al., 2014), however recovery outcomes appear to be highly contingent on the 
combination of irradiation and injury severity (Giacci et al., 2014; Hu et al., 2016). Furthermore, 
it has been proposed that increasing dosage is necessary for increasing injury severity, but that 
overdose may be harmful (Chu-Tan et al., 2016). Thus, while red light treatment may offer 
potential benefits for attending sports related injuries such as reducing recovery time (Stergioulas, 
2004) and pain (Bertolini et al., 2011; Hu et al., 2016), in order to optimise treatment outcomes 
it is necessary to determine the penetration parameters for delivery of an appropriate dose, as well 
as identifying body regions that are accessible to light treatment.  
To optimise treatment, the delivery of light to target tissues must be known, which is affected by 
the duration and interval of light exposure, and the intensity of light. However, while all these 
parameters are easy to control from the light source itself, the quantity of photons that reach the 
tissue of interest is currently difficult to establish, and there are currently no clear guidelines that 
provide information about the penetration of light into different body parts. Once light hits 
biological tissues, scattering of photons and absorbance by photoacceptors by different tissue 
layers attenuate the light. The main aim therefore, is to examine the effects of light intensity, skin 
tone and bone/muscle content on red light penetration at common sites of sport injuries, and 
thereby provide a basic guideline for establishing the likelihood of red light penetration for 
different body parts. Establishing parameters that ensure red light is deliverable to a structure of 
interest is essential to facilitate decisions about red light treatment dosage for treatment and future 
research. The other aim was to determine whether embalmed cadaveric tissue serves is an 
adequate model for predicting penetration in live human participants, which would be valuable 
for future studies on regions that are not otherwise accessible in live subjects.  
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2.3 Methods 
2.3.1 Subjects 
This study was conducted under the ethics approval of the Human Research Ethics Committee at 
the Australian National University (protocol no: 2015/288). Nine live human participants were 
recruited (6 males & 3 females; age = 26.9 ± 2.1 years) and classified into three different skin 
tones (light, medium and dark). Subjects were asked to fill out a questionnaire to determine their 
Fitzpatrick skin type (Fitzpatrick, 1988). Light skin toned participants were all Caucasian 
(Fitzpatrick skin type scores: 9, 11, 12); medium skin toned participants were of Iranian, Eastern 
European and Afghan descent (Fitzpatrick skin type scores: 16, 18 and 23 respectively); dark skin 
toned participants were of Indian and Sri Lankan descent (Fitzpatrick skin type scores: 25, 30 and 
33 respectively). Human tissues from 6 cadavers (donation to the Australian National University 
Medical School Anatomy program) were also included in this study (terminal age = 81.3 ± 4.3 
years). Sixteen sites of the limbs and cranium were tested (Figure 2.1a). The upper limb sites 
included the shoulder joint, upper arm and elbow joint; the lower limb sites included the wrist 
(distal radioulnar joint), the thumb (1st metacarpophalangeal joint) and the middle finger (3rd 
metacarpophalangeal joint). The lower limb sites included thigh, knee, calf, and ankle. At the 
elbow, knee and ankle, measurements were performed in 2 planes, sagittal (anterior-posterior), 
and coronal (lateral-medial). In the arm and thigh, two measurements were performed; one which 
the light path included the bony structures (humerus, femur), and the other which was limited to 
the soft tissues (biceps brachii, hamstring muscles). Cranium measurements were obtained 
through the dura at the inion or at bregma from human cadavers. 
2.3.2 LED irradiation and measurement 
A custom-built 660 nm LED device, with varying output intensities ranging from 
15-500 mW/cm2 measured at the aperture window, was situated on each testing site. A light probe 
tuned to 670 nm (Thorlabs, PM100D) was placed on the opposing side of the respective body part 
(Figure 2.1a). For cranium measurements, a smaller custom-built 670 nm light probe was used as 
previously described (Hu et al., 2016). The LED was placed either at the Bregma or the inion and 
the measurement was taken transcranially with the light probe placed on the dura on the opposing 
side of the LED. Within this light probe, light was detected by a photodiode chip (surface area, 
0.62 mm2; maximal response (>95 %) to 630-685 nm; ODD-660W, Opto Diode Corp.) and then 
amplified (AD8304, Analog Devices). The readings were then calibrated against the Thorlab light 
probe. There was negligible difference when the tuneable light probe was set at 670 or 660 nm, 
however it was necessary to match the readings to the custom light probe which was fixed at 670 
nm. Both probes measure the amount of 670 nm light in µW/cm2. Readings ≥ 0.1 µW/cm2 were 
considered as positive for penetration. The thickness of each testing site was measured using 
digital Vernier callipers. Minimum force was applied to avoid squeezing and multiple 
measurements were taken to ensure accuracy and consistency. Ambient lights were kept to a 
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minimum and the probe was positioned so that no positive reading was observed from the ambient 
light probe before the LED was switched on. The minimum LED output intensity was 15 mW/cm2 
and it was increased incrementally to a maximum output of 500 mW/cm2 while penetration 
readings were recorded for each increment. 
2.3.3 Statistics 
Statistical analysis was carried out using R (version 3.2.1) (R Core Team, 2016). General linear 
mixed models with Satterthwaite’s approximation (LMER; lmer function in R) were used for 
multiple factor analysis accounting for random effects (Kuznetsova et al., 2016), or analysis of 
variance models (without random factors; AOV; aov function in R) where appropriate. Log 
transformations (log[x+1]) were performed on heteroscedastic data, and all statistical models 
were validated by inspection of residual plots. For data that were inappropriate for LMER, a 
Cumulative Link Mixed Model was fitted, accommodating one random factor, with the Laplace 
approximation (CLMM; clmm2 function in R) (Christensen, 2015), or a Kruskal-Wallis rank sum 
test (non-parametric test without random factors) was performed where appropriate. CLMM 
required categorising scores into bins that best represented the data. Histograms of complete data 
sets (blind to groups) were inspected to determine natural breaks in the data to define categories. 
Post-hoc comparisons for non-parametric data were performed using a Wilcoxon rank sum test 
on raw scores where applicable. Post-hoc p-value adjustments were conducted using the 
Benjamini-Yekutieli procedure (Benjamini and Yekutieli, 2001). P-values less than 0.05 were 
considered statistically significant. All data are expressed as mean ± SEM unless otherwise stated. 
2.4 Results 
2.4.1 670 nm LED at 100 mW/cm2 can penetrate tissues up to 50 mm thick 
Light penetration readings were acquired from all 9 live subjects, and 2 or 3 of 6 individual 
cadavers depending on the site. 670 nm successfully penetrated through the entire tissue in 9/15 
sites in at least two live subjects, and 10/16 sites in at least one cadaver.  The proportion of sites 
that were penetrable at ≤ 500 mW/cm2 for each body site is summarised in Figure 2.1a. The 
sagittal elbow plane was the only site where penetration was observable in some of the live 
subjects (3/9) and in none of the cadavers (0/3). Complete penetration was observed at intensities 
≤ 500 mW/cm2 from the wrist, thumb and middle finger in all live and cadaver subjects, and the 
cranium in all cadaver subjects. In addition to these structures, the humerus (8/12), biceps (8/12) 
and coronal (6/11) and sagittal ankle (6/11) were penetrated in at least half of all (live + cadaver) 
subjects. These observations demonstrate that at intensities ≤ 500 mW/cm2, red light has the 
capacity to penetrate the entire thickness of the distal upper limb and cranium in all subjects, and 
the upper arm and ankle joint in half or more subjects. 
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To examine the effects of tissue thickness and light intensity on red light penetration,  penetration 
against tissue thickness at 100, 300 and 500 mW/cm2 for all structures tested in live (Figure 2.1b) 
and cadaver (Figure 2.1c) subjects was plotted. Structures with optical paths < 50 mm were 
penetrated by all intensities (≥ 100 mW/cm2) in 100% of cases examined in the 9 live subjects 
(n = 27 individual structures across 9 live subjects). These structures were either wrist, thumb, or 
middle finger. The following linear models describe the relationship between red light penetration 
of lean structures in µW/cm2 (y) and tissue thickness in mm (x) between the range of 22-49 mm 
in live subjects from a light source with intensities of 100 (Equation 2.1), 300 (Equation 2.2) and 
500 mW/cm2 (Equation 2.3): 
Equation 2.1 Penetration of 670 nm light at 100 mW/cm2 𝑦 = 10%.'().*+, − 1 
Equation 2.2 Penetration of 670 nm light at 300 mW/cm2 𝑦 = 10..)	(	).*%, − 1 
Equation 2.3 Penetration of 670 nm light at 500 mW/cm2 𝑦 = 100.+	(	).*1, − 1 
In cadavers (n = 22 individual structures across 6 cadavers), structures with a thickness less than 
50 mm included biceps, humerus, hamstring, calf and coronal ankle, in addition to the 
aforementioned three hand structures. 68% (at 100 mW/cm2) and 77% (at 300 and 500 mW/cm2) 
of these structures were penetrated by red light in cadavers, however as for live subjects, 100% 
of the three hand structures were penetrated in cadavers. The increased intensity significantly 
(p = 3.0e-15, LMER) elevated penetration in both live subjects (100: 23 ± 8 µW/cm2; 
300: 67 ± 24 µW/cm2; 500: 169 ± 59 µW/cm2) and cadaveric specimens (100: 44 ± 35 µW/cm2; 
300: 83 ± 65 µW/cm2; 500: 177 ± 134 µW/cm2). 
In structures with optical paths between 50 and 95 mm, the proportion of structures from live 
subjects demonstrating complete penetration at 100 mW/cm2 was 9% of all structures tested 
(n = 53; 0.011 ± 0.005 µW/cm2), 28% at 300 mW/cm2 (0.045 ± 0.013 µW/cm2), and 43% at the 
500 mW/cm2 (0.119 ± 0.033 µW/cm2). These structures included biceps, humerus, sagittal and 
coronal elbow, coronal knee, calf, and sagittal and coronal ankle. The proportion of cadaver 
structures demonstrating complete penetration of all structures tested (n = 18 individual structures 
across 6 cadavers) was 11% at 100 mW/cm2 (0.091 ± 0.080 µWcm2) and 28% at both 300 and 
500 mW/cm2 intensities (300: 0.316 ± 0.265 µW/cm2; 500: 1.036 ± 0.906 µW/cm2). These 
structures included shoulder, humerus, sagittal and coronal elbow, femur, sagittal and coronal 
knee, calf, and sagittal ankle. While there was an overall significant increase in the penetration 
for structures of thicknesses between 50-95 mm as the intensity was increased (p < 2.09e-09, 
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LMER), there was no significant effect of intensity increase on penetration between 100 and 300 
mW/cm2 (p = 0.256) and 300 and 500 mW/cm2 (p = 0.466) in cadaver structures.  
There were an additional 55 structures with thickness between 95 and 150 mm that were tested in 
the 9 live (but not cadaver) subjects. These structures included the shoulder, humerus, coronal 
elbow, hamstring, femur, sagittal and coronal knee, calf, and sagittal ankle. No detectable readings 
were obtained at 100 and 300 mW/cm2 intensities, however, 5.5% of structures demonstrated red 
light penetration at an intensity of 500 mW/cm2. These data indicate: 1) 100 mW/cm2 is sufficient 
to reliably penetrate through tissue structures of 50 mm or less in live subjects, 2) increasing the 
intensity to 500 mW/cm2 increases the penetration, and 3) complete penetration of red light is 
negligible in tissues with an optical path greater than 95 mm, even at 500 mW/cm2. 
2.4.2 670 nm LED penetration is not affected by skin tone 
As melanin is a key chromophore in the skin (Anderson and Parrish, 1981), the next objective 
was to examine the effect of skin tone on red light penetration. First, the minimum intensity 
necessary for red light to penetrate structures as a function of tissue thickness for each skin tone 
(light, n = 21; medium, n = 14; dark n = 18) and cadaveric tissues (n = 22; Figure 2.1d) was 
plotted. Skin tone did not have a significant effect on red light penetration (p = 0.52, AOV), nor 
did the subjects (live vs cadaveric tissue; p = 0.83, AOV). A piecewise envelope was then applied 
that captures the minimum intensity required to penetrate tissues at a given thickness. This 
envelope comprises of two boundary lines (dotted, Figure 2.1d), one relatively flat and other 
relatively steep, that captures all data points with the exception of three (13.6%) cadaver outliers. 
The two boundary lines intersect at an intensity of 100 mW/cm2 and a tissue thickness of 50 mm, 
indicating that 100 mW/cm2 is sufficient to penetrate all tissues (i.e. skin tones and cadaver 
material) to a depth of 50 mm, with the exception of one cadaver outlier which came from the 
humerus site of a cadaver. For the majority of tissues greater than 50 mm of thickness, a 
disproportionately greater intensity is required for successful penetration (Figure 2.1d). At an 
intensity of 100 mW/cm2 and at tissue thicknesses of ≤ 50 mm, there was no difference in red 
light penetration among the different skin tones of live subjects (p = 0.62, LMER), or between 
live vs cadaveric tissues (p = 0.20, LMER).  
To minimise the effect of tissue thickness when evaluating the effect of skin tone on red light 
penetration, wrist, thumb and middle finger sites were selected for comparisons. These structures 
were selected because: 1) there was no significant difference among each of the respective 
structures across all live and cadaver subjects (Figure 2.2a; p = 0.17, AOV), 2) all these structures 
from live and cadaver subjects were ≤ 50 mm and therefore penetrated by red light, and 3) each 
respective structure contains the same layers of tissue elements, thereby minimising any random 
factors between groups. The mean light penetration at all intensities investigated for each skin 
tone and cadaveric tissues are shown for the wrist, thumb and middle figure (Figure 2.2b-d 
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respectively). There was no significant effect of skin tone or live/cadaveric tissues on red light 
penetration for all intensities at the wrist (Figure 2.2b; skin tones, p = 0.52; live vs cadaver 
subjects, p = 0.45, LMER), thumb (Figure 2.2c; skin tones, p = 0.96; live vs cadaver subjects, 
p = 0.84, LMER), or middle finger (Figure 2.2d; skin tones, p = 0.74; live vs cadaver subjects, 
p = 0.08, LMER). 
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Figure 2.1 Penetration of red light (670 nm) in tissues from live and cadaver subjects. 
(a) Sites of LED light source (red asterisks) and recording probe (round/oval black circles) are 
illustrated. Numbers of subjects that demonstrated red light power readings at an intensity of 
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≤ 500 mW/cm2, and total numbers of subjects tested are shown for each site and each subject 
group. For the cranium, readings were measured in cadavers, using a custom-made probe (see 
methods). (b) Penetration of 670 nm at 100, 300 and 500 mW/cm2 intensity plotted against tissue 
thickness for all structures (n = 135) measured in live subjects. Statistical comparisons of 
penetration following 100, 300 and 500 mW/cm2 intensities for tissue thicknesses between 
0-50 mm, 50-95 mm and 95-150 mm are indicated. (c) Same as shown in b for all cadaveric 
tissues ≤ 95 mm thickness (n = 38). (d) The minimum light intensity required for detection 
through all penetrable structures (as per a) in live (colour coded for skin tone) and cadaver (grey) 
subjects are shown as a function of tissue thickness. The dotted line indicates a piecewise 
envelope for live subjects. Sample size (n) for each skin tone and cadaver subjects are indicated 
in the legend. *** p < 0.001; # p < 0.05 for 100 vs. 500 mW/cm2; ns p > 0.05; LMER.   
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Figure 2.2 Penetration of 670 nm through hand structures in live and cadaver subjects. 
Penetration of 670 nm at varying intensities was measured through the wrist, thumb and middle 
finger sites in live subjects with light (light orange), medium (orange) and dark (brown) skin 
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tones, as well as human cadavers of unknown skin tone (grey). (a) Thickness of tissues subjected 
to light penetration measurements are shown for live subjects of each skin tone as well as cadaver 
subjects. (b) Penetration of 660 nm through the wrist at different red light intensities. (c) 
Penetration of 660 nm through the thumb at different red light intensities. (d) Penetration of 660 
nm through the middle finger at different red light intensities. Data expressed as mean ± SEM; 
sample sizes (n) indicated; ns p > 0.05 (a: AOV; b-d: LMER).  
 
2.4.3 670 nm LED penetrates better in tissues with bone component 
Since bone and muscle tissue have different optical properties (Jacques, 2013), it is worthwhile 
examining the effect of bone/muscle content on red light penetration. The penetration between 
the thumb and the middle finger was first compared. These two structures were not significantly 
different in thickness (Figure 2.2a; live subjects, p = 0.12; cadaver subjects, p = 0.65, paired t-
test), but contain vastly different proportions of bone and muscle content. It was found that the 
middle finger joint, a structure with a greater proportion of bone to muscle compared to the thumb, 
had significantly more penetration across live and cadaver subjects (p < 2e-16; LMER). The 
penetration of the upper arm through two sites was then compared; one that passed exclusively 
through muscle (biceps site) and the other that includes muscle and the long bone (humerus site). 
There was no significant difference in tissue thickness among the different skin tone groups (p = 
0.60, AOV) of the biceps (Figure 2.3a) or humerus (Figure 2.3b) in live subjects, however, the 
thickness of cadaver specimens was greatly reduced compared to the live tissues for both 
structures (p = 3.76e-08, AOV). Furthermore, the humerus site in live subjects was overall 
significantly thicker compared to the biceps site (p = 0.003, AOV), but this was not apparent for 
the cadaver subjects alone (p = 0.48, Tukey HSD post-hoc). 
Next, all subjects that were penetrable at ≤	500 mW/cm2 were selected and plotted penetration 
against light intensity for the biceps (Figure 2.3c) and humerus (Figure 2.3d). To obtain an 
overview of the effect of skin tone, and live vs. cadaveric tissues, data from each individual was 
colour coded to their respective groups. The left end of each line represents the minimum intensity 
by which red light penetrated the tissue; the right end of each line indicates the penetration at 
maximum red light intensity. In live tissues, there was no obvious relationship between skin tone 
and the minimum intensity required to penetrate, or penetration at maximum red light intensity 
over the ranges investigated. The two cadaver specimens demonstrated a greater penetration in 
the biceps (Figure 2.3c), however, statistical analysis on all available data indicated that the only 
difference between live and cadaver subjects occurred at intensities of 60-100 mW/cm2 (p ≤ 0.039, 
Kruskal-Wallis rank sum test). Colour coding was applied for tissue thickness below and above 
50 mm. Colour coding was applied for tissue thickness below and above 50 mm (Figure 2.3e-f 
for biceps and humerus respectively) to facilitate the interpretation of Figure 2.3c-d. Despite the 
CHAPTER 2 
 48 
humerus being thicker compared to the biceps (Figure 2.3a-b), overall, penetration was 
significantly greater in the humerus (p = 0.0012, LMER).  
 
Figure 2.3 Penetration of 670 nm through the upper arm in live and cadaver subjects. 
(a) Tissue thickness of bicep sites in live and cadaver subjects. (b) Tissue thickness of humerus 
sites in live and cadaver subjects. (c) Individual data points shown for penetration of 670 nm 
through the biceps at different red light intensities in all live and cadaver subjects that 
demonstrated penetration at ≤ 500 mW/cm2 (n = 8). (d) Same as panel c but for the humerus (n = 
8). (e) Panel c is reproduced with subjects colour coded by tissue thickness (≤ 50 mm, blue scale; > 
50 mm, purple scale). (f) Panel d is reproduced with subjects colour coded for tissue thickness. 
*** p < 0.001 for comparisons between live and cadaver subjects (AOV); ns p > 0.05 for 
comparison between different skin tones of live subjects (AOV). 
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In summary, the results indicate that in live subjects, irrespective of skin tone, red light readily 
penetrates tissues up to 50 mm of thickness and requires 100 mW/cm2 or less. The presence of 
bone and/or reduction of muscle increase the level of penetration in live subjects. Cadaveric 
tissues generally appear to require similar levels of light intensity to that of live tissues to achieve 
penetration but demonstrate greater variability. 
2.5 Discussion 
PBM is increasingly becoming popular as an alternative therapy for sports related injuries (Chang 
et al., 2014; Vanin et al., 2016), however there are no standard treatment regimens at present. 
Irradiation intensity is a key parameter that influences treatments but may be affected by 
numerous factors. The main aim was to determine clinically relevant parameters for red (670 nm) 
light irradiation, by improving the understanding of the relationship between light intensity and 
tissue penetration under the influence of factors such as tissue thickness, skin tone and 
bone/muscle composition. The secondary objective was to compare penetration in live and 
cadaveric tissues so that future studies using cadaveric tissues can extrapolate findings to live 
tissues. The results indicated that penetration of 670 nm irradiation: i) is complete up to 50 mm 
below the skin surface in tissues comprising skin, tendon, bone and muscle at an intensity of 
100 mW/cm2, ii) is largely unaffected by skin tone, and iii) is improved in tissues that comprise a 
greater proportion of bone and/or reduced proportion of muscle for a given tissue thickness. 
Furthermore, cadaveric tissues can be used to model live tissue, however with a few caveats that 
will be discussed below. 
The main finding is that red light can successfully penetrate up to 50 mm below the skin surface 
in the tissues and intensities that were examined in live and cadaver subjects. Future studies can 
use the equations to estimate the penetration of 670 nm light for any given tissue thickness 
(between 20 and 49 mm) at 100, 300, and 500 mWcm2. It was also demonstrated that increasing 
the intensity beyond 100 mW/cm2 did not greatly improve penetration, and therefore it is proposed 
to use 100 mW/cm2 as an intensity starting point for red light treatment for tissues of less than 
50 mm of thickness. However, while penetration is evident up to 50 mm of tissue thickness, the 
intensity is in the µW/cm2 range. The biological effect (if any) at this level of red light irradiation 
warrants further investigations. For structures approaching 50 mm of thickness, one strategy to 
increase photon delivery to tissues would be to apply the light source from multiple sides of the 
site of interest.  
Light intensity and tissue thickness are two important factors governing the level of red light 
penetration through human tissues. Increasing the intensity results in an increase in the delivery 
of photons to the site, and thereby improves penetration, while tissue layers act as a barrier that 
absorb and scatter the incoming photons and thereby reduces penetration (Anderson and Parrish, 
1981). Tissue thickness has a nonlinear effect on light penetration because changing this 
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parameter results in: 1) a change in the optical path length and 2) alterations in absorbance and 
scattering that is dependent on the additional tissue layers and/or layer thicknesses. Tissue 
thickness readings could have been affected by varying force applied when using callipers, 
however the measuring error is estimated to be within (1-3 mm), and therefore unlikely to greatly 
affect the findings. 
While tissue thickness is the main determinant of penetration, improved penetration through the 
humerus compared to the biceps in live subjects was observed, despite that the humerus site was 
thicker. Greater penetration was also observed in the middle finger compared to the thumb, 
despite these structures showed no significant difference in tissue thickness. The main difference 
in the optical path between the structures compared above is the proportion of bone and muscle 
content. Compared to bone, muscle has a relatively greater capacity to absorb 670 nm due to the 
higher content of both deoxygenated and oxygenated haemoglobins (Bashkatov et al., 2011; 
Maud and Foster, 2006), myoglobins (Barham et al., 2010). Based on combined absorbance and 
scattering coefficients (Bashkatov et al., 2011; Tuchin et al., 2006), the following order of 
penetration between 600-700 nm (ordered least to most) would be expected for the following 
tissues: 1) subcutaneous fat, 2) skin, 3) muscle, and 4) bone. The absorbance coefficient of bone 
is 20%-60% lower than muscle, while the scattering coefficient for both these tissues are similar 
(Bashkatov et al., 2011; Jacques, 2013; Tuchin et al., 2006), thus the additional proportion of 
bone content in the humerus and middle finger is likely to have improved the level of penetration 
compared to the biceps and thumb respectively. 
No effect of skin tone on red light penetration was found. Melanin is a key chromophore in the 
skin and is the primary determinant of skin tone thus subjects with darker skin tone have more 
melanin present. Melanin has an absorption spectrum that increases with shorter wavelengths; at 
670 nm, melanin absorption is reduced to approximately 55% compared to at 500 nm, and 35% 
compared to at 400 nm (Anderson and Parrish, 1981; Meglinski and Matcher, 2002). Furthermore, 
the absorption coefficients of skin at 670 nm for different Fitzpatrick skin types (II-VI) are 
between 0.5-2 cm-1 (Saager et al., 2015). As the melanin layer is relatively thin compared to other 
tissue layers, its impact on overall penetration is negligible compared to layers with thicknesses 
that are several orders of magnitude greater. The findings that 670 nm penetration was largely 
unaffected by skin tone is therefore consistent with these studies characterising melanin 
absorption at this wavelength. 
Compared to skin, the absorption and scattering coefficients of fat are ~50% and 200% greater 
respectively, over the 600-700 nm range (Bashkatov et al., 2011). Fat content would therefore 
greatly affect penetration because: 1) the interaction of absorbance and scattering is not linear and 
increasing both is likely to greatly reduce penetration (Meglinski and Matcher, 2002; van Gemert 
et al., 1989), and 2) skin layers are generally thinner, and can be up to an order of magnitude 
thinner, than fat layers. While fat content was not measured in this study, lean subjects were 
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recruited to minimise any random effects of fat. Furthermore, the statistical model incorporated 
each subject as a random factor which would accommodate for unique variations, including the 
effects of individual fat content. 
It was set out to determine if cadaveric tissues can serve as a good model for extrapolating 
penetration data to live tissues. In structures that were relatively low in muscle content, such as 
the distal upper limb, it was found that tissue thickness and light penetration in cadaver structures 
were comparable to that of live subjects (Figure 2.2). One possible confounding factor between 
live and cadaver subjects is the embalming medium, which could potentially alter the way light 
is scattered and absorbed. As there was no significant difference in thickness or penetration 
between cadaver and live subjects within the wrist, thumb and middle finger comparisons, it 
suggest that the embalming process had minimal impact on these structures. However, data from 
the upper arm revealed that body sites with larger proportions of muscle content (i.e. the biceps 
vs humerus sites) resulted in significant reductions in the overall structural thickness compared 
to live subjects (e.g. Figure 2.3a-b). The reduced muscle bulk is likely to occur from the removal 
of water content which is expected from the embalming process and/or the refrigeration storage 
of tissues, however age-related muscle size and water content differences may exist between the 
live and cadaver subjects. Reduced tissue thickness would improve penetration due to the reduced 
optical path length. However, with the exception of reduced water content, the overall matter 
within tissues of embalmed structures remains similar to live subjects, thus it is reasonable to 
expect similar levels of penetration in cadavers when accounting for the reduced optical path 
length in dehydrated tissues. Another difference between live and cadaveric tissues may be the 
displacement of blood in cadaveric tissues which may impact on the penetration. The greater 
variability of penetration observed in cadaver (Figure 2.1c) compared to live (Figure 2.1b) 
structures may therefore have resulted from the displacement of blood that is dependent on many 
variables during the embalming process. 
The purpose of making measurements in cadavers is to enable light readings that could otherwise 
not be performed in live subjects. In this study, the penetration through the cranium of cadavers 
was quantified. Given the minimal muscle content overlaying the cranium, tissue shrinkage is 
unlikely to have played a major impact on the optical path length. Assuming minimal fat content 
between the skin and the brain, this study would suggest that 100 mW/cm2 is sufficient to reach 
the external layers of cortex in live human subjects.  
2.6 Conclusion 
In conclusion, the data demonstrates that at an intensity of 100 mW/cm2, 670 nm light can reach 
a depth of approximately 50 mm below the surface of structures comprising skin, bone muscle, 
tendons and ligaments, irrespective of skin tone. While increasing the light intensity increases 
penetration, it does not greatly increase the capacity to for light to penetrate thicker tissues over 
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the intensities studied. While 50 mm penetration is insufficient to completely penetrate many 
body parts, it is sufficient to access most of the distal limb structures that are commonly injured 
by athletes (Garrett, 1996), and applying light from multiple sides of the structure would increase 
photon delivery for larger structures. Mathematical models were provided that will give 
practitioners and researchers the capacity to estimate red light penetration for lean structures of 
interest. Finally, it was shown that penetration parameters for inaccessible regions can be 
determined by the use of cadaveric tissues when accounting for tissue thickness. 
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3.1 Abstract 
The development of hypersensitivity following spinal cord injury can result in incurable persistent 
neuropathic pain. The objective was to examine the effect of red light therapy on the development 
of hypersensitivity and sensorimotor function, as well as on microglia/macrophage 
subpopulations following spinal cord injury. Wistar rats were treated (or sham treated) daily for 
30 minutes with an LED red (670 nm) light source (35 mW/cm2), transcutaneously applied to the 
dorsal surface, following a mild T10 hemicontusion injury (or sham injury). The development of 
hypersensitivity was assessed and sensorimotor function established using locomotor recovery 
and electrophysiology of dorsal column pathways. Immunohistochemistry and TUNEL were 
performed to examine cellular changes in the spinal cord. It was demonstrated that red light 
penetrates through the entire rat spinal cord and significantly reduces signs of hypersensitivity 
following a mild T10 hemicontusion spinal cord injury. This is accompanied with improved 
dorsal column pathway functional integrity and locomotor recovery. The functional 
improvements were preceded by a significant reduction of dying (TUNEL+) cells and activated 
microglia/macrophages (ED1+) in the spinal cord. The remaining activated 
microglia/macrophages were predominantly of the anti-inflammatory/wound-healing sub-
population (Arginase1+ED1+). These were expressed early and in up to 7-fold greater numbers 
than that found in sham-treated animals. These findings demonstrate that a simple yet inexpensive 
treatment regime of red light reduces the development of hypersensitivity along with sensorimotor 
improvements following spinal cord injury, and may therefore offer new hope for a currently 
treatment resistant pain condition. 
3.2 Introduction 
The experience of pain serves as an essential survival mechanism that motivates us to protect 
ourselves from harm; however, following spinal cord injury, the development of treatment-
resistant neuropathic pain often ensues, bringing no advantage to the sufferer but severely 
reducing quality of life. Chronic pain affects a vast sector of the population for which the 
socioeconomic cost exceeds that of heart disease, cancer and diabetes (Gaskin and Richard, 2012); 
thus, successfully treating neuropathic pain would bring significant benefits.  
The non-invasive application of light, at wavelengths that penetrate transcutaneously (Anderson 
and Parrish, 1981), has begun to emerge as a potential therapy for improving functional outcomes 
from a variety of neural injuries (Fitzgerald et al., 2013). Photobiomodulation with wavelengths 
ranging from 630-1100 nm have demonstrated positive effects in animal models of 
neurodegenerative diseases such as: Alzheimer’s (Grillo et al., 2013) and Parkinson’s (El Massri 
et al., 2015), genetic models of dementia (Purushothuman et al., 2015), as well as acute nervous 
injuries to the retina (Albarracin et al., 2011; Eells et al., 2003; Giacci et al., 2014), optic nerve 
(Fitzgerald et al., 2010; Giacci et al., 2014), sciatic nerve (Barbosa et al., 2010; Bertolini et al., 
2011; Cidral-Filho et al., 2013; Hsieh et al., 2012; Medalha et al., 2012) and spinal cord (Byrnes 
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et al., 2005). In humans, photobiomodulation has been reported to be effective against a variety 
of pain conditions including mucositis (Hodgson et al., 2012), carpel tunnel syndrome (Elwakil 
et al., 2007; Naeser, 2006; Shooshtari et al., 2008), orthodontic pain (Turhani et al., 2006), 
temporomandibular joint pain (Maia et al., 2012), neck pain (Chow et al., 2009) and neuropathic 
pain resulting from amputation (Ribas et al., 2012).  
Inflammatory mediators have long been implicated in the development and maintenance of pain 
(Lees et al., 2013; Lees et al., 2015; Schomberg et al., 2012; Yezierski, 2000). These chemical 
mediators are controlled by a variety of immune cells including the balance of pro- and 
anti inflammatory microglia/macrophage subpopulations (Clark et al., 2015; David and Kroner, 
2011; Kigerl et al., 2009; Mantovani et al., 2013; Mantovani and Locati, 2009; Mantovani et al., 
2004; Murray and Wynn, 2011). As in non-neural tissues, macrophages can be activated by T 
helper cell type 1 (Th1) or type 2 (Th2) to generate opposing immune responses following spinal 
cord injury (David and Kroner, 2011; Kigerl et al., 2009). Th1 activated microglia/macrophages 
(M1) have been considered potentially damaging to healthy tissues, as they induce a 
pro inflammatory response and have been shown to inhibit axonal regeneration (David and 
Kroner, 2011). Conversely, Th2 activated microglia/macrophages (M2) have been considered 
protective, as they have a role in suppressing the pro-inflammatory response by producing anti-
inflammatory mediators (David and Kroner, 2011; Kigerl et al., 2009). Following spinal cord 
injury, there is evidence suggesting that the M1 response prevails over a more transient M2 
response, and this observation has been proposed to contribute to the poor regenerative capacity 
of the spinal cord following injury (David and Kroner, 2011; Kigerl et al., 2009). Consistent 
among various in vitro and in vivo studies, including spinal cord and peripheral nerve injury 
models, are reports of reduced levels of pro-inflammatory cell mediators, including as IL6, iNOS, 
MCP-1, IL1β, and TNFα in response to treatment with various wavelengths including 633 nm 
(Safavi et al., 2008), 660 nm, 780 nm (Fernandes et al., 2015), 810 nm (Byrnes et al., 2005), and 
950 nm (Cidral-Filho et al., 2013). Coincidently, these pro-inflammatory cell mediators are 
secreted by M1 cells; thus, it is worthwhile to examine the effect of light treatment on 
microglia/macrophage populations.  
There are various wavelengths used throughout the literature which demonstrate biological effects. 
In an attempt to find the better wavelength option for treating nervous system injuries, one study 
compared the effects of two wavelengths in a variety of CNS injury models, to find that 670 nm 
treatment resulted in better outcomes for a number of parameters when compared to 830 nm 
(Giacci et al., 2014). The aim therefore was to evaluate the effect of the 670 nm wavelength 
following spinal cord injury on a variety of functional parameters, namely the development of 
hypersensitivity to innocuous stimuli (allodynia), as well as on (tactile) sensory pathway 
conduction and locomotor recovery, and to see if there were alterations to the M1/M2 
sub populations. It was found that red light treatment significantly reduced the severity of 
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hypersensitivity while improving sensorimotor function, and that these improvements were 
preceded by an anti-inflammatory microglia/macrophage cell population in the injury zone. 
3.3 Methods 
3.3.1 Hemicontusion spinal cord injury   
All animal work was approved by the ANU Animal Experimentation Ethics Committee. 
Hemicontusion spinal cord injuries were performed on 7 week old Wistar rats under isoflurane 
(1.7-2.3% v/v) anaesthesia. Following hair removal, a laminectomy of T10 vertebral body and 
removal of dura and arachnoid was performed, followed by a spinal cord hemicontusion using a 
customized impactor system (Vijayaprakash and Sridharan, 2013) comprising of a cylindrical 
10 g weight with a 1 mm diameter tip that was guided onto the right dorsal horn and dropped from 
25-50 mm above the spinal cord.  
3.3.2 Treatment and experimental groups 
Injured animals were divided into 670 nm treated (SCI+670) and sham-treated (SCI) groups. 
SCI+670 rats received 30 min of 670 nm irradiation commencing 2 hrs after surgery, then every 
24 hrs after locomotor assessment for the remainder of the recovery period. A commercially 
available 670 nm LED array (WARP 75A, Quantum Devices, Barneveld, WI; 75 mm2 treatment 
area) was used for treatment. Spectral characteristics and power output (Figure 3.1) of the LED 
were measured using a spectrometer (CCS175, Thorlabs) and custom made power meter that was 
calibrated against a commercially available power meter (PM100D, ThorLabs). Treatment was 
delivered through a transparent treatment box which was used to confine the animal within its 
home cage. This resulted in a 7 mm distance between the dorsal surface of the animal and the 
LED array, and delivery of 35 mW/cm2 (fluence = 63 J/cm2) of 670 nm at the contact surface of 
the animal’s dorsum. SCI rats (n=29) were restrained in the identical way as the SCI+670 group 
(n=29), but without the LED device switched on to control for 30 mins restraint in the transparent 
treatment box. Three additional control groups were included: an intact uninjured group (control; 
n=7) was untreated and did not receive any sham operations or sham treatment; a sham-injured 
group (shamSCI; n=8) underwent the spinal surgery, but without the contusion, and were 
subjected to sham treatment; a sham-injured 670 nm-treated group (shamSCI+670; n=10) 
underwent spinal surgery without the contusion and received daily 30 min treatments.  
3.3.3 Light penetration 
Uninjured, unshaven animals (n=6) were euthanized with sodium pentobarbital solution 
(325 mg/ml; Virbac; dosage, 100 mg/kg). The overlaying heart, great vessels and muscles were 
detached from the anchoring connective tissues and retracted to the side to expose the underlying 
vertebral column. The T10 vertebral body was eroded with a dental drill to expose the spinal cord 
from the ventral surface. The sacrificed rat was placed on its back in an inverted transparent 
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treatment box so that the dorsum of the sacrificed rat could be positioned over the 670 nm LED 
array and the ventral surface of the rat was accessible to enable placement of a custom-built light 
measuring device. This device comprised of a photodiode chip (surface area, 0.62 mm2; maximal 
response (>95%) to 630-685 nm; ODD-660W, Opto Diode Corp.) that was fixed to the bottom of 
an aluminium cylinder (height, 7.0 mm; external diameter, 8.7 mm). The top of the cylinder was 
sealed with a glass coverslip and the entire probe was painted with black paint, but leaving a small 
circular window (4.0 mm diameter) centred over the chip sensor. This left a ~2.4 mm lip between 
the external edge of the glass window and the external circumference of the cylinder. When 
pressed onto the ventral surface of the spinal cord, no light could penetrate from the side because 
the chip was located 7.0 mm behind the 4.0 mm aperture, thus only light rays between 71-90 
degrees are able to reach the surface of the sensor; angles deviating from 90 degrees do not hit 
the entire surface of the photosensitive diode and therefore contribute less to the total power 
reading. The signal from the probe was amplified by a custom amplifier built for purpose. The 
key component was the logarithmic converter amplifier (AD8304, Analog Devices). The readings 
were then calibrated against a commercially available light power meter tuned at 670 nm 
(PM100D ThorLabs) by producing a calibration table for different radiant power (controlled by 
distance from the light source), and subsequently converted into intensity (power/unit area). The 
probe was used to determine light intensity from the 670 nm array through: i) the treatment box, 
ii) the spinal cord and dorsal overlying structures, and iii) the equivalent space through the air to 
provide a measure of attenuation over the distance of the light path. Prior to activating the LED, 
ambient lights were switched off, however it also confirmed that no photons were detected by the 
light meter with the ambient lights on. Three repeat readings were acquired for each measurement.  
Example images were obtained with a D1X Nikon (5.3 megapixels) camera and 120 mm lens 
(Medical NIKKOR) with a ×2 adaptor and built in ring flash. Images were captured with both the 
ambient lights and LED array on, then repeated in the same position with the ambient lights off.   
3.3.4 Temperature measurement  
A temperature probe (ML309/MLT422, ADInstruments) connected to a data acquisition system 
(PowerLab 26T, LabChart v7.3.7, ADInstruments) was attached to the dorsum of the animals 
prior to, and 2 minutes after sham or light treatment on consecutive days from 4 sham- and 4 
light-treated rats.  
3.3.5 Sensitivity assessment 
Sensitivity assessment was carried out on day 7 post-injury prior to locomotor and 
electrophysiological assessments. To assess hypersensitivity, a nylon filament (OD: 1.22 mm) 
was used to deliver innocuous tactile stimuli over 6 defined regions over the animals’ dorsum; 
Above-Level (dermatomes C6-T3), At-Level (dermatomes T9-T12) and Below-Level 
(dermatomes L2-L5) on ipsi- and contralateral sides relative to the injury. The boundary for each 
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of the 6 regions was marked on the animals’ back, and 10 consecutive innocuous “pokes” were 
delivered in each boundary at an inter-poke-interval of approximately 1-2 s, or until the animal 
recovered from movement evoked from the previous poke if longer than 2 seconds. Prior to testing, 
the operator practiced the stimulus procedure. This ensured that each poke was as brief as possible, 
that the filament landed normal (90°) to the skin surface, and that the final position of the filament 
handle was approximately half the distance to that of the distance at initial contact of the filament. 
This protocol ensured pokes of consistent duration and maximum force which was confirmed 
using a weighing balance (maximum bending force: 2.86 ± 0.09 g; n = 10 pokes). During 
sensitivity testing, animals were “semi-restrained” in a V-shaped plastic box. This restricted the 
animal’s ability to avoid the testing procedure and thereby facilitated the operator’s accuracy of 
each poke, but enabled sufficient movement for the animal to display behavioural responses of 
interest. Testing was recorded using a webcam (Logitec HD Pro C920). Videos were assessed 
blind to the observer in slow motion play back by evaluating the response to each innocuous poke 
that was graded into one of four categories as: I) no response;  II) mild response characterized by 
acknowledgment of the stimulus, head turns, brief shuddering of the contacted skin, but no 
obvious pain avoidance behaviours; III) medium response, characterized by moderate signs of 
pain perception, including moderate avoidance attempts by moving away from the stimulus; IV) 
severe response, characterized by severe signs of pain perception, including attacking the stimulus 
and “desperate” avoidance attempts and escape behaviours including jumping, running, writhing 
or audible vocalization. The four categories, I-IV, were chosen because these behaviours are 
easily distinguishable. The frequency of each response category was multiplied by a weight; 
categories I-IV were multiplied by 0, 1, √2, and 2 respectively to provide greater separation 
between ordinal pain behaviours between non-painful and painful (Coderre et al., 1993), as well 
as to help minimize heteroscedasticity of the data. The sum of the 10 weighted responses provided 
a regional sensitivity score (RSS) for each region. This paradigm enables high resolution 
measures of sensitivity to 10 innocuous pokes with each possible RSS ranging between 0 and 20. 
Scores from ipsi- and contralateral regions were pooled to determine level sensitivity scores (LSS) 
above, at and below the level of injury. A cumulative sensitivity score (CSS) was derived for each 
animal by summing the RSS from all 6 regions; the maximum CSS possible is therefore 120. The 
hypersensitivity threshold was defined by the mean + 2 standard deviations (confidence interval 
of 95.5%) of CSSs calculated from uninjured intact rats (control group).  
3.3.6 Somatosensory assessment  
Animals were anaesthetized with urethane (12.5% w/v; 1.4 g/kg; i.p.) and maintained at 37 °C on 
a heating mat. A tracheotomy was performed and animals were placed in a stereotaxic frame. The 
gracile nuclei were exposed through the foramen magnum by head flection and removal of 
overlying muscles and meninges. Both left and right sciatic and sural nerves were exposed by 
removal of the overlying skin followed by a splitting incision of the gluteus maximum and 
semimembranosus muscles respectively. The exposed nerves were isolated from adjacent 
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connective tissues and bathed in paraffin oil. Silver wire bipolar hook electrodes were used to 
stimulate sural nerves and a single hook silver wire electrode was used to record from sciatic 
nerves to ensure complete recruitment of all sural nerve fibres upon electrical stimulation (square 
wave pulse, 0.5-1.1 mA, 0.05 ms). A platinum wire electrode was used to record from a single 
midline position on the brainstem at a location that was established to provide evoked potentials 
of equal magnitude and latency from left and right sural nerve stimulation. 33 individual evoked 
potentials were recorded and averaged from the sciatic nerve and the brainstem in response to 
repeated sural nerve stimulations. Signals recorded from the brainstem were then processed 
offline (MATLAB, MathWorks). The averaged signal was band-pass filtered (500 Hz – 3350 Hz) 
and response magnitudes calculated from the integral of rectified signals (integral limits: 5.00 ms 
before and 8.75 ms after the primary peak) after subtraction from baseline levels obtained prior 
to the stimulus. Latency was measured from the filtered signal where it first exceeded 3 standard 
deviations (confidence interval 99.7%) of background levels.  
3.3.7 Locomotor assessment  
Prior to surgery, animals were trained to run along an 80 cm custom build transparent walking-
track with mirrors that reflected left and right sides and underneath of the animal. This enabled 
exquisite locomotor detail from all sides of interest to be video captured simultaneously from a 
single viewpoint. 2 h following surgery, initial recordings of animals running 3 consecutive times 
down the walking-track were acquired with a digital camera (Sony, NEX-VG20EH) at 50 frames 
per second, which provided adequate data for detailed gait analysis. Recordings were repeated 
every 24 hrs post-surgery for 7 consecutive days. Each video file was coded and assessed blind 
by one assessor. The BBB locomotor scale (Basso et al., 1995) for the left and right hind-limbs 
was used to generate locomotor scores from video files assessed in slow motion.  
3.3.8 Immunohistochemistry and TUNEL  
Animals from both groups (SCI, n = 15; SCI+670, n = 15) were divided into 3 recovery time 
points and sacrificed at 1, 3 and 7 days post-injury. At the end of designated recovery periods, 
animals were transcardially perfused with saline and 4% buffered paraformaldehyde (w/v). 
Harvested spinal cords were cryoprotected in 30% sucrose (w/v), cryosectioned at 20 µm in the 
longitudinal plane using a Leica CM1850 cryostat, and dorsal sections labelled with primary 
antibodies (1:200) against rat CD68 (ED-1 clone, MAB1435, Millipore), and Arginase-1 
(AB60176, Abcam) or CD80 (AB53003, Abcam) to quantify microglia/macrophages (ED1+) and 
polarized subtypes M1 (CD80+ED1+) and M2 (Arginase1+ED1+) respectively. Tissue was 
subsequently incubated with the appropriate secondary antibodies (1:1000, Invitrogen, Alexa 594 
conjugated chicken anti-goat #A21468, Alexa 488 conjugated goat anti-mouse #A31619, Alexa 
594 conjugated goat anti-mouse #A31623, Alexa 488 conjugated donkey anti-rabbit #A21206). 
Slides were then incubated in Hoechst solution (2 µg/ml Sigma-Aldrich). Standard 
immunohistochemical controls were included. 
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To detect cells undergoing apoptosis/necrosis, a TUNEL assay was performed. Slides were 
incubated with 1:10 Terminal Deoxynucleotidyl Transferase (TdT) buffer (125 mM Tris-HCl, 
1M Sodium Cacodylate, 1.25 mg/ml BSA, pH 6.6) for 10 min and then 1hr incubation at 37 °C 
with reaction mixture [0.5 enzyme unit/µl TdT (Roche Applied Science), and 2.52 µM 
Biotin 16 dUTP (Roche Applied Science) diluted in 1:10 TdT buffer]. This was followed by 
15 min incubation in 1:10 saline Sodium Citrate (SSC) buffer (175.3 mg/ml Sodium Chloride, 
88.2 mg/ml Sodium Citrate, pH 7.0) and blocked with 10% normal goat serum in 0.1M PBS for 
10 min before incubating with secondary antibody in 0.1M PBS (1:1000 dilution, Invitrogen, 
Alexa 488 conjugated streptavidin S11223) at 37 °C for 30 min.   
All image analysis was performed blind to the experimental group. 2D images were constructed 
from three colour channel (red, green and blue) images acquired from a LED fluorescent 
microscope (Carl Zeiss Colibri) with a 20× objective and digital camera (AxioCam MRc 5) with 
all settings kept constant for each channel. Cells with co-labelling were quantified with ImageJ 
(v1.46r) using the Cell Counter plugin that enables the placement of different classes of markers 
onto an image. Cytoplasmic markers, a class for each channel, were used to tag positive label in 
a single focal plane for all green and red channels that were examined independently. To define 
ED1+ cells, the accompanying DAPI+ nucleus (blue channel) was tagged for cells where ED1 
staining was clearly complementing the DAPI surface profile. Double labelled cells (i.e. 
ED1+Arginase1+ or CD80+) were evaluated by scrutinising all tagged DAPI+ cells for co-labelling 
in red and green channels. These cells were tagged again with another marker class. All markers 
were automatically quantified for each class by the software.  Cells out of focus were not included. 
Cell counts were obtained from dorsal horn regions with viable tissue and quantified as the mean 
of duplicate images, each covering a minimum area 0.05 mm2. The areas of interest were defined 
and quantified prior to cell quantification, and included the dorsal horn grey matter region as well 
as the white matter in the surrounding dorsal columns and lateral funiculus. Cell quantification is 
expressed as the number of cells per unit area (mm2).   
3.3.9 Statistics  
All data expressed as box plots and individual points in figures or as mean ± SEM in the main 
text unless otherwise stated. Box plots indicate the median, upper and lower quartiles with 
whiskers extending to maximum and minimum values excluding outliers (more than 1.5 times 
respective quartiles). Statistical analysis was carried out using R or MATLAB, and a criterion 
alpha level of 0.05 was adopted as statistically significant. Data sets were tested for normality and 
homoscedasticity and t-tests, ANOVA, linear mixed models were applied for normally distributed 
data (indicated by *) and Wilcoxon rank-sum (indicated by †) where data was not normally 
distributed. 
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3.4 Results  
3.4.1 Red light penetrates the spinal cord 
It was first set out to demonstrate that red light can pass through superficial and deep structures 
underlying the dorsal exterior surface and penetrate the entire spinal cord (Figure 3.1). The 
penetrating light could be seen with the naked eye (example, Figure 3.1a-b). The dorsal surface 
of uninjured rats (n = 6) was exposed to the LED array and 670 nm light intensity measured at: 
the light source surface thorough the transparent treatment box which directly contacts the rat 
dorsum during treatment (Figure 3.1c, intensity at dorsal surface; 35.4 ± 0.05 mW/cm2), and the 
ventral surface of the spinal cord, where light had to pass through an additional ~10 mm of the 
animals’ tissues from dorsal surface (Figure 3.1c, intensity at ventral surface; 3.2 ±  0.6 mW/cm2). 
These data show that 91.1 ± 1.8% of the light from the LED array was absorbed/dispersed by the 
tissues between the dorsal surface of the animal and the ventral surface of the spinal cord (Figure 
3.1c, black arrow). To indicate the approximate attenuation over the distance of light travelling 
from the light source through to the ventral spinal cord surface, the intensity at the approximate 
distance (10 mm) thorough the air was measured (33.0 ± 0.5 mW/cm2). This demonstrated that 
the expected attenuation (~7%) of light is negligible over the distance required to travel to the 
ventral surface of the cord.  
 
 
Figure 3.1 Externally applied red light penetrates through the entire rat spinal cord. 
(a) Photograph shows the ventral surface of the spinal cord following removal of the T10 vertebral 
body in a sacrificed rat. Topography of the vertebral column is shown centred around the 10th 
vertebral body under normal light conditions. (b) The identical region as shown in a, with a 
670 nm LED array light source (35 mW/cm2) placed directly on the dorsum of the animal and 
with ambient lights switched off. Note the visible red light illuminating from the ventral surface 
of the cord (exposed, arrow) indicating excess penetration through dorsal layers of hair, skin, 
muscle, bone and spinal cord. (c) Intensities measured by a 670 nm power meter are shown for 6 
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freshly sacrificed rats (each dot represents the mean of triplicate readings). Readings shown are 
taken at the light source (through the Perspex restraining box, intensity at dorsal surface) and at 
the ventral surface of the spinal cord as shown by the white arrow in b (intensity at ventral 
surface). Black arrow indicates proportion of light absorbed and/or scattered by intervening 
tissues. (d) Spectral analysis of the light source indicating central frequency of 675 nm.   
 
3.4.2 Surface temperature changes following light treatment  
The surface temperature of rats was measured directly before, and 2 minutes after treatment. 27 
readings from sham-treated, and 25 readings from light-treated animals were acquired from 4 
animals in each group over consecutive days of treatment. While there was no significant 
difference in the surface temperature of sham-treated animals (before, 33.6 ± 0.23 ℃; after, 
33.6 ± 0.25 ℃) there was a small, but significant increase following light treatment (before, 
32.8 ± 0.36 ℃; after, 33.5 ± 0.22 ℃; p = 0.038, paired t-test).  
3.4.3 Red light reduces allodynia following spinal cord injury 
To examine the effect of red light on the development of neuropathic pain, allodynia was assessed 
on 6 regions over the rat dorsum using a T10 hemicontusion spinal cord injury model that results 
in clear development of hypersensitivity in most animals within 7 days.  The T10 spinal 
hemicontusion resulted in 63% of animals (n = 12) developing hypersensitivity in both sham-
treated (SCI, n = 19) and light-treated (SCI+670, n = 19) groups at 7 days post-injury. The 
hypersensitive subpopulation of rats from the SCI group had a mean CSS (SCI, CSS: 25.3 ± 4.5) 
that was 3.7 × the hypersensitive threshold (Figure 3.2a). The mean CSS was significantly 
reduced by 40% (SCI+670, CSS: 14.5 ± 1.6; 2.1 × the hypersensitivity threshold) in the 
hypersensitive subpopulation of rats from the SCI+670 group. Light treatment significantly 
reduced At- (T9-T12 dermatomes) and Below- (L2-L5 dermatomes) LSSs, which arose from 
contralateral At-Level and both ipsi-and contralateral Below-Level regions (Figure 3.2b). 
Compared to the uninjured control group (control, Figure 3.2c), sham injury without light 
treatment (shamSCI, n = 8) had no significant effect on LSS or RSS despite two sham-injured 
animals developing At-Level hypersensitivity. Light treatment of sham-injured animals 
(shamSCI+670, n = 10) resulted in significant reductions of At- and Below-LSS compared to the 
shamSCI group (Figure 3.2c). Thus, while the incidence of hypersensitivity was not altered by 
red light, the level of hypersensitivity was markedly reduced At- and Below-levels in T10 
contused light-treated allodynic animals. Red light also caused a significant reduction in 
sensitivity in 670-treated sham-injured animals (shamSCI+670, CSS: 0.8 ± 0.5) compared to 
uninjured control animals (control, CSS: 2.8 ± 0.8) as well as normosensitive spinal cord injured 
animals (SCI, CSS: 3.5 ± 0.9), even though these animals were not hypersensitive.  
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Figure 3.2 Hypersensitivity is reduced by red light treatment at 7 days post T10 
hemicontusion spinal cord injury. 
(a) CSSs (see the “Methods” section) for all groups are separated by the hypersensitivity threshold 
(6.9; indicated by dotted green line) into normosensitive (CSS < hypersensitivity threshold) and 
hypersensitive (CSSs > hypersensitivity threshold) subpopulations. (b) RSSs in hypersensitive 
sham-treated (SCI, dark blue) and 670 nm-treated (SCI+670, dark red) spinal cord injured animals 
(location of injury indicated). RSSs are represented as the mean ± SEM (colour-coded according 
to the insert: mean + SEM, mean, and mean − SEM concentrically represented) for the six tested 
regions (left and right sides; “Above-Level”, “At-Level” and “Below-Level” relative to the 
injury). RSSs are overlaid on schematic representations of the rat dorsum, with C2, T1, L1 and 
S2 dermatomes, and the midline, indicated (grey). Individual RSSs and LSSs are compared 
between hypersensitive subpopulation of the two groups. (c) RSSs shown for normal uninjured 
rats (control, green), sham-injury + sham-treatment (shamSCI, light blue, data includes both 
normo- and hypersensitive subpopulations), and sham-injury + 670 nm treatment (shamSCI+670, 
light red). Pairwise statistical comparisons are indicated for RSSs and LSSs by respective group 
colours. Note: statistical comparisons of CSSs from shamSCI+670 group in a is to the 
normosensitive subpopulation of SCI (indicated in dark blue) and to control groups (indicated in 
green); Statistical comparisons of RSSs from control group in c is to SCI (indicated in dark blue) 
or to SCI+670 (indicated in dark red) in b. * p < 0.05 (Student’s t test); † p < 0.05, †† p < 0.01, ††† 
p < 0.001, †††† p < 0.0001, (Wilcoxon rank-sum); ns, p > 0.05; n values indicated. 
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3.4.4 Red light improves sensory conduction through dorsal column 
pathways 
Could red light cause an anaesthetic-like effect on somatosensation that resulted in reduced 
sensitivity scores? To rule out the possibility that red light causes a reduced responsiveness to 
innocuous stimuli by bringing about a generalized inhibitory effect on somatic neural pathway 
conduction, the functional integrity of the sensory dorsal column pathway was quantified, at 7 
days post-injury. The dorsal column pathways were activated by electrical stimulation of the left 
and right sural nerves, and a recording electrode was placed on the midline of the gracile nuclei 
(Figure 3.3a). Stimulation of left and right nerves from control animals (n = 7) evoke responses 
of equal magnitude (Figure 3.3b; right side: 101 ± 8% of left side) and latency (Figure 3.3c; 
left-right side latency difference: 0.09 ± 0.03 ms) on both sides when recorded from the same 
midline-positioned recording electrode, while sham-treated T10 hemicontusion spinal cord injury 
(n = 7) resulted in a 37% reduction in magnitude (right side: 63 ± 16% of left side), and a 
0.48 ± 0.09 ms delay of the injured (right) pathway, when comparing the intact (left) side. Red 
light treatment (n = 7) rescued both the magnitude (Figure 3.3b; right side: 93 ± 17% of left side) 
and latency (Figure 3.3c; left-right side latency difference: -0.05 ± 0.35 ms) deficits otherwise 
observed in the SCI group, indicating that red light treatment restored sensory pathway 
conduction, rather than impeding it. Furthermore, the rescued magnitude and latency deficits in 
the SCI+670 group indicates that their reduced sensitivity scores (Figure 3.2) were unlikely to 
have resulted from a generalized reduction of somatic neural conduction.  
A variety of control experiments were performed to validate the interpretations. There was no 
observable difference of conduction magnitudes or latencies in any of the sham injured animals 
(shamSCI, n = 4; shamSCI+670, n = 4). There was no significant difference between gracile 
nuclei potentials evoked from the left sural nerve in any of the groups (SCI, 15.9 ± 1.8 µV·ms; 
SCI+670, 11.9 ± 2.4 µV·ms; control, 16.2 ± 3.6 µV·ms; shamSCI, 10.8 ± 2.6 µV·ms; 
shamSCI+670, 15.0 ± 2.8 µV·ms; p = 0.70, one-way ANOVA). Similarly, there was no 
significant difference of response latencies when evoked on the left side for all groups (SCI, 
33.7 ± 0.3 µV·ms; SCI+670, 34.0 ± 0.4 µV·ms; control, 34.0 ± 0.4 µV·ms; shamSCI, 
34.2 ± 0.5 µV·ms; shamSCI+670, 34.7 ± 0.3 µV·ms; p = 0.51, one-way ANOVA). These control 
experiments indicated that dorsal column pathway response magnitudes and latencies were 
similar between the different groups and largely unaffected contralateral to the injury. 
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Figure 3.3 Dorsal column somatosensory functional deficits from T10 hemicontusion spinal 
cord injury is reversed by red light treatment. 
(a) Schematic of experimental paradigm for evaluating somatosensory (dorsal column pathway) 
functional integrity illustrating left and right dorsal column pathways (grey), T10 hemicontusion 
injury on right side, stimulation of sural nerves, and location of recording electrode on midline of 
gracile nucleus. The same electrode position on the midline acquires somatosensory responses 
independently evoked from both left and right sural nerves, enabling direct comparable 
quantification of sensory pathways on both sides. Examples of responses (between 5-15 ms post-
stimulus; 500-3350 Hz bandpass) evoked from left and right sides shown for respective groups 
(colour-coded as per legend in c and Figure 3.2). Arrowheads indicate latency of response onset. 
(b) Quantification (integral of rectified signals) of gracile nucleus response magnitudes (right 
expressed as a percent of left). (c) Difference in latencies of evoked responses between left and 
right sides. Note magnitudes and latencies from intact animals are equal on both sides (control 
group). * p < 0.05; ** p < 0.01, Student’s t-test, Tukey’s post-hoc in c). 
 
3.4.5 Red light improves locomotor recovery 
Could red light treatment cause motor deficits and thereby result in reduced sensitivity scores? 
To rule out the possibility that the red light impeded the animals’ ability to perform escaping 
locomotor behaviours, daily locomotor recovery was examined blind to the experimental group 
(Figure 3.4). It was found that rather than impeding locomotion, the SCI+670 group (n = 11) 
demonstrated improved locomotor recovery as early as 2 days post-injury on the ipsilateral side, 
and 3 days post-injury on the contralateral side compared to the sham-treated group (n = 10). 
Although a group effect of red light improvement was evident on the ipsilateral side (p = 0.026, 
linear mixed effects model with repeated measures), this failed to reach significance on the 
contralateral side (p = 0.055). There was a highly significant effect of time for both sides 
(p < 2e-16). Locomotor improvements observed in the SCI+670 group indicate that reduced 
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sensitivity scores in light treated animals (Figure 3.2) could not have resulted from locomotor 
deficits.  
 
 
Figure 3.4 Locomotor recovery is improved by red light treatment following T10 
hemicontusion spinal cord injury. 
Daily locomotor scores (BBB, see methods) following a right-sided hemicontusion spinal cord 
injury are shown for the contralateral (a) and ipsilateral (b) sides. Red light treatment results in 
significant locomotor improvements on both sides over the period indicated by the black bar 
(large asterisk, ANOVA/linear mixed effects model with repeated measures). Point-wise 
comparisons between groups for individual time points are also shown (small asterisks, Student’s 
t-test). Individual data points are presented as open square or circular dots; lines indicate the group 
means. * p < 0.05; ** p < 0.01. 
 
3.4.6 Red light reduces cell death at the injury zone 
To examine the effect of red light on cell death following injury, the number of TUNEL+ cells 
was quantified at 1, 3 and 7 days post-injury in dorsal regions of the T10 spinal cord (Figure 3.5, 
n = 5 for each time point). The SCI group resulted in an increased density of TUNEL+ cells in the 
dorsal spinal cord ipsilateral to the injury as early as day 1 (contralateral 1.5 ± 1.5 cells/mm2; 
ipsilateral 96.8 ± 41.1 cells/mm2), reaching maximum levels by day 3 (contralateral 13.1 ± 5.6 
cells/mm2; ipsilateral 126.8 ± 41.5 cells/mm2). The contralateral side had much fewer cells where 
maximum levels were reached by day 7 (Figure 3.5; contralateral 32.5 ± 32.5 cells/mm2; 
ipsilateral 74.2 ± 43.7 cells/mm2). Red light treatment resulted in a significant group reduction of 
TUNEL+ cells in the ipsilateral side, notably significant at the day 3 time point when TUNEL+ 
cells were maximal in the sham-treated group (1-dpi: 49.6 ± 25.2 cells/mm2; 3-dpi 18.2 ± 3.9 
cells/mm2; 7-dpi 22.0 ± 6.1 cells/mm2). There was no significant difference in TUNEL labelling 
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on the contralateral side between groups (1-dpi: 2 ± 2 cells/mm2; 3-dpi 6.2 ± 2.1 cells/mm2; 7-dpi 
5.0 ± 3.9 cells/mm2).  
 
 
Figure 3.5 Cell death is reduced by red light following T10 hemicontusion spinal cord injury. 
Quantification of cells undergoing cell death (TUNEL+) contralateral (a) and ipsilateral (b) to the 
injury. Example images are from SCI (c) and SCI+670 (d) dorsal horn ipsilateral to the injury at 
3 days post-injury. Schematic cross section of spinal cord (bottom) indicates location of injury 
(dark grey penumbra) and region of quantification (light grey region). Scale bars: 50 µm. 
* p < 0.05 (Student’s t-test); ** p < 0.01 (linear mixed model). 
 
3.4.7 Red light reduces total activated microglia/macrophages but 
promotes the expression of the anti-inflammatory/wound healing 
(M2) subtype.  
Inflammation has long being implicated in the development of neuropathic pain (Schomberg et 
al., 2012). Activated microglia/macrophages (ED1+ cells) were therefore quantified at 1, 3 and 7 
days post-injury in dorsal regions of T10 spinal cord (Figure 3.6a-d, n = 5 for each time point). 
T10 spinal contusion resulted in an increase in ED1+ cell density as early as day 1 post-injury, 
reaching maximum levels by day 3 in the ipsilateral side. Maximum levels were also reached at 
day 3 on the contralateral side but there were negligible ED1+ cells at days 1 and 7. Light treatment 
significantly reduced ED1 expression ipsilateral to the injury to approximately half that of the 
SCI group. Despite the low levels of ED1+ cells in the contralateral side, red light treatment also 
resulted in a significant reduction of ED1+ cells at the 3-day time point.  
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Microglia/Macrophages can adopt pro- or anti-inflammatory states (David and Kroner, 2011). To 
determine the effect of red light treatment on the expression of pro-inflammatory (M1) cells, cells 
co-expressing CD80 and ED1 were quantified as a proportion of total ED1+ cells (Figure 3.6e-h, 
n = 5 for each time point). The proportion of CD80+ED1+ cells ipsilateral to the injury was 
maximal at day 1 and remained greater than 40% of the ED1 population at days 3 and 7 in more 
than half of animals. CD80+ED1+ cells were only found at day 3 on the contralateral side which 
coincided with the maximum number of ED1+ cells at that time point. Red light treatment did not 
have a significant impact on the proportion of M1 cells on either the ipsi- or contralateral sides. 
Note that no CD80+ED1+ cells were encountered at days 1 and 7 contralateral to the injury as 
ED1+ cells were also in small quantities at these time points (Figure 3.6a).  
To determine the effect of red light treatment on the expression of anti-inflammatory/wound 
healing (M2) microglia/macrophages, ED1+ cells co-expressing Arginase-1 were quantified as a 
proportion of total ED1+ cells (Figure 3.6i-l, n = 5 for each time point). In the SCI group 
Arginase-1 expression increased with time ipsilateral to the injury (p = 0.0048, one way ANOVA), 
but peaked at day 3 contralateral to the injury at the time when most ED1+ cells were present in 
that region. Ipsilateral to the injury the SCI+670 group displayed significantly increased 
proportions of Arginase1+ED1+ cells from day 1, reaching approximately 7 fold that of the SCI 
group. This greater Arginase1+ED1+ proportion in light treated animals was maintained at over 
one third of ED1+ cells for the entire duration investigated for the majority of animals. No 
Arginase1+ED1+ cells were detected contralateral to the injury in the SCI+670 group, however, 
there were very few ED1+ cells in this region (Figure 3.6a). The group effect failed to reach 
significance contralateral to the injury (p=0.0628) despite a significantly greater level of 
Arginase1+ED1+ cells in the SCI group.  
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Figure 3.6 Anti-inflammatory microglia/macrophages are promoted early by red light 
treatment following T10 hemicontusion spinal cord injury. 
(a-d) Total activated microglia/macrophages (ED1+) per mm2 contralateral (a) and ipsilateral 
(b) to the injury and example images from SCI (c) and SCI+670 (d) groups. (e-h): M1 
(pro-inflammatory) microglia/macrophages (CD80+ED1+ double labelled) expressed as a 
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proportion of total ED1+ cells contralateral (e) and ipsilateral (f) to the injury and example 
images from SCI (g) and SCI+670 (h) groups. (i-l): M2 (anti-inflammatory) 
microglia/macrophages (Arginase1+ED1+ double labelled) expressed as a proportion of total 
ED1+ cells contralateral (i) and ipsilateral (j) to the injury and example images from SCI (k) and 
SCI+670 (l) groups. All example images are taken from the injury zone of the dorsal horn at 7 
days post-injury. Schematic cross section of spinal cord (bottom) indicates location of injury 
(dark grey penumbra) and region of quantification (light grey region). Scale bars: 50 µm. 
* p < 0.05 (linear mixed model); ** p < 0.01, *** p < 0.001 (Student’s t-test); † p < 0.05, 
†† p < 0.01, ††† p < 0.001 (Wilcoxon rank-sum). 
 
3.5 Discussion  
Following spinal cord injury, 35 mW/cm2 of red (670 nm) light transcutaneously applied for 30 
min/day for 7 days to the dorsal surface of rats is sufficient to reach the entire spinal cord and 
reduce the expression of pain behaviours. These reduced signs of allodynia are not due to 
sensorimotor deficits, as red light treatment improves both sensory and motor function. Alleviated 
hypersensitivity, improved tactile/proprioception (dorsal column) pathway functional integrity, 
and locomotor functional outcomes are preceded by reduced numbers of dying cells and reduced 
numbers of activated microglia/macrophages around the injury zone. Furthermore, the proportion 
of anti-inflammatory/wound healing (M2) microglia/macrophages is greatly enhanced by 24 
hours following light treatment.  
The power output of the red light was sufficient to penetrate the entire rat spinal cord as red light 
could be seen with the naked eye illuminating through to the ventral surface of the cord in the 
sacrificed rat models. While penetration through to the rat spinal cord was achievable with an 
intensity of 35 mW/cm2, future studies would be required to determine the exposure parameters 
to achieve an equivalent level of irradiation in humans. The finding of 91% absorption (9% excess 
penetration) is a conservative measure for two main reasons: i) penetration measurements were 
obtained through the hair of unshaven sacrificed rats (the injury site of all injured animals was 
shaven), and ii) deoxygenated haemoglobin absorbs 670 nm significantly more than oxygenated 
haemoglobin (Meglinski and Matcher, 2002; Tin and Lal, 2015). Measurements from freshly 
scarified animals are therefore likely to have increased levels of deoxygenated blood, and thus 
reduced penetration, compared to live animals. Another factor to consider is the small attenuation 
of light as a function of distance from its source. The estimation indicates that over 93% of the 
light would have reached the spinal cord ventral surface if no intervening tissues were present to 
absorb the light, thus the effect of distance appears to be negligible. 9% excess penetration (i.e. 
91% absorption) from the surface of skin (with hair intact) through all intervening tissue layers 
to the ventral surface of the spinal cord with a device delivering approximately 35 mW/cm2 is 
consistent with a recent study that demonstrated an excess penetration of 6.6% through the surface 
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of the skin and the muscle overlying the spinal cord with a device producing approximately 
16 mW/cm2 in sacrificed Fisher rat (Giacci et al., 2014).  
Temperature of sham-treated animals was not significantly different before and after treatment, 
while light treated animals’ experienced a significant 1.2℃ increase. This increase does not 
exceed the normal range for rat tail skin temperature variations which have been reported to 
oscillate by ± 2℃ within a 2-hour time frame (Gordon et al., 2002). However, as there was a 
significant temperature increase 2 minutes after light treatment, it is likely that there was a larger 
temperature difference during the 30 min treatment period. Therefore the possibility that 
temperature increases did not impact on the findings cannot be ruled out. Nevertheless, red light 
treatment does result in significant functional and cellular improvements; regardless if 
temperature is a contributing factor. If temperature increases were to contribute toward improved 
outcomes, it would be in contrast to studies of hypothermic treatment which propose superior 
outcomes following spinal cord injury (Ahmad et al., 2014; Alkabie and Boileau, 2016; Maybhate 
et al., 2012). As the mechanism(s) of action for light-treatment improvements remain to be 
elucidated, future investigations isolating the effect of temperature and light are warranted.  
This study is the first to report a red light-induced locomotor improvement following a spinal cord 
injury, which contradicts the only other study by Giacci et al. (2014) that examined 670 nm on 
locomotor recovery with a daily dose of 28.4 J/cm2; an intensity of 15.8 mW/cm2 for 30 mins, i.e. 
less than half the intensity of the present study. The compounded effect of reduced intensity and 
a more severe contusion injury in their study may explain this difference, and furthermore, 
suggests that matching the appropriate light dosage to the injury severity is of paramount 
importance.  
The T10 hemicontusion injury model resulted in allodynia within 7 days in a subset of animals. 
This injury model results in neuropathic pain because hypersensitivity developed above and 
below the level, as well as contralateral to the injury, i.e. at dermatomes that receive their 
innervation from outside the injury epicentre. This observation is also consistent with findings 
from an investigation using a C5 hemicontusion injury model, and which also found a subset of 
animals developing allodynia from 7 days post-injury that lasted for least 42 days (Detloff et al., 
2013). The current observation of allodynia on the animals’ dorsum is also consistent with a T13 
hemi-section injury model, that also results in clear development of hypersensitivity in most 
animals within 7 days and that remains persists for several weeks (Christensen and Hulsebosch, 
1997).  
It was found that red light treatment reduced the severity, but not the incidence of hypersensitivity 
at 7 days post-injury. As allodynia reached sensitivity levels of almost four times that of the 
hypersensitivity threshold, a milder injury causing sensitivity scores closer to the hypersensitivity 
threshold boarder would result in a reduction of both the severity and incidence of hypersensitivity. 
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The finding that the shamSCI+670 group demonstrated sensitivity significantly lower than that 
of the intact control and shamSCI groups was curious. Sham injury may have activated anti-
nociceptive descending pathways such as periaqueductal grey/raphe magnus-mediated inhibition 
of dorsal horn nociceptive inputs (Ossipov et al., 2010). Thus, endogenous central anti-
nociceptive mechanisms, compounded by a red light-induced anti-inflammatory 
microenvironment, could be responsible for the sham-injured-light-treated animals expressing 
less sensitivity than observed in uninjured animals. This speculation warrants further investigation 
as red light-augmented relief from pain would have significant clinical relevance for post-surgical 
pain treatment.  
Quantification of pain behaviours relies on sensory and motor functional integrity. The reduced 
expression of allodynia in red light treated animals was not due to diminished general somatic 
sensation or impeded motor function because red light improved, rather than impeded these 
parameters. Locomotor recovery and sensitivity testing was scored blind to the experimental 
group and therefore any subjective bias was eliminated. Sural nerve evoked somatosensory 
potentials in the gracile nuclei provided an objective and precise measure of somatic sensory 
functional integrity of both left and right dorsal column pathways. Sural nerves were stimulated 
to recruit all nerve fibres, and therefore input to the spinal cord was identical on both sides, while 
the recording conditions on the midline of the gracile nuclei were also identical during the 
acquisition of evoked potentials elicited from pathways of both sides. Therefore, the only 
difference in the responses between the left and right sides was due to alterations within their 
respective dorsal column pathways. It was further confirmed by demonstrating equal magnitudes 
and latencies of somatosensory potentials in the gracile nuclei when evoked from left and right 
sural nerves of intact and sham injured animals. Thus, the current data indicates that reduced 
expression of behavioural signs of pain following red light treatment are unlikely to have resulted 
from locomotor or sensory deficiencies, but rather, represent a true reduction of pain experienced 
by the light treated rats.  
Whilst this study is the first to demonstrate red light-induced pain relief from spinal cord injury, 
it is consistent with peripheral nerve injury studies that report pain relief accompanied by 
light-induced alterations to the inflammatory response (Bertolini et al., 2011; Cidral-Filho et al., 
2013; Giuliani et al., 2004; Hsieh et al., 2012; Lorenzini et al., 2010). The functional 
improvements found in red light treated animals were observed after a significant reduction in 
cell death was apparent at day 3 post-injury; a time coincident with maximal levels of activated 
microglia/macrophages in the injury zone of sham-treated animals. The observations of reduced 
ED1+ cells in 670 nm treated animals is consistent with that found in retinal damage (Albarracin 
et al., 2011), as well as another study that demonstrated similar proportions of ED1 cell 
suppression lasting up to 14 days post corticospinal tract lesion in rats that received daily 810 nm 
diode laser treatments (Byrnes et al., 2005). In the latter study by Byrnes et al., they also 
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demonstrated functional improvements of some motor tasks; also consistent with improved 
locomotor function observed in this study. While the mechanisms for 810 nm vs. 670 nm 
wavelengths to suppress microglia/macrophage activation and improve motor function cannot be 
speculated, it is noteworthy that both wavelengths evoke peak levels of cytochrome C oxidase 
activity and ATP production (Desmet et al., 2006). However, wavelength (i.e. 660 nm vs. 780 nm) 
has been shown to alter the expression of inflammatory mediators expressed by activated pro-
inflammatory microglia/macrophages (Fernandes et al., 2015), and light dosage has been shown 
to alter the balance of M1/M2 cell expression (von Leden et al., 2013). These in vitro studies 
suggest that other mechanisms, unrelated to cytochrome C oxidase, may influence the 
inflammatory microenvironment following light treatment. Furthermore, they highlight the 
necessity for thorough investigations to establish the therapeutic limits of any wavelength under 
investigation. 
While others have demonstrated the impact of wavelength and dose on inflammatory cells in vitro 
(Fernandes et al., 2015; von Leden et al., 2013), this study is the first to demonstrate the effect of 
670 nm light on the polarization of activated microglia/macrophages following spinal cord injury 
in vivo. The pattern and sequence of pro-inflammatory M1 (CD80+ED1+) cell activation, cell 
death, followed by anti-inflammatory/wound-healing M2 (Arginase1+ED1+) recruitment 
observed in sham-treated animals in this study is consistent with what is expected under 
conditions of spinal cord injury and repair (David and Kroner, 2011; Kigerl et al., 2009). However, 
the current data indicates that red light-induced reduction of cell death is preceded by the 
upregulation of M2 cells as early as one day post-injury. This is intriguing because the M2 cell 
expression preceded that of the M1 cells, indicating that red light drastically altered the normal 
sequence of inflammatory events. It is therefore speculated that the early presence of protective 
M2 cells may have caused the reduced subsequent population of dying (TUNEL+) cells. 
Insufficient expression of the M2 subtype in spinal cord injury, in contrast to peripheral nerve 
injury, has been suggested to be a contributing factor to the poorer regenerative capacity and 
functional outcomes in spinal cord injury compared to peripheral nerve injury (David and Kroner, 
2011; Kigerl et al., 2009). That red light had a strong impact on promoting the M2 cell types as 
early as 24 h after treatment followed by reduced levels of cell death and then improved sensory 
and motor functional outcomes thereafter, is consistent with previous suggestions that enhancing 
the M2 population during recovery from spinal cord injury may indeed significantly contribute to 
improving functional outcomes following spinal cord injury (Kigerl et al., 2009).  
3.6 Conclusion 
Modulating the severity of neuropathic pain by simply applying red light is an exciting prospect 
with great significant clinical relevance, despite not yet fully understanding the mechanism behind 
photobiomodulation. The current data demonstrates that red light treatment, a non-invasive and 
cost-effective treatment, is able to significantly reduce the severity of pain in rats acutely after 
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spinal cord injury, and these behavioural changes are accompanied by alterations to the 
alternatively activated macrophage population. Early pain intervention is considered important to 
avoid the prospects of developing chronic pain (Siddall et al., 2003). As 670 nm light therapy is 
FDA approved, it could be quickly adopted as an adjunct to early treatment of spinal cord injury. 
Not only could this minimize the severity of pain to sufferers, it may also provide collateral 
benefits which include functional improvements to other sensory/motor systems. However, 
translation to human patients requires further studies to determine exposure parameters such as 
the light intensity necessary to penetrate the human spinal cord.  
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4.1 Abstract 
Many spinal cord injured patients develop neuropathic pain, which may be driven by spinal cord 
inflammatory mediators. It was previously demonstrated that treatment using 670 nm (red) light 
irradiation alters microglia/macrophage responses and alleviates mechanical hypersensitivity at 7 
days post-injury. Here, the effects of red light on the development of mechanical hypersensitivity 
following spinal cord injury preceding the 7 days post-injury, and on pain associated cells and 
cytokines were investigated. A mild T10 hemicontusion spinal cord injury was induced in 8-
week-old male Wistar rats (n = 64). Two additional age-matched groups received sham surgeries 
(n = 18). A subset of animals was subjected to daily red light-treatment (30 min/day; 670 nm LED; 
35 mW/cm2). Mechanical sensitivity of the rat dorsum was assessed from 1 day post-injury and 
repeated every second day. The spinal cords of these animals were also collected from 1, 3, 5 and 
7 days post-injury for analysis of astrocyte activation (GFAP) and pro-inflammatory markers 
(IL1β and iNOS) in microglia/macrophages at the injury level. Red light treatment significantly 
reduced the chance of developing mechanical hypersensitivity following spinal cord injury (p < 
0.05) for the first 5 days. This effect was accompanied by a reduction in astrocyte activation (p < 
0.05) and a reduction in iNOS expression in IBA1+ cells (p < 0.05). However, IL1β expression in 
GFAP+ and IBA1+ cells were not altered by red light treatment throughout the recovery period. 
The results indicate that red light treatment decreases the development of mechanical 
hypersensitivity over the first 5 days post-injury while reducing mechanical sensitivity in 
normosensitive animals. These effects are associated with reduced iNOS expression in 
microglia/macrophages and a reduction in astrocytes that do not express IL1β. 
4.2 Introduction 
The World Health Organisation estimates between 250,000 and 500,000 people suffer from spinal 
cord injury each year globally with an incidence of up to 1000 per million (Singh et al., 2014; 
World Health Organization and International Spinal Cord Society, 2013). About 65-80% of spinal 
cord injured patients develop neuropathic pain (NP) (Dijkers et al., 2009; Jensen and Finnerup, 
2014; Pascoal-Faria et al., 2015; Turner et al., 2001) which is considered severe in 20-30% of 
cases (Bryce, 2009). Multi-therapeutic approaches utilising combinations of pharmacological 
intervention, exercise, massage and physiotherapy are often employed to manage NP, however, 
these approaches require significant resources from different professionals and family members, 
and are generally inefficient (Bryce, 2009; Widerstrom-Noga et al., 2014). 
Hyperalgesia and allodynia are two NP characteristics where the pain threshold is reduced, 
resulting in an “exaggeration” or “false alarm” of pain perception respectively (Jensen and 
Finnerup, 2014). The understanding of the mechanisms of NP development remain incomplete, 
but there is consensus that NP following spinal cord injury is implicated with alterations in the 
central nervous systems (D'Angelo et al., 2013). Activated glial cells, namely 
microglia/macrophages and astrocytes, have long been associated with both the development and 
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the maintenance of NP, through their complex secretory profile (Chiang et al., 2012). The major 
cytokine secreted by glial cells, interleukin-1 beta (IL1β), is believed to sensitize dorsal horn 
neurons that are responsible for both the development of, and providing positive feedback to 
enhance and maintain NP (Ji et al., 2009; Kobayashi et al., 2011; McMahon and Malcangio, 2009; 
Nakagawa and Kaneko, 2010; Nakajima et al., 2011). Nitric oxide (NO), which is mainly derived 
from microglial inducible NO synthase (iNOS), has been shown to modulate long-term 
potentiation of C-fibres that eventually leads to hypersensitivity (Ikeda et al., 2006). Several 
studies have shown that by altering some of these key inflammatory mediators, it might be 
possible to stall the development of NP, or even depress its severity following spinal cord injury 
(Galan-Arriero et al., 2014; Hu et al., 2016; Tateda et al., 2017; Watanabe et al., 2015). 
Light therapy refers to the application of light irradiation, using laser or light emitting diodes 
(LED), to modulate the cellular biology in the pursuit of clinical benefits. Wavelengths between 
630 nm and 830 nm have been demonstrated to reduce glial activation and reduce secretion of 
inflammatory cytokines in different injury models, including spinal cord injury (Byrnes et al., 
2005; Yang et al., 2010). It has been previously established that 670 nm treatment reduces 
microglia/macrophage activation and alleviates mechanical hypersensitivity at 7 days post-injury 
(dpi) following spinal cord injury (Hu et al., 2016).  
The aims here are to examine the effects of 670 nm treatment on: i) the development of 
mechanical hypersensitivity during the subacute phase of recovery (prior to 7-dpi) following 
spinal cord injury, and ii) the astrocyte and microglia/macrophages presence in the spinal cord 
and their associated IL1β and/or iNOS expression in the white matter tracts. It was found that red 
light treatment using 670 nm LED irradiation significantly decreases the proportion of animals 
that develop mechanical hypersensitivity within the first 5 days. This improvement is 
accompanied by reduced astrocyte activation and reduced microglia/macrophage iNOS 
expression in the white matter tracts; however, glial IL1β expression in either GFAP (astrocyte 
marker) and IBA1 (microglia/macrophage marker) positive cells was not affected. These findings 
implicate a mechanism by which red light treatment reduces mechanical hypersensitivity through 
an iNOS-dependent pathway, but which is independent, or downstream of IL1β effects. 
4.3 Methods 
4.3.1 Spinal cord injury 
Sibling male Wistar rats, 52 ± 4 days old, were used for this study with ethics approvals from the 
ANU Animal Experimentation Ethics Committee. Animals were held in individually ventilated 
cages with environmental enrichment, standard food and water ad libitum. The housing facility 
was maintained at 20 ℃ with a 12-hour dark/light cycle. Animals were housed for 2 weeks prior 
to experimentation, and all experiments were carried out during the light cycle. Animals were 
anaesthetised using isoflurane (1.7-2.3 v/v %) while being maintained at 37 ℃ by a heat mat 
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during all surgical procedures. Laminectomy was performed at the T10 vertebra where the dura 
mater and arachnoid were removed. A 10 g weight drop from 25 mm above the spinal cord was 
used to induce a hemicontusion on the right side of the spinal cord (Hu et al., 2016; Vijayaprakash 
and Sridharan, 2013). Sham-injured animals underwent the same surgical procedures without the 
impaction. All animals received subcutaneous injections of antibiotics (Cephalothin Sodium; 
DBL) after surgery and once every 24 hrs throughout the recovery period at a dosage of 
15 mg/kg/12 hrs. Animals were returned to their home cage after the effects of anaesthesia had 
subsided. 
4.3.2 Treatment  
Spinal cord injured animals were divided into untreated (SCI; n=36) and 670 nm treated (SCI+670; 
n=28) groups. Sham-injured animals were divided into untreated (shamSCI; n=8) and 670 nm 
treated (shamSCI+670; n=10) groups. Treatments commenced 2 hrs after the surgery and were 
repeated every 24 hrs after sensitivity testing. For the duration of the treatment, animals were 
contained in a transparent Perspex box in their own cages. A commercially available LED array 
(75 mm2) that provided light at 670 ± 15 nm with a measured irradiance of 35.4 ± 0.05 mW/cm2 
(WARP 75A; Quantum Devices, Inc) was placed directly above a Perspex box for light-treated 
animals (SCI+670 and shamSCI+670 groups). Details of the spectral features and irradiance 
measurements of this light source has been previously described (Hu et al., 2016). The treatments 
were delivered for 30 mins per day (63.7 ± 0.09 J/cm2 per session) to the dorsal surface of the 
animal. Untreated animals (SCI and shamSCI groups) were handled in the same way without the 
LED being turned on (sham-treatment).  
4.3.3 Sensitivity testing 
All animals were subjected to sensitivity testing from 1 day post-injury (dpi) on every odd day. 
Briefly, a nylon filament (OD: 1.22 mm, mass delivered: 2.86 ± 0.09 g) was used to deliver 
non-noxious tactile stimuli to 6 defined regions: dermatomes innervated by nerves above the level 
of the injury (dermatomes C6-T3), at the level of the injury (dermatomes T9-T12) and below the 
level of the injury (dermatomes L2-L5) on both ipsilateral and contralateral sides. At each region, 
10 consecutive stimuli were applied, and responses were categorized into four different categories: 
I) no response; II) acknowledgement of the stimulus; III) sign of pain avoidance behaviour 
including moving away from the stimulus; IV) severe pain avoidance behaviour including 
jumping, running and vocalisation. The categories were then assigned a weight individually, 0, 1, 
√2, 2 and the summation of the 10 responses gave the regional sensitivity score (RSS). The 
summation of the six RSSs gave the cumulative sensitivity score (CSS). A group of age-matched 
male Wistar rats, as non-injured control animals (NIC; n=7) were also included in the sensitivity 
testing. A hypersensitivity threshold was defined as 2 standard deviations above the mean of NIC 
animals. Hypersensitivity incidence was thus calculated as the percentage of animals whose CSS 
exceeded hypersensitivity threshold. See Hu et al. (2016) for a more details on sensitivity testing. 
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4.3.4 Immunohistochemistry 
At the end of designated recovery periods (1, 3, 5 and 7 days post-injury), animals were 
euthanized and perfused transcardially with 0.9% (w/v) saline followed by 4% (w/v) 
paraformaldehyde. Harvested spinal cords were cryoprotected for at least 24 hrs before 
cryosectioned at 20 µm in the horizontal plane on a Leica CM1850 cryostat. Slices around the 
injury epicentre were dehydrated in 70% ethanol and then rehydrated in distilled water and 
subsequently in 0.1M PBS. The antigen retrieval step involved incubation in Reveal-it solution 
(AR2002, ImmunoSolution) for 6-12 hrs at 37 ℃ followed by 0.1M PBS washes. Slides were 
blocked in 20% (v/v) normal donkey serum in 0.1M PBS with 0.1% (w/v) bovine serum albumin 
(BSA) for 1 hr at room temperature before the addition of primary antibodies. Primary antibodies 
[GFAP (1:1000, Dako Z0334); IL1β (1:200, R&D systems AF501-NA); IBA1 (1:200, Wako 019-
19741 and Abcam ab5076); UNOS (1:150, Invitrogen PA1-039)] were diluted in 0.1M PBS 
containing 2% (v/v) normal donkey serum and 0.1% (w/v) BSA and incubated overnight at 4 ℃. 
Negative controls were also included where the primary antibodies were excluded. Slides were 
washed with 0.1M PBS followed by secondary antibody incubations at room temperature for 
1-2 hrs. Secondary antibodies [donkey anti-goat Alexa Fluor 594 (1:500, Abcam ab150132); 
donkey anti-rabbit Alexa Fluor 488 (1:1000, Invitrogen A-21206)] were diluted in the same way 
as primary antibodies and followed by 0.1M PBS washes. Slides were then incubated in 1:1000 
(v/v) diluted Hoechst solution (94403; Sigma-Aldrich) and then washed off using 0.1 M PBS. 
4.3.5 Image acquisition and quantification 
Images were scanned and imaged using a Nikon A1 confocal microscope fitted with Nikon 
DS-Qi1 camera. In GFAP/Hoechst staining, the entire cross-section of the spinal cord at the injury 
level was scanned using two lasers (405 nm and 488 nm) under ×10 magnification with a z-plane 
of at least 10 µm in depth. In GFAP/IL1β/Hoechst, IBA1/IL1β/Hoechst, and 
IBA1/UNOS/Hoechst staining, six representative images were taken in the dorsal, lateral and 
ventral spinal cord funiculi at the injury level on both ipsilateral and contralateral sides under ×20 
magnification using three lasers (405 nm, 488 nm and 561 nm) and the same z-plane configuration 
as above. All imaging and laser settings were kept constant for all animals for each staining. 
Images were then analysed offline using ImageJ v1.46r (Schneider et al., 2012). GFAP was 
analysed as fluorescence per % area while GFAP/IL1β/Hoechst, IBA1/IL1β/Hoechst, and 
IBA1/UNOS/Hoechst were analysed using Cell Counter plugin as described earlier (Hu et al., 
2016). The areas of interest were defined and quantified prior to cell counting covering a 
minimum area of 0.1 mm2. Cell quantification is expressed as the number of cells per unit 
area (mm2). 
4.3.6 Statistical analysis 
All data were expressed as mean ± SEM unless otherwise stated. Statistical analysis was carried 
out using R (R Core Team, 2016). General linear mixed model and Satterthwaite’s approximation 
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(LMER; lmer function in R) were used for multiple factor analysis accounting for random effects 
(Kuznetsova et al., 2016), followed by the Benjamini-Hochberg procedure for multiple 
comparison post-hoc p-value adjustments (Benjamini and Hochberg, 1995). Log transformations 
(log[x+1]) were performed when the data was heteroscedastic. Residual plots were used to inspect 
LMER model fitting.  
For data that failed to fit LMERs, a Cumulative Link Mixed Model was fitted, accommodating 
one random factor, with the Laplace approximation (CLMM; clmm2 function in R) (Christensen, 
2015). CLMM required categorising scores into bins that best represented the data. Histograms 
of complete data sets (blind to groups) were inspected to determine natural breaks in the data to 
define each category. CLMM models were inspected by plotting the observed data against the 
model predicated values, and comparing a linear model made with these data, to a line with an 
intercept of zero and a slope of 1. Post-hoc comparisons were performed using a Wilcoxon rank 
sum test on raw scores where applicable.  
Both models accommodated up to 4 fixed factors (treatment, side, regions and time), and one 
(CLMM: animal identification) or two (LMER: animal identification nested within their 
respective families) random factors. Models of CSSs were confirmed against models of RSSs, 
which enable more factors and thereby improved model fitting and statistical power. P values less 
than 0.05 were considered as statistically significant. 
4.4 Results 
4.4.1 Red light reduces mechanical hypersensitivity  
Hypersensitivity was defined relative to normal animals (n = 7).  To determine the range of 
cumulative sensitivity scores (CSSs) of uninjured animals, mechanical sensitivity in non-injured 
control animals was quantified (NIC; n=7; Figure 4.1a). The majority of animals had a mix of 
category I and category II responses except for one animal that demonstrated two category III 
responses at the contralateral Above-Level region. The NIC group resulted in a mean CSS of 
2.75 and a standard deviation of 2.09 and consequently a hypersensitivity threshold of 6.92 
(mean + 2×SD) was established. The Above-Level was more sensitive than the At-Level 
(p = 0.036, CLMM), while side differences failed to reach significance (p = 0.054).  
Mechanical sensitivity responses at 1-7 days post spinal cord injury in animals with a spinal cord 
injury (SCI, untreated) and spinal cord injury with 670 nm light treatment were then quantified 
(SCI+670, Figure 4.1b; see Figure 4.2 for n values). Compared to NICs, CSSs were significantly 
elevated in the SCI group (p = 0.009, CLMM), which was evident as early as day 1 (p = 0.0046, 
Wilcoxon rank sum test) and day 3 (p = 0.0099, Wilcoxon rank sum test), while there was no 
significant difference between the NIC and SCI+670 groups (p = 0.23) over the 7 day recovery 
period. Furthermore, the SCI+670 group displayed a significant reduction of CSSs compared to 
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the SCI group (p = 0.0097, CLMM), however there was no time effect (p = 0.96) or treatment/time 
interaction (p = 0.79).   
To establish whether increases in sensitivity in SCI and SCI+670 groups were due to spinal cord 
injury but not the surgical procedures, two sham-injured groups were also included (sham-injured 
+ untreated, shamSCI; sham-injured + 670 nm treated shamSCI+670) and subjected to the same 
sensitivity testing (Figure 4.1c). CSSs of shamSCI animals were not significantly different to 
those of the NIC group (p = 0.52, CLMM); however interestingly, the CSSs of the shamSCI+670 
group were significantly reduced (p = 0.009). The shamSCI+670 group was also significantly 
reduced compared to the shamSCI group (p = 0.03, CLMM), there was a marginally significant 
effect of time (p = 0.052), however no treatment/time interaction (p = 0.76).  
 
 
Figure 4.1 Cumulative sensitivity is increased up to 7-dpi following mild T10 hemicontusion 
spinal cord injury but reduced after red light treatment. 
(a) RSSs in the NIC group (n=7) showing the mean + SEM, mean, and mean – SEM in concentric 
order as indicated by the colour scale and accompanying grey legend (insert). RSSs, obtained 
from six regions (left and right sides; “Above-Level”, “At-Level”, and “Below-Level” relative to 
T10 injury), are overlayed on a schematic representation of the rat dorsum, with C2, T1, L1 and 
S1 dermatomes and midline indicated (grey lines). Statistical comparison between levels is 
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indicated by the black bracket. (b) CSSs in all spinal cord injured animals with (SCI+670) or 
without (SCI) red light treatment. (c) CSSs in all sham-injured animals with (shamSCI+670) or 
without (shamSCI) red light treatment. Green-dashed line indicates hypersensitivity threshold 
(6.92) derived from control group (see Section 4.3). Statistical comparison between levels in NIC 
group (vertical bracket, CLMM) and between SCI and SCI+670 groups across the time points 
(black line, CLMM) are indicated. Data is expressed as mean ± SEM; * p < 0.05, ** p < 0.01. See 
Figure 4.2 for n values for all groups at each time point. Abbreviations: CSS, cumulative 
sensitivity score (sum of RSSs); NIC, non-injured control; RSS, regional sensitivity score; SCI, 
spinal cord injured untreated; SCI+670, spinal cord injured + light-treatment; shamSCI, 
sham-injured untreated; shamSCI+670, sham-injured + light-treatment. 
To increase the resolution of the effects of injury and treatment on mechanical hypersensitivity, 
regional sensitivity scores (RSSs) in 6 regions were analysed (Figure 4.2) which enabled the use 
of more powerful statistical models. Congruent with the analysis above, the SCI+670 group 
displayed an overall reduction in mechanical sensitivity compared to the SCI group (p = 0.004, 
CLMM; Figure 4.2a-d, left panel), and similarly, the shamSCI+670 group also displayed a 
significant reduction in mechanical sensitivity compared to the shamSCI group (p = 0.006; 
CLMM; Figure 4.2a-d, right panel). For injured groups, the treatment effect was most evident at 
1-dpi (p = 0.012, Figure 4.2a, left) and 3-dpi (p = 0.017, Figure 4.2b, left); a treatment/region 
interaction was also apparent at 1-dpi, where the At- Level (p = 0.003) and Above-Level 
(p = 0.014) regions were significantly reduced by red light treatment (Figure 4.2a, left). For the 
sham-injured groups, the effect of red light was most obvious at 1-dpi (p = 0.031, Figure 4.2a, 
right) but just failed to reach statistical significance  at 7-dpi (p = 0.091, Figure 4.2d, right). 
The injured groups displayed a strong effect of spinal level (p < 2e-16, CLMM); the Below-Level 
always displayed the lowest RSSs compared to the other two levels (p ≤ 9e-16), and the highest 
RSSs occurred at the At-Level (p < 9e-5 compared to Above-Level), irrespective of treatment, 
side, and time. A region effect was also apparent in the sham-injured groups (p = 0.036); the 
At-Level was significantly greater than the Above-Level region (p = 0.016), but failed to be 
significantly greater than the Below-Level region (p = 0.080). There was no significant effect of 
time (p ≥ 0.37) on mechanical sensitivity for either the SCI or SCI+BPM groups. While the 
shamSCI group failed to demonstrate a significant time effect (p = 0.096), a time effect was 
evident for the shamSCI+670 group (p = 0.006). The ipsilateral side had greater RSSs compared 
to the contralateral side in all injured groups (p = 0.038, CLMM), but not sham-injured groups 
(p = 0.64). 
In summary, these results indicated that 1) spinal cord injury elevates mechanical sensitivity 
scores, but these are not due to surgical procedures; 2) red light treatment reduces mechanical 
sensitivity scores following spinal cord injury and sham injury; 3) the effects of red light treatment 
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in injured animals are most pronounced in the early time points (1 to 3-dpi), at and above the level 
of injury.  
 
 
Figure 4.2 At-Level and Above-Level regional sensitivity are reduced by red light treatment. 
RSSs in SCI (blue), SCI+670 (red), shamSCI (light blue), and shamSCI+670 (pink) animals at 
(a) 1-dpi, (b) 3-dpi, (c) 5-dpi, and (d) 7-dpi are shown for all animals investigated. Arrowheads 
indicate location of T10 hemicontusion injury (small back circles) in spinal cord injured groups. 
Statistical comparisons between 2 groups across all time points (black bracket, CLMM), across 
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all levels at individual time point (black lines, CLMM) and between 2 groups at different levels 
(grey lines, CLMM) are indicated. Data is expressed as mean ± SEM as per Figure 4.1a inset; n 
values indicated for each group; * p < 0.05, ** p < 0.01, p value indicated for 0.1 < p < 0.05. See 
Figure 4.1 for abbreviations. 
 
4.4.2 Red light reduces the incidence of developing hypersensitivity up to 
5 days but without reducing mechanical sensitivity of hypersensitive 
animals 
Not all animals develop hypersensitivity following mild spinal cord injury. Animals were 
therefore separated into hypersensitive (CSS > hypersensitivity threshold) and normosensitive 
populations (CSS ≤ hypersensitivity threshold). Figure 4.3 shows the percentage of hypersensitive 
animals in both spinal cord injured animals (Figure 4.3a) and sham-injured animals (Figure 4.3b). 
Following injury, over half of the SCI group developed hypersensitivity up to 5-dpi, and only 
approximately 1/3 in the SCI+670 group. While the effect of red light significantly reduced the 
incidence of developing hypersensitivity over the 1 to 5-dpi period (p = 0.030), the effect just 
failed to reach significance across the entire 7-day period (p = 0.058). Red light also failed to 
demonstrate a significant effect on sham-injured animals developing hypersensitivity (Figure 4.3b; 
p = 0.061), note however, that only a small number in this group became hypersensitive (see 
Figure 4.4 for n values).  
In spinal cord injured animals that developed hypersensitivity (Figure 4.3c, see Figure 4.4 for n 
values), no significant overall effects on CSSs of time (p = 0.3420, LMER) or 670 nm light 
treatment (p = 0.23, LMER) were detected. Only 1 or 2 sham-injured animals developed 
hypersensitivity at each time point (Figure 4.3d, see Figure 4.4 for n values).  
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Figure 4.3 Red light treatment reduces hypersensitivity incidence as well as sensitivity in 
normosensitive animals following a mild T10 hemicontusion spinal cord injury. 
(a) Hypersensitivity incidence following spinal cord injury is expressed as the percentage of 
animals with scores above the hypersensitivity threshold (Figure 4.1), and is shown for untreated 
and red light-treated groups. (b) Hypersensitivity incidence following sham injury is shown for 
untreated and red light-treated groups. (c) CSSs are shown for the hypersensitive subpopulation 
of spinal cord injured animals in light-treated and untreated groups. (d) CSSs are shown for the 
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hypersensitive subpopulation of sham-injured animals in light-treated and untreated groups. (e) 
CSSs are shown for the subpopulation of spinal cord injured animals in light-treated and untreated 
groups that were below the hypersensitivity threshold (referred to here as “normosensitive”). (f) 
CSSs are shown for the normosensitive subpopulation of sham-injured animals in light-treated 
and untreated groups. Green line indicates hypersensitivity threshold. Statistical comparisons 
between 2 groups (independent of time, black lines, CLMM); see Figure 4.2, Figure 4.4 and 
Figure 4.5 for n values at different time points for a-b, c-d and e-f respectively. Data is expressed 
as mean ± SEM (unless n = 1); * p < 0.05, ** p < 0.01, p value indicated for 0.05 < p < 0.1. See 
Figure 4.1 for abbreviations. 
 
Despite the absence of a significant effect of red light across the time points (p = 0.1 at 7-dpi), 
hypersensitive spinal cord injured animals showed the highest RSSs at 7-dpi compared to 1-dpi 
and 3-dpi (p ≤ 0.007, CLMM; Figure 4.4), while no time effect was observed for the SCI+670 
group (p = 0.49) overall. This was most obviously at the Below-Level region in the SCI group (p 
< 0.01 compared to 1-dpi and 3-dpi, Wilcoxon rank sum test). However, in the SCI+670 group, 
RSSs were significantly increased at 5-dpi (p = 0.034 compared to 3-dpi, Wilcoxon rank sum test) 
and then significantly decreased at 7-dpi (p = 0.034 compared to 5-dpi, Wilcoxon rank sum test). 
The ipsilateral side displayed higher RSSs that was significant in the Above-Level region only (p 
= 0.0002) across all time points in both groups. Spinal cord injured animals always displayed the 
lowest RSSs in the Below-Level compared to the other two levels (p ≤ 1.9e-11), and the highest 
in the At-Level compared to the other two levels (p ≤ 8.8e-07), irrespective of treatment, side, 
and time. In sham-injured groups, insufficient animals developed hypersensitivity to perform 
detailed statistics analyses. 
In summary, these results indicate that red light treatment reduces the incidence of developing 
hypersensitivity over the first 5 days, however it has no significant impact on animals that do 
become hypersensitive following injury over this recovery period. 
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Figure 4.4 RSSs are largely unaffected by red light treatment in hypersensitive animals in 
the first 5 days following mild T10 hemicontusion spinal cord injury. 
RSSs in SCI (blue), SCI+670 (red), shamSCI (light blue), and shamSCI+670 (pink) animals at 
(a) 1-dpi, (b) 3-dpi, (c) 5-dpi, and (d) 7-dpi are shown for hypersensitive animals 
(CSSs > hypersensitivity threshold). Asterisk next to the animal indicates comparison to the 
indicated day at the same level and group. Statistical comparisons between 2 groups across all 
levels at individual time point (black lines, CLMM) and between days at the same level and group 
(asterisks above indicated DPI, CLMM) are shown. Data is expressed as mean ± SEM as per 
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Figure 4.1a inset; n values indicated for each group; * p < 0.05, ** p < 0.01, p value indicated for 
0.1 < p < 0.05. See Figure 4.1 for abbreviations.  
 
4.4.3 Red light reduces mechanical sensitivity in animals that do not 
develop hypersensitivity 
In spinal cord injured normosensitive animals (Figure 4.3e), CSSs remained constant throughout 
the recovery period in SCI animals (p = 0.81, CLMM), but were significantly reduced by 670 nm 
treatment (p = 0.0012, see Figure 4.5 for n values). In sham-injured normosensitive animals 
(Figure 4.3f, see Figure 4.5 for n values), 670 nm treatment significantly reduced CSSs in 
sham-injured animals (p = 0.040, CLMM). Both sham groups displayed significantly reduced 
CSSs as compared to their respective spinal cord injured group (p < 5.3417e-05, CLMM).  
Analysis of RSSs confirmed that there was no time effect in the normosensitive subpopulation of 
spinal cord injured animals (Figure 4.5; p = 0.28, CLMM), and furthermore, demonstrated that 
there was no difference in RRSs between the sides ipsilateral and contralateral to the injury 
(p = 0.98, CLMM). Spinal cord injured animals always displayed the lowest RSSs in the 
Below-Level region compared to the other two spinal levels (p ≤ 1.5e-05) irrespective of treatment, 
side, and time. The 670 nm treatment reduction in RSSs of spinal cord injured animals (p = 0.0016, 
CLMM) was most significant at 1-dpi (p = 0.017) and 3-dpi (p = 0.028). In sham-injured 
normosensitive animals, RSSs were uniform across the sides (p = 0.87) and spinal levels 
(p = 0.12). 670 nm light treatment significantly reduced RSSs (p = 0.024) which was most 
significant at 1-dpi (p = 0.044).  
In summary, these results indicate that red light treatment reduces mechanical sensitivity, 
particularly within the first 3 days post-injury, in animals that do not develop hypersensitivity in 
both spinal cord injured and sham-injured animals. 
  
CHAPTER 4 
 93 
 
Figure 4.5 RSSs of normosensitive animals are reduced by red light treatment at early time 
points. 
RSSs in SCI (blue), SCI+670 (red), shamSCI (light blue), and shamSCI+670 (pink) animals at 
(a) 1-dpi, (b) 3-dpi, (c) 5-dpi, and (d) 7-dpi are shown for normosensitive animals (CSSs ≤ 
hypersensitivity threshold). Statistical comparisons between 2 groups across all time points (black 
bracket, CLMM) and across all levels at individual time point (black lines, CLMM) are indicated. 
Data is expressed as mean ± SEM as per Figure 4.1a inset; n values indicated for each group; 
* p < 0.05, ** p < 0.01. See Figure 4.1 for abbreviations.  
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4.4.4 Red light reduces astrocyte reactivity after 1-dpi in the ipsilateral 
spinal cord 
Both astrocytes and microglia/macrophages have been associated with the development and the 
maintenance of NP (Chiang et al., 2012), and it has been previously demonstrated reductions in 
activated microglia/macrophage following 670 nm treatment in spinal cord injured rats following 
7 days of spinal cord injury recovery (Hu et al., 2016). Therefore it was worthwhile to examine 
astrocytic involvement in the spinal cord response to injury and red light treatment. Astrocyte 
activation was quantified as the percentage area of GFAP positive immunofluorescence (Figure 
4.6) across 6 regions of the spinal cord (Figure 4.6a). Examples of GFAP+ staining for SCI and 
SCI+670 groups are shown in Figure 4.6b. Ipsilateral regions were significantly increased 
(p = 6.3e-14, LMER) compared to the contralateral side at all levels, particularly at 1-dpi 
(p < 2e-16) and 7-dpi (p = 0.027, LMER). GFAP+ staining was similar across the three funiculi. 
There was an overall significant reduction of GFAP+ area in the 670 nm light-treated animals 
throughout the spinal cord (p = 0.009, LMER).  
In the dorsal regions (Figure 4.6c-d), the contralateral side contained significantly less GFAP 
staining compared to the ipsilateral side (p = 2.6e-07, LMER), and red light treatment significantly 
reduced GFAP expression throughout (p = 0.003, LMER). In the SCI group, approximately 10% 
of the contralateral dorsal region of the spinal cord was GFAP+, which was maintained throughout 
the recovery period, while SCI+670 group showed significantly reduced GFAP+ staining (Figure 
4.6c; p = 0.020; LMER). In the SCI group in the ipsilateral dorsal region (Figure 4.6d), GFAP+ 
staining was approximately 20-30% of the area, while this elevation was significantly reduced in 
the SCI+670 group (p = 0.0013), which was notable starting from 3-dpi. In the lateral regions 
(Figure 4.6e-f), the contralateral side was again significantly reduced compared to the ipsilateral 
side (p = 6.879e-05, LMER) but there was no overall red light treatment effect across both sides 
of the cord. In the lateral region on the contralateral side of the spinal cord (Figure 4.6e), both 
groups showed similar levels of GFAP+ staining throughout the recovery period. However, on the 
ipsilateral side (Figure 4.6f), GFAP+ staining was only similar at 1-dpi, as the SCI+670 group 
displayed significantly less GFAP from 3 to 7-dpi (p = 0.043, LMER). In the ventral region of 
the spinal cord (Figure 4.6g-h), the contralateral side was significantly reduced compared to the 
ipsilateral side (p = 7.694e-06, LMER) and there was an overall red light treatment effect across 
both sides of the cord (p = 0.046). While the two groups showed similar GFAP+ staining again on 
the contralateral side (Figure 4.6g), red light treatment significantly reduced GFAP+ staining on 
the ipsilateral side from 3 to 7-dpi (Figure 4.6h, p = 0.017).  
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Figure 4.6 Spinal cord injury-induced astrocyte activation is reduced following red light 
treatment. 
(a) The schematic representation of the spinal cord illustrates the dorsal, lateral and ventral 
regions of interest for analysis (enclosed by dashed lines, area of each box: 0.1 mm2). 
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Approximate location of injury is indicated by the purple shaded area. (b) Example images are 
shown of positive GFAP labelling (green) from untreated and light-treated groups ipsilateral to 
the injury at the dorsal region at 3-dpi. (c-d) Quantification of GFAP positive labelling, expressed 
as the percentage area of positive label above threshold within the dorsal regions of interest 
contralateral (c) and ipsilateral (d) to the injury of untreated and light-treated groups. (e-f) GFAP 
positive label in the lateral regions of interest contralateral (e) and ipsilateral (f) to the injury. (g-
h) GFAP positive label in the ventral regions of interest contralateral (g) and ipsilateral (h) to the 
injury. n values indicated (legend) are for each time point. Statistical comparisons between SCI 
and SCI+670 groups across all time points and regions (black bracket, LMER) and across the 
time points at individual region (black line, LMER) are indicated. Data is expressed as mean ± 
SEM; * p < 0.05, ** p < 0.01. See Figure 4.1 for abbreviations.  
 
As there was no difference in GFAP on the contralateral side between the two groups at the 1-dpi, 
the relative GFAP expression compared to normal animals was determined. Another age, sex and 
sibling matched cohort of animals were included: non-injured controls (NIC), sham-injured 
untreated (shamSCI), and spinal cord injured untreated (SCI). Their spinal cords were processed 
at 1-dpi and stained for GFAP+ expression (Figure 4.7). These experiments demonstrate that 
compared to non-injured (p < 2e-16) or sham-injured (p < 2e-16) animals, GFAP expression was 
significantly elevated across the entire cord within 24 hours following injury. The ipsilateral side 
was significantly increased only in the SCI group (p = 0.03) as seen in Figure 4.6 but this trend 
was not observed in NIC or shamSCI groups. 
In summary, these results demonstrate that the astrocyte reactivity was elevated across the entire 
spinal cord at the injury level following hemicontusion from 1-dpi, but more so on the ipsilateral 
side. GFAP expression is not affected by red light at 1-dpi, but is significantly supressed by 670 
nm treatment from 3 to 7-dpi.  
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Figure 4.7 GFAP increases within 24 hrs following a mild T10 hemicontusion injury. 
(a) Example images of GFAP positive staining (green) from non-injured, spinal cord injured 
(1-dpi) and sham-injured (1-dpi) animals ipsilateral to the injury in the dorsal region. (b-c) 
Quantification of GFAP positive labelling at 1 day post-injury, expressed as the percentage area 
of positive label above threshold within the region of interest, in the dorsal, lateral and ventral 
regions of the spinal cord, contralateral (b) and ipsilateral (c) to the injury of non-injured, spinal 
cord injured (1-dpi) and sham-injured (1-dpi) groups. Vertical brackets indicate statistical 
comparisons among three groups across all regions (general linear mixed model). Data is 
expressed as mean ± SEM; *** p < 0.001. See Figure 4.1 for abbreviations. 
 
4.4.5 Red light does not affect IL1β expression in astrocytes 
Astrocytes, when activated, secret a group of cytokines to alter and maintain the 
microenvironment of the tissues. IL1β is a pro-inflammatory cytokine believed to take part in 
pain signal alteration and processing (Ji et al., 2013). IL1β expression was therefore investigated 
in astrocytes in the 6 regions across the spinal cord (Figure 4.8a) following hemicontusion and 
670 nm treatment. Examples of IL1β+/GFAP+ cells, defined as triple positive for IL1β, GFAP and 
DAPI, are shown in Figure 4.8b. Throughout the spinal cord (Figure 4.8c-h), IL1β+/GFAP+ cell 
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density was elevated on the ipsilateral side compared to the contralateral side (p = 2.6e-07, LMER) 
and there was no overall significant effect of red light treatment (p = 0.28).  
Across the dorsal region (Figure 4.8c-d), there was a significant time effect (p = 0.033, LMER) 
but no treatment effect (p= 0.30): the contralateral side (Figure 4.8c) was elevated at the 3-dpi 
(p = 0.05) and 5-dpi (p = 0.05) after which it returned to the 1-dpi level by 7 days; the ipsilateral 
side (Figure 4.8d) was significantly elevated at 5-dpi only (p = 0.03 compared to both 1-dpi and 
3-dpi). In the lateral (Figure 4.8d-e) and ventral (Figure 4.8f-g) regions, there was no difference 
between sides (p = 0.40) or time points (p = 0.42), however the lateral regions were significantly 
reduced compared to the dorsal regions (p = 0.02). 
In summary, these results indicate that IL1β expressing astrocytes are present throughout the 
spinal cord and peak at 5-dpi in the dorsal region only, following hemicontusion. While there is 
an overall suppression of GFAP, 670 nm red light treatment has no impact on the expression of 
IL1β producing astrocytes. 
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Figure 4.8 IL1β producing astrocyte cell density is not affected by red light treatment 
following mild T10 hemicontusion. 
(a) The schematic representation of the spinal cord illustrates the dorsal, lateral and ventral 
regions of interest for analysis (enclosed by dashed lines, area of each box: 0.1 mm2). 
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Approximate location of injury is indicated by the purple shaded area. (b) Example images of 
IL1β (red), GFAP (green), and DAPI (blue) triple positive cells from spinal cord injured untreated 
and light-treated groups ipsilateral to the injury in the dorsal region at 7-dpi. (c-d) Quantification 
of IL1β+GFAP+DAPI+ cells, expressed as triple positive cell density within the region of interest, 
in the dorsal region of the spinal cord, contralateral (c) and ipsilateral (d) to the injury of untreated 
and light-treated groups. (e-f) IL1β+GFAP+DAPI+ cell density in the lateral regions of interest 
contralateral (e) and ipsilateral (f) to the injury. (g-h) IL1β+GFAP+DAPI+ cell density in the 
ventral regions of interest contralateral (g) and ipsilateral (h) to the injury. n values indicated 
(legend) are for each time point. Statistical comparisons between time points (capped bracket, 
LMER) are indicated. Data is expressed as mean ± SEM; * p < 0.05. See Figure 4.1 for 
abbreviations.  
 
4.4.6 Red light does not affect IL1β expression in microglia/macrophages 
Another important cell type that produce IL1β are microglia/macrophages. To examine the effects 
of IL1β derived from microglia/macrophages, the six spinal cord regions (Figure 4.9a) were triple 
stained with IBA1, IL1β and DAPI to investigate the density of IL1β expressing 
microglia/macrophages in the spinal cord following injury and red light treatment. An example 
of staining is shown in Figure 4.9b. IL1β expressing microglia density was mostly within 
50 cells/mm2 and was significantly reduced compare to IL1β expressing astrocytes 
(p = 1.69887e-35, paired t-test; compared with Figure 4.8). Throughout the 6 regions (Figure 
4.9c-g), the ipsilateral side to the injury showed consistently increased IL1β+/IBA1+ cell density 
compared to the contralateral side (p = 3.7e-06, LMER). 670 nm light treatment had no significant 
effect on IL1β+/IBA1+ cell density (p = 0.95, LMER), nor was there an effect of time (p = 0.13, 
LMER), but perhaps an effect of region (p = 0.055, LMER). 
These results indicated that IL1β was produced throughout the spinal cord following 
hemicontusion and more on the ipsilateral side. More IL1β was produced by astrocytes as 
compared to microglia/macrophages. 670 nm light treatment had no significant effect on IL1β 
from either astrocytes or microglia/macrophages.  
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Figure 4.9 IL1β producing microglia/macrophage population is not affected by red light 
treatment following T10 hemicontusion. 
(a) The schematic representation of the spinal cord illustrates the dorsal, lateral and ventral 
regions of interest for analysis (enclosed by dashed lines, area of each box: 0.1 mm2). 
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Approximate location of injury is indicated by the purple shaded area. (b) Example images of 
IL1β (red), IBA1 (green), and DAPI (blue) triple positive cells from spinal cord injured untreated 
and light-treated groups in the dorsal region, ipsilateral to the injury at 7-dpi. (c-d) Quantification 
of IL1β+IBA1+DAPI+ cells, expressed as triple positive cell density within the region of interest, 
in the dorsal region of the spinal cord, contralateral (c) and ipsilateral (d) to the injury of untreated 
and light-treated groups. (e-f) IL1β+IBA1+DAPI+ cell density in the lateral regions of interest 
contralateral (e) and ipsilateral (f) to the injury. (g-h) IL1β+IBA1+DAPI+ cell density in the ventral 
regions of interest contralateral (g) and ipsilateral (h) to the injury. n values indicated (legend) are 
for each time point. Data is expressed as mean ± SEM. See Figure 4.1 for abbreviations.  
 
4.4.7 Red light reduces iNOS expressing microglia/macrophages at the 
injury zone 
Another pro-inflammatory molecule that is associated with pain following spinal cord injury is 
NO, which can is by iNOS in microglia/macrophages (Hulsebosch et al., 2009). As 
microglia/macrophages only produce the iNOS isoform, and UNOS detects all three nitric oxide 
synthases isoforms (eNOS, nNOS, and iNOS), six spinal cord regions (Figure 4.10a) were triple 
stained for UNOS/IBA1/DAPI to investigate the density of iNOS expressing 
microglia/macrophages in the spinal cord following injury and red light treatment. An example 
of staining is shown in Figure 4.10b. Throughout the 6 regions (Figure 4.10c-h), there were 
significantly greater UNOS+/IBA1+ cell density on the ipsilateral side (p = 1.2e-05, LMER), a 
strong effect of time (p = 0.0005), and an overall effect of treatment (p = 0.020).  
In the dorsal region of the spinal cord, UNOS+/IBA1+ cells were maintained below 50 per mm2 
on the contralateral side throughout the recovery period in both groups (Figure 4.10c). However, 
on the ipsilateral side (Figure 4.10d), there was an increase compared to the contralateral side 
(p = 0.07). After 1-dpi, UNOS+/IBA1+ cell density increased on the ipsilateral side (p = 0.077, 
1-dpi vs 3-dpi; p = 0.004, 1-dpi vs 5-dpi; LMER) before decreasing at 7-dpi (p = 0.015, 5-dpi vs 
7-dpi).  UNOS+/IBA1+ cell density in the ipsilateral dorsal region was significantly reduced by 
red light treatment (p = 0.008; LMER). Figure 4.10e-h also demonstrated similar time effects, but 
there were no significant effects of light treatment at these deeper levels.  
In summary, these results suggest that iNOS expressing IBA1 cells are present, predominantly on 
the ipsilateral to the injury following hemicontusion, and red light treatment reduces iNOS 
expression in the ipsilateral dorsal region. 
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Figure 4.10 iNOS expressing microglia/macrophages are reduced by red light treatment 
following T10 hemicontusion. 
(a) The schematic representation of the spinal cord illustrates the dorsal, lateral and ventral 
regions of interest for analysis (enclosed by dashed lines, area of each box: 0.1 mm2). 
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Approximate location of injury is indicated by the purple shaded area. (b) Example images of 
UNOS (red), IBA1 (green), and DAPI (blue) triple positive cells from spinal cord injured 
untreated and light-treated groups in the dorsal region, ipsilateral to the injury at 7-dpi. (c-d) 
Quantification of UNOS+IBA1+DAPI+ cells, expressed as triple positive cell density within the 
dorsal region of interest, contralateral (c) and ipsilateral (d) to the injury of untreated and 
light-treated groups. (e-f) UNOS+IBA1+DAPI+ cell density in the lateral regions of interest 
contralateral (e) and ipsilateral (f) to the injury. (g-h) UNOS+IBA1+DAPI+ cell density in the 
ventral regions of interest contralateral (g) and ipsilateral (h) to the injury. n values indicated 
(legend) are for each time point. Statistical comparisons between time points (capped bracket, 
LMER), between SCI and SCI+670 groups across all time points and regions (black bracket, 
LMER) and across the time points at individual region (black line, LMER) are indicated. Data is 
expressed as mean ± SEM; * p < 0.05, ** p < 0.01, p value indicated for 0.05 < p < 0.1. See Figure 
4.1 for abbreviations. 
 
4.5 Discussion 
It was set out to investigate changes in mechanical sensitivity and the spinal cord cellular 
environment following spinal cord injury and 670 nm treatment. It was demonstrated that a mild 
weight-drop hemicontusion spinal cord injury causes increase in mechanical sensitivity with 
around half of the population being hypersensitive from 1-dpi, and persisting for at least 7 days. 
This increase in mechanical sensitivity was mostly due to spinal cord damage rather than the 
surgical procedures. Daily 30 min treatments of 670 nm at 35 mW/cm2 reduces mechanical 
sensitivity, particularly within the first 3 days post-injury. The red light-induced overall reduction 
in mechanical sensitivity in the first 5 days appears to result from two components: 1) a reduction 
in the percentage of animals developing hypersensitivity, and 2) a reduction in the mechanical 
sensitivity of the sub-population that did not develop hypersensitivity (normosensitive). Red light 
also alleviated mechanical sensitivity caused by surgical procedures in sham-injured animals, 
with evidence of possible mild effects lasting as long as 7 days post-surgery. These functional 
improvements in spinal cord injured animals were accompanied by reduced astrocyte activation 
and reduced iNOS+ microglia/macrophage presence in the injured spinal cord. 
A mechanical testing paradigm was used that allowed assessment of above-, at-, and below-injury 
dermatomes, which could provide more insight as to how mechanical sensitivity is changed 
following spinal cord injury. Categories I and II are characterised by no or minimal 
acknowledgement to the stimuli which are not characteristic of nocifensive behaviours in 
laboratory rats while categories III and IV are inexorable behavioural responses to aversive 
stimuli including basic/integrated motor responses (jumping, avoidance and aggression) and 
vocalization (Institute for Laboratory Animal Research (U.S.). Committee on Recognition and 
Alleviation of Pain in Laboratory Animals., 2009). As the NIC group generally displayed 
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categories I and II responses (Figure 4.1a), the mechanical sensitivity testing paradigm used in 
the current study does not induce pain in normal rats. The paradigm used to assess mechanical 
sensitivity in the present study presents some advantages over conventional assessment methods 
which use von Frey filaments to assess paw withdrawal threshold in preclinical models of SCI 
pain (Bartus et al., 2014; Kanno et al., 2014; Tateda et al., 2017; Yu et al., 2013). Conventional 
methods focus on the assessment of below or above the level of the injury, and requires complete 
intact motor function of the respective limbs (Detloff et al., 2010). The mechanical assessment 
paradigm used in the present study allows assessment of above-, at-, and below-injury 
dermatomes, which could provide improved resolution of mechanical sensitivity changes 
following spinal cord injury. In addition, the display of nocifensive behaviour is not affected by 
hind limb(s) motor deficits; animals are capable of avoidance behaviours using the front limbs 
only. 
Using the pre-defined hypersensitivity threshold based on responses from normal intact animals, 
the experimental groups were separated into hypersensitive and normosensitive subpopulations. 
This separation in mechanical sensitivity is also observed in spinal cord injured patients (Dijkers 
et al., 2009; Jensen and Finnerup, 2014; Turner et al., 2001). Spinal cord injury induced 
mechanical allodynia in at least 50% of the rats from 1-dpi, while the proportion developing 
hypersensitivity was reduced by 670 nm treatment from 1-dpi to 5-dpi (Figure 4.3a). This 
mechanical hypersensitivity incidence in untreated spinal injured animals is consistent with 
another study which reported 67% (Siddall et al., 1995), and with the previous study of 
hypersensitivity incidence at 7-dpi using a more severe injury model (Hu et al., 2016). The current 
study provides the first evidence that 670 nm treatment, or photobiomodulation in general, 
reduces hypersensitivity incidence following spinal cord injury in rats. There could be two 
possible explanations for the early reduction in hypersensitivity incidence; 670 nm light could 
either 1) delay, or 2) accelerate the development and recovery of mechanical hypersensitivity. 
The second hypothesis was favour because 670 nm treatment has been shown to accelerate 
cellular processes and increase metabolism (Begum et al., 2015; Eells et al., 2003; Yip et al., 
2011). Furthermore, the peak hypersensitivity in the light-treated group was at 5-dpi, while the 
untreated injured group appeared to continue to develop hypersensitivity over the 7-day recovery 
period, and therefore, might require more time to fully develop maximal hypersensitivity.  
Only a few sham-injured animals were categorised as hypersensitive, suggesting that the surgical 
procedure does not produce excessive pain in the dorsum of the animal, and therefore, the 
hypersensitivity spinal cord injured animals were due to changes in the spinal cord. 
Hypersensitive untreated spinal cord injured animals develop mechanical hypersensitivity mostly 
in the At-Level regions from 1-dpi with the potential to develop Below-Level hypersensitivity by 
7-dpi (Figure 4.4). These results are consistent with spinal cord injured patients in clinical settings. 
NP patients develop both early-onset At-Level and late-onset Below-Level 
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allodynia/hyperalgesia (Bryce, 2009; Finnerup et al., 2009; Gwak et al., 2012; Hulsebosch et al., 
2009; Jensen and Finnerup, 2014; Widerstrom-Noga et al., 2014). Although changes at the spinal 
and the supraspinal level have been correlated with the development of these two distinct pain 
phenotypes, the exact underlying mechanism remains unclear (Hari et al., 2009; Jensen and 
Finnerup, 2014; Siddall et al., 2003; Wrigley et al., 2009).  
While there was an overall treatment effect (Figure 4.2), 670 nm did not change the mechanical 
sensitivity of hypersensitive animals from 1 to 5-dpi (Figure 4.4). The failure to reach a significant 
difference between the hypersensitive subpopulations at 7-dpi (p = 0.10) is likely to have resulted 
from the high variability in mechanical sensitivity in combination with an insufficient number of 
animals developing hypersensitivity at 7-dpi. In support of this, it has been previously 
demonstrated that a significant difference existed between light-treated and untreated groups in a 
study with a larger sample size following a mild/moderate hemicontusion spinal cord injury (Hu 
et al., 2016). Furthermore, the observation from the present study, of a significant difference in 
the trajectory of pain development (i.e. at the below level regions) between the two injured groups 
over the 5 and 7-day recovery periods, further supports the notion of light-induced changes in the 
hypersensitive population from 7-dpi.  
Mechanical testing over the 7-day period is unlikely to desensitize the animals to the stimulus, 
which is supported by the lack of a time effect in sham-injured animals. By definition, the 
mechanical sensitivity observed in normosensitive SCI animals is within the range of uninjured 
animals, and therefore indicates a lack of pain. However, their sensitivity scores were significantly 
elevated compared to the shamSCI normosensitive population, suggesting that some degree of 
discomfort may be experienced in the normosensitive SCI group. Interestingly, 670 nm light 
reduces mechanical sensitivity in normosensitive spinal cord injured animals, as well as 
sham-injured animals (Figure 4.3c and Figure 4.5). As previously shown, the reduction in 
sensitivity is not due to reduced functional integrity of the dorsal column pathway (Hu et al., 
2016), suggesting it arises from the anterolateral system. Following the surgery, bradykinins are 
released which elicits pain/sensitisation in the skin, while endogenous opioids such as endorphins 
are produced to control the pain (Stein et al., 2009). Photobiomodulation has been shown to 
decrease bradykinins while increasing endorphins (Chaves et al., 2014; Lins et al., 2010), 
therefore the effect of red light in the present study may result from alterations to bradykinins 
and/or endogenous opioids, leading to an overall reduction in sensitivity across all groups. Further 
studies pursuing this line of reasoning would be of great interest. 
Following spinal cord injury, pro-inflammatory cytokines are secreted by activated glial cells, 
both microglia/macrophages and astrocytes. During the post-injury period, astrocytes, together 
with microglia/macrophages, are activated through a combination of different mechanisms that 
involve neuro-inflammation, ionic imbalance and cytokines/chemokines (Gwak et al., 2012). 
Regional and global increases in GFAP expression have been documented from 2 hours and to 
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persist for at least 6 months (Gwak et al., 2012). The increased GFAP expression throughout the 
cord segment within 24-hours post-injury (Figure 4.7), which persisted for at least 7 days (Figure 
4.6), is consistent with this earlier study. Also congruent with previous studies (Hernangomez et 
al., 2016; Lee-Kubli et al., 2016), are reports of similar GFAP basal levels of 5% or below, in 
uninjured animals (Figure 4.7). Limited studies have shown the effect of 670 nm treatment 
following spinal cord injury on astrocyte activation or GFAP upregulation, although similar 
effects using 810 nm have been documented (Byrnes et al., 2005). Other groups have previously 
demonstrated a reduction in GFAP expression following light treatment in Müller cells in the 
retina (Begum et al., 2013; Marco et al., 2013), and a decrease in GFAP expression by 670 nm 
irradiation in the brain of monkeys with Parkinson’s disease (El Massri et al., 2016). The present 
study is the first demonstration that astrocytic hypertrophy is reduced by daily 670 nm treatment 
from 3-dpi following spinal cord injury. The reduced GFAP cannot account for the early (i.e. 
1-dpi) red light-induced pain relief, as GFAP expression was not observed at this time. However, 
it would be interesting to examine GFAP at time points at, and beyond 7-dpi, when pain relief in 
the hypersensitive population appears to commence. Surprisingly the reduction in GFAP did not 
appear to arise from the IL1β+ astrocyte subpopulation (Figure 4.8). This is unexpected because 
IL1β is strongly implicated in the development of hypersensitivity (Calvo et al., 2012). 
Subpopulations of GFAP+ astrocytes have been reported before and IL1β+ astrocytes are 
considered to be pro-inflammatory and neurotoxic (Liddelow et al., 2017). However, no other 
studies may provide clues as to what astrocyte subpopulation was affected by red light in the 
present study. This is an area requiring further studies. 
IL1β, produced by both astrocytes and microglia/macrophages, is a cytokine that not only 
augments inflammation, but also acts on both pre- and post-synaptic terminals to initiate and 
maintain pain (Calvo et al., 2012; Clark et al., 2015). 670 nm treatment had no effect on IL1β 
production in microglia/macrophages following spinal cord injury from 1 to 7-dpi (Figure 4.9). 
This observation is consistent with the previous study (Hu et al., 2016) showing no effect of 670 
nm on pro-inflammatory microglia/macrophage (M1), and another study where the authors 
showed no effect of 810 nm on IL1β expression at either 6-hours post-injury or 4-dpi following 
spinal cord injury (Byrnes et al., 2005). However, other studies have reported decreases in IL1β 
expression by light treatment in other injury models (Lee et al., 2016; Sahu et al., 2015). This 
discrepancy suggests that light treatment may activate different cell pathways in different injury 
models. As IL1β is a significant player in the regulation of pain, the present study suggests that 
the pain-alleviating effect of 670 nm light treatment may be independent, or downstream to IL1β, 
at least up to the first 7 days. 
There was a significant decrease in UNOS expression, a surrogate marker for iNOS in 
microglia/macrophages, following 670 nm treatment in spinal cord injured animals (Figure 4.10). 
Byrnes et al. (2005) 
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RT-PCR at 6 hours post-injury but not at 4 dpi using 810 nm treatment. The discrepancy between 
this study and that of Byrnes et al. (2005) at the 3 to 4-dpi might indicate a different mechanism 
of action between 670 nm and 810 nm, or that the reduction of iNOS+ microglia/macrophages 
was masked by an increase of iNOS other cells types not observed by Byrnes et al. 
It is interesting how IL1β and iNOS, both considered markers of classically activated 
microglia/macrophages (M1), were affected differently by red light treatment. In the previous 
study, it was demonstrated that red light did not alter the proportion of M1 cells, however, the 
proportion of M2 cells was increased (Hu et al., 2016). The current study is partly consistent with 
this idea: IL1β expressing cells (M1 phenotype) were not altered by red light treatment, however 
the iNOS (M1 phenotype) expressing cells were reduced. iNOS down regulation may indirectly 
indicate conversion towards arginase upregulation (Lee et al., 2003) and therefore conversation 
towards the M2 phenotype. It may be possible that iNOS and IL1β are produced by different 
microglia/macrophages and that the decrease in iNOS expression in microglia/macrophages 
might occur in response to the increase in M2 microglia/macrophages (Hu et al., 2016). 
In addition to the beneficial effect of a less inflammatory microenvironment, the decreased iNOS 
expression in microglia/macrophage could also contribute to the reduced mechanical sensitivity 
in 670 nm treated animals. Studies have shown that pain following spinal cord injury could be 
reduced, or reversed, by iNOS inhibitors or general NOS inhibition (Fairbanks et al., 2000; Yu et 
al., 2004). The present study supports the idea that 670 nm may act on a pain modulation pathway 
that is iNOS-dependent, but IL1β-independent. Future studies examining these ideas would be of 
interest.  
4.6 Conclusion 
It was demonstrated that daily 670 nm irradiation reduces the chance of developing 
hypersensitivity up to 5 days post spinal cord injury. Mechanical sensitivity in normosensitive 
injured and sham-injured animals are also reduced by red light treatment. The early (pre-3-dpi) 
pain-alleviating and desensitizing effects may involve iNOS expression in 
microglia/macrophages in the spinal cord, while astrocytes that do not express IL1β, may only 
impact sensitivity after 1 day post-injury. The combined reduction of iNOS+ 
microglia/macrophages and IL1β negative astrocytes may therefore impact different stages of 
pain and non-pain sensitivity.  
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The main aim of this thesis is to investigate the effects of daily 30 min 670 nm LED treatment on 
spinal cord injury in rats. The first experimental chapter (Chapter 2) showed that 670 nm of 100 
mW/cm2 can successfully penetrate both live and cadaveric human tissues with a thickness of up 
to 50 mm. This phenomenon is independent of skin tones (Fitzpatrick types II-V) while the 
presence of bone tissue aids the penetration of 670 nm light. The second experimental chapter 
(Chapter 3) investigated the effects of 670 nm LED treatment in spinal cord injured rats. Daily 30 
min treatment improves locomotor recovery, sensory conduction along the posterior columns, and 
reduces mechanical sensitivity over a 7-day recovery period, while minimizing cell death, 
reducing microglia/macrophage activation, and promoting anti-inflammatory macrophage 
subpopulation. The third experimental chapter (Chapter 4) examined the earlier development of 
mechanical sensitivity over the course of 7 days following spinal cord injury. Daily 30 min 670 
nm treatment reduces hypersensitivity incidence up to 5 days and reduces mechanical sensitivity 
in normosensitive animals up to 7 days while reducing astrocyte activation from 3 days and iNOS+ 
microglia/macrophage cell density up to 7 days. The current chapter outlines the main findings 
from the three experimental chapters in two main parts: penetration of 670 nm LED (Section 5.1) 
and its therapeutic effects following spinal cord injury (Section 5.2). The overall conclusions will 
be presented in Section 5.3. 
5.1 Penetration of 670 nm LED  
This thesis contains the first study that measures the penetration of 670 nm LED (15-500 mW/cm2) 
in live and cadaveric human tissues (Chapter 2). The penetration of 670 nm LED is dependent on 
the radiosity of the light source, the composition of the tissue, and the thickness of the tissue, but 
not the skin tone. It is common sense that the larger the radiosity, the greater the penetration in a 
given tissue. However, there has been no consistent approach for determining the extent to which 
tissues below the skin surface are exposed when applying photobiomodulation among the various 
studies. The results from Chapter 2 therefore provide a guide that enables future researchers 
and/or therapists to make practical decisions about exposing target tissues with red light. 
The effect of skin tone is also of interest. Melanin has always been a hot topic in the field of 
photobiomodulation. However, it is important to realise that the effect of melanin on penetration 
is largely wavelength-dependent (Figure 1.3) and that its absorption of red light may be minimal 
compared to the effect of other chromophores, due to its relatively thin layer in the skin. Results 
from this thesis (Figure 2.2) and another study (Saager et al., 2015) showed a minimal effect of 
melanin on the penetration of 670 nm light in human tissues. This result can give clinicians 
confidence when treating patients of different skin tones up to Fitzpatrick’s skin type V. While 
this thesis covered a broad range of skin tones, future studies, covering the lightest and darkest 
skin tone (i.e. Fitzpatrick’s skin types I and VI) would be of great value. 
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Compared to skin tone, differences in the photobiological properties of muscles and bones might 
be a bigger contributor to the variation in penetration (Figure 2.3). This difference is likely to be 
due to the presence of some major chromophores in muscles (Section 1.2.1.2). A more thorough 
investigation, taking into account the relative thickness of the two tissue types, needs to be carried 
out in order to establish a model for light penetration in tissues with muscle and bone. As 
concluded in Chapter 2, the use of cadavers may facilitate investigations of a particular 
wavelength in sites not readily available in live humans, e.g. the spinal cord. 670 nm light of 100 
mW/cm2 is found to penetrate tissues up to 50 mm thick (Figure 2.1). This thickness is more than 
the distance from the posterior skin to the epidural space at C5-6 in humans (Zhao et al., 2014). 
This thesis reports ~91% attenuation of 670 nm LED (35 mW/cm2) through a rat’s spinal cord, 
giving an irradiance of 3.2 mW/cm2 at the targeted site (Figure 3.1). While this data provides 
some insight into light attenuation through multiple tissue layers (hair, skin, muscle, bone, various 
connective tissues, and spinal cord) in the rat, translation to humans requires direct measurement 
of irradiance at the target site in order to attain the desired exposure necessary to achieve 
therapeutic effects (AlGhamdi et al., 2012). The commonly reported unit for photobiomodulation 
studies is J/cm2 (1 J = 1 W.s), however this unit, reflecting both the irradiance and the irradiation 
time, may be rather misleading. It is rather unlikely that a small irradiance, with a long irradiation 
time, will provide the same effect as a large irradiance, with a short irradiation time; these 
combinations have largely different outcomes on penetration and therefore tissue exposure at 
deeper levels. 
5.2 Therapeutic effects of 670 nm LED treatment following 
spinal cord injury 
Chapter 3 and Chapter 4 focused on the effects of 670 nm treatment, following spinal cord injury 
in rats. As mentioned in Section 1.1.1, the pathophysiology of spinal cord injury starts with 
immediate changes in the cellular microenvironment (Section 1.1.1.1), which ultimately lead to 
long-term functional deficits (Section 1.1.1.2). The results of these two chapters are discussed 
below and divided into cellular (Section 5.2.1) and functional (Section 5.2.2) changes. 
5.2.1 Cellular changes 
A large variety of cellular events takes place in response to spinal cord injury (Section 1.1.1.1). 
This thesis examined the impact of red light on inflammation (Section 5.2.1.1), gliosis 
(Section 5.2.1.2), and cell death (Section 5.2.1.3) in the subacute phase of spinal cord injury, 
between 1 and 7 days.  
5.2.1.1 Inflammation 
Following spinal cord injury, microglia and macrophages are activated (David and Kroner, 2011). 
They secrete numerous cytokines and other molecules at the injury site, which cause long-term 
inflammation, and ultimately function loss. One of the keys to better recovery is a balanced and 
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controlled inflammation (Section 1.1.1.1). Ren and Young (2013) reviewed a number of ways to 
manage inflammation following spinal cord injury. One of them is reducing the recruitment and 
the infiltration of macrophages/monocytes. While results from this thesis (Figure 3.6) and another 
study using 810 nm laser treatment in a corticospinal lesion (Byrnes et al., 2005), show that red 
light treatment reduces the number of microglia/macrophages, it is not clear how many of those 
were microglia and macrophages. ED1 and IBA1 were used to detect macrophages and microglia 
in this thesis. While both markers have been shown to be expressed in both macrophages and 
microglia (Sasaki et al., 2001; Wu et al., 2005), it is very likely that ED1 is expressed in 
macrophages and some activated microglia, while IBA1 is expressed in all the microglia. This 
claim is based on the evidence that some activated microglia (amoeboid shape) express high levels 
of ED1 while others do not (Graeber et al., 1990; Slepko and Levi, 1996). A study in spinal cord 
injury also demonstrated that IBA1+ and ED1+ cells are two separate populations but the two 
markers co-localise only in some cells with an amoeboid shape (Wu et al., 2005). With a better 
understanding of microglial- and macrophage-specific markers, future studies could focus on the 
effect of red light on these two separate populations. 
Activated macrophages and microglia can display two extreme phenotypes; pro- (M1) and anti-
inflammatory (M2). Ren and Young (2013) suggested two alternative ways to manage 
inflammation by targeting M1 and M2 individually, and one of them is by blocking the M1 
activation pathway. However, there is controversy surrounding this approach, as M1 clears up 
tissue debris and is therefore an essential part of the recovery process (Kong and Gao, 2017). 
Instead of blocking M1 activation, reducing M1 activation might be more appropriate. Chapter 3 
demonstrates that although the proportion of M1 (ED1+/CD80+) cells is unaffected by red light 
treatment, there is a significant overall decrease of microglia/macrophages (ED1+) following 
670 nm treatment. The total number of M1 cells would therefore fall by the same proportion as 
ED1+ cells are reduced (Figure 3.6). Chapter 4 demonstrates that while red light treatment does 
not change the IL1β+ M1 microglia/macrophage population density (Figure 4.9), it significantly 
reduces the iNOS+ M1 microglia/macrophage population in the injured spinal cord (Figure 4.10). 
Both IL1β and iNOS are robust M1 markers (Jablonski et al., 2015). This discrepancy in the M1 
microglia/macrophage results between Chapters 3 and 4 may suggests the existence of distinct 
IL1β and iNOS M1 subtypes, and furthermore, highlights the necessity for a more comprehensive 
suite of markers when studying microglia/macrophage subtypes. Microglia/macrophage subtypes 
are named based on the relative abundance of markers on the cell surface or in the cytosol. In the 
tissue environment, the expression of these markers on microglia might be on a continuous scale 
and these extreme phenotypes (M1 and M2) might not exist at all (Ransohoff, 2016). However, 
the study of M1 and M2 phenotypes is good starting point and is helpful for understanding the 
complex inflammatory response following injury. 
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Another way to manage inflammation is by promoting the M2 phenotype (Ren and Young, 2013). 
Following spinal cord injury, 670 nm light treatment significantly increases M2 proportion of the 
activated microglia/macrophages (Figure 3.6). This novel finding is significant as it is the first 
evidence that red light treatment can affect microglia/macrophage polarisation in vivo. A 
subsequent study by another group also showed similar results by using 810 nm laser irradiation 
in a crush injury model (Song et al., 2017). It is very likely that these M2 microglia/macrophages 
arise from M0 (non-polarised) microglia/macrophages, as no change in the M1 
microglia/macrophages are found. Alternatively, the M2 microglia/macrophages could have arose 
from iNOS+ M1 microglia/macrophages, since arginase (M2 marker) expression leads to 
decreased translation of iNOS (Lee et al., 2003). However, it is not clear whether 670 nm 
treatment affects M2 macrophage and microglia equally, although it is clear that the effects on 
M2 are different to the effects on M1. Future studies should separate M2 macrophage and M2 
microglia, as well as study their origins. Moreover, to expand on the suggestion by Ren and Young 
(2013), studies to investigate the effects of PBM on proliferation, differentiation, and survival of 
microglia/macrophages following spinal cord injury are also essential, as PBM has been 
demonstrated to help proliferation of epithelial and bone cells, and cell survival in various neural 
injuries (Section 1.2.2).  
5.2.1.2 Gliosis 
In addition to macrophages and microglia, astrocytes are activated in the injured spinal cord 
within the first 24 hrs on both sides following a hemicontusion (Figure 4.7). These astrocytes stay 
active for at least 7 days (Figure 4.6) and others have reported up to 6 months (Gwak et al., 2012). 
With 670 nm treatment, GFAP expression is significantly reduced from 3 days, but only in the 
astrocytes that do not express IL1β (Figure 4.8). This is the first report of GFAP reduction 
following spinal cord injury with 670 nm treatment. It is rather interesting to discover that 
astrocytes may have subpopulations following spinal cord injury. A new concept, astrocyte 
polarisation, has emerged in recent years. This concept is based on the fact that astrocytes can 
display pro- and anti-inflammatory phenotypes both in vitro and in vivo following LPS injection 
and cytokine induction (Jang et al., 2013). The two astrocyte phenotypes are characterised by the 
secretion/production of pro- and anti-inflammatory cytokines, similar to M1 and M2 
microglia/macrophage. The pro-inflammatory astrocytes (A1), which can be activated by M1, 
express pro-inflammatory markers such as IL1β and iNOS, and are neurotoxic in a range of 
neurodegenerative diseases (Liddelow et al., 2017). Results from this thesis indicate that 670 nm 
has no effect on A1. A number of follow-up studies could be carried out, for example an 
investigate of astrocyte polarisation and its role in spinal cord injury, and another into the 
long-term effect of 670 nm on astrocyte activation and polarisation. 
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5.2.1.3 Cell death 
Following spinal cord injury, cells undergo necrosis and/or apoptosis immediately, and therefore 
the amount of cell death in the dorsal region of the spinal cord was assessed at 1, 3, and 7 days 
(Figure 3.5). More cell death was observed on the ipsilateral side of the spinal cord than on the 
contralateral side. This phenomenon further clarifies that the injury is confined to one side in this 
hemicontusion model. Cell death maximises at 3 days following the injury in the untreated group. 
With 670 nm treatment, cell death is significantly reduced from 1 day and the peak is shifted from 
3 days to 1 day. This shifting in peak cell death is an interesting observation. It is likely that the 
light treatment is accelerating the course of pathophysiology, which can be supported by 
accelerated cellular processes and increased metabolism in other injury models (Begum et al., 
2015; Eells et al., 2003; Yip et al., 2011). Cell death following spinal cord injury could be due to 
a variety of causes, and one of them is energy depletion (Boutilier, 2001). Light treatment, 
therefore, may revert this energy depletion and reduce the number of compromised cells that 
would otherwise succumb to cell death by promoting metabolism. Cell death could also be 
inflammatory-mediated, through IL1β and/or NO secretion from M1 microglia/macrophages 
(Merrill and Scolding, 1999; Streit et al., 1998). The mechanism(s) by which 670 nm reduces 
inflammatory-evoked cell death may therefore be related to the reduction of the overall 
microglia/macrophages, and hence, the overall decrease in the M1 subpopulation (Figure 3.6), 
and/or the reduction in iNOS+ M1 microglia/macrophages (Figure 4.10), but not IL1β+ M1 
microglia/macrophages (Figure 4.9).  
The cytoprotective effect of light therapy has been demonstrated in a variety of neural injury 
models (Albarracin et al., 2011; Huang et al., 2012; Snyder et al., 2002), including an 
ischemia-induced spinal cord injury using 810 nm (Sotoudeh et al., 2015). This study in Chapter 
3 is the first to report the cytoprotective effect of 670 nm light treatment following spinal cord 
injury. This cytoprotective effect of 670 nm treatment may, in the short-term, weaken 
degeneration and demyelination, and may ultimately provide functional benefits. However, it is 
not clear what types of cells are saved by 670 nm treatment. Both glial and neuronal cells undergo 
apoptosis following spinal cord injury, though different mechanisms (Kuzhandaivel et al., 2011). 
It would be of interest to study whether the cytoprotective effect of 670 nm light is cell-specific 
or not. Cell death at regions outside the local injury site, including at supraspinal regions, have 
been demonstrated (Casha et al., 2001; Hains et al., 2003; Lee et al., 2004). It is therefore 
worthwhile investigating whether local light treatment at the spinal cord region can alter cell death 
at distal areas and/or at supraspinal levels. It is important to bear in mind that these changes may 
require days or even weeks to develop. Future studies should be designed regarding the relative 
timeframe. 
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5.2.2 Functional changes 
As a consequence of cellular changes, spinal cord injury leads to various functional deficits 
(Section 1.1.1.2). This thesis investigated the changes in both motor (Section 5.2.2.1) and sensory 
function (Section 5.2.2.2) in the subacute phase of spinal cord injury, over the course of 1 to 7 
days post-injury. 
5.2.2.1 Motor function 
Rats with hemicontusion spinal cord injury display locomotor deficits from 1 day and recover 
spontaneously after 7 days (Figure 3.4). Although the injury is mild and confined mostly to the 
dorsal region of the spinal cord, damage to the ipsilateral corticospinal tract is expected because 
this tract is located in the dorsal spinal cord in rats (Schwartz et al., 2005). As some stages of the 
BBB scale assess the coordination of the limbs, the contralateral score is also affected to some 
extent. 670 nm LED treatment (daily dosage of 63.7 J/cm2) significantly accelerates the recovery 
of locomotor function. This is the first report on the beneficial effect of 670 nm treatment on 
locomotor recovery following spinal cord injury. In another study using 810 nm laser treatment 
(daily dosage of 1,589 J/cm2), rats with the treatment were significantly better at performing a 
ladder/grid walking test at 9 weeks post-injury following a corticospinal tract lesion (Byrnes et 
al., 2005). These results suggest that light treatment, within the optical window, could 
significantly improve locomotor function following spinal cord injury. However, another study 
using both 670 nm (daily dosage of 28.4 J/cm2) and 830 nm (daily dosage of 22.4 J/cm2) on rats 
with severe spinal cord injury found no functional improvements in BBB scores, gait or ladder 
performance tasks (Giacci et al., 2014). The contradiction between that study with Chapter 3 is 
likely to be due to a combination of a more severe injury with a lower daily dosage. Future studies 
should take into consideration the injury intensity when choosing the daily dosage, i.e., a more 
severe injury might require a higher daily dosage. 
5.2.2.2 Sensory function 
Since the injury is focused on the dorsal surface of the spinal cord, it is expected to affect signal 
transduction along the posterior columns (Section 1.1.1.2). The traditional method of 
somatosensory assessment involves stimulation of the periphery while recording somatosensory 
evoked potentials from the cortex. This approach provides an overview of the entire posteriors 
columns including the periphery, the spinal cord, and supraspinal regions. Since plasticity and 
reorganisation occur at both spinal and supraspinal levels following spinal cord injury (Reed et 
al., 2016), functional alterations may reflect synaptic adaptations at supraspinal levels. The 
approach adopted by this thesis, which only focuses on the changes in the spinal cord region, 
provides advantages over the traditional assessment. By electrical stimulation of the ipsilateral 
sural nerve, the evoked field potential from the brainstem gracile nucleus surface reflects the 
functional integrity of the ipsilateral posterior columns. This approach enables an objective 
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measure of functional damage in that pathway when compared to the contralateral nerve (the 
uninjured side), which provides a relative control response. 
Spinal cord injured animals display significantly decreased gracile nuclei response magnitudes 
and significantly increased latency at 7 days compared to normal animals (Figure 3.3). These 
sensory deficits could be due to Wallerian degeneration and demyelination respectively 
(Section 1.1.1.1), and may be indicative of oligodendrocyte apoptosis in the spinal cord (Crowe 
et al., 1997). With 670 nm treatment, these sensory deficits are restored to a level similar to normal 
animals. This is the first evidence that 670 nm treatment, or photobiomodulation in general, can 
improve non-pain related sensory recovery following spinal cord injury. This sensory restoration 
by red light treatment might be related to reduced cell death (Section 5.2.1.3). Future studies could 
investigate the effects of 670 nm on oligodendrocyte apoptosis, in addition to axonal degeneration 
and demyelination. As these processes are ongoing, future studies could also focus on the 
long-term sensory changes. 
Pain 
Spinal cord injury induces mechanical hypersensitivity for at least the first 7 days in rats (Chapter 
3 and Chapter 4). The percentage of hypersensitive animals is similar to that in the clinical settings 
(Dijkers et al., 2009). It is not yet clear why some develop hypersensitivity, and others do not. 
However, evidence suggests that following spinal cord injury, anatomical and physiological 
changes at the spinal and/or supraspinal levels may result in pain (Section 1.1.1.2). With 670 nm 
treatment, the incidence of developing hypersensitivity is significantly reduced for the first 5 days 
(Figure 4.3) and the mechanical sensitivity at 7 days in hypersensitive animals is also reduced 
(Figure 3.2). Cytokines and free radicals secreted by M1 microglia/macrophages, e.g., IL1β and 
NO, have been shown to enhance synaptic strength and induces LTP in the spinal cord (Clark et 
al., 2015; Ikeda et al., 2006), and is proposed to result in pain development following spinal cord 
injury (Hulsebosch et al., 2009). Therefore, the reduction of hypersensitivity incidence by 670 nm 
treatment could have resulted from the decrease in the M1 microglia/macrophage population 
(Figure 3.6), especially the iNOS+ M1 microglia/macrophage (Figure 4.10). It is therefore 
worthwhile to investigate the expression of these inflammatory cells in the hypersensitive animals 
and the effects of 670 nm treatment, and compare those to animals that do not develop 
hypersensitivity. It remains unclear how 670 nm treatment reduces mechanical sensitivity in 
hypersensitive animals only at 7 days. It is possible that at this later time point, a different 
mechanism is involved, or that it takes at least 7 days to develop at a level that can be sufficiently 
detected. It has been reported that axonal sprouting occurs around 7 days post-injury (Rust and 
Kaiser, 2017) and that inappropriate intraspinal sprouting may lead to the development of pain 
following spinal cord injury (Christensen and Hulsebosch, 1997). The effect of red light during 
long-term recovery on axonal sprouting in hypersensitive animals would provide useful insight 
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into the possibility of red light-induced axonal changes and pain development following spinal 
cord injury. 
In normosensitive animals, spinal cord injury induces some injury-related sensitivity (as 
compared to the sham-injured animals), but the level of this sensitivity is within the range of 
normal animals and therefore not hypersensitivity or allodynia by definition (Figure 4.5). 670 nm 
treatment significantly reduces mechanical sensitivity in both normosensitive injured and 
sham-injured animals. This interesting result might be due to the upregulation of endogenous 
opioids and the downregulation of bradykinins by red light treatment (Chaves et al., 2014; Lins 
et al., 2010; Pereira et al., 2017). Future studies could further investigate the effects of 670 nm 
treatment on the endogenous opioid system. The thesis shows the first evidence of the analgesic 
effects of 670 nm treatment following spinal cord injury. It is effective in the entire population of 
spinal cord injured animals, both hypersensitive and normosensitive subpopulations. These results 
grant further investigation into the analgesic effects of 670 nm treatment, e.g., the cause and the 
duration of such benefits, and the effect of larger light doses. A better understanding of the 
sensitivity development following spinal cord injury and the endogenous opioid system would be 
invaluable to subsequent studies.  
5.3 Conclusions and future directions 
The effects of 670 nm LED treatment has been documented in this thesis regarding both cellular 
changes and functional improvements. The treatment is shown to modulate 
microglial/macrophage populations, reduce cell death, improvement sensorimotor function, and 
reduce pain in a mild hemicontusion spinal cord injury in rats. However, the results of this study 
are only a snapshot of the whole recovery process. Long-term studies will be needed as spinal 
cord injury is a chronic condition. When designing long-term studies, investigating changes in 
the supraspinal regions would also be greatly beneficial. Furthermore, studies on treatment 
strategies would be of interest. There are a number of treatment-related parameters that can be 
modulated to achieve the maximum effects, as well as determine the therapeutic window 
boundaries of over-treatment. Parameters, such as the time of treatment period, the duration, the 
interval and intensity of treatment, all need to be taken into careful consideration before 
introduction into clinical studies. Given the successfully penetration of 670 nm (100mW/cm2) in 
50 mm of human tissue, future studies are warranted to study the penetration of red light at the 
cervical and thoracic vertebral levels in humans. In particular, what is the required radiosity of 
the device to reach the desired irradiance at the spinal cord? The use of cadavers would also be 
beneficial for those studies. The results from this thesis provide guidance for future studies on 
670 nm treatment (or photobiomodulation in general) and its effects in spinal cord injury, and 
furthermore, are encouraging for the use of red light therapy of the upper spinal cord.  
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